ALK2 antibodies and methods of use thereof
By combining ALK2 antibodies with ALK2 receptors, the treatment problems of various diseases such as bone diseases, anemia, and ectopic ossification have been solved, and effective treatment effects and side effects have been reduced, especially in osteoporosis and fractures. Significant bone density improvement.
Patent Information
- Application Number
- CN202411099364.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2018-10-23
- Filing Date
- 2019-10-23
- Publication Date
- 2024-11-15
AI Technical Summary
The prior art is difficult to effectively treat bone diseases, anemia, ectopic ossification, Sjogren's syndrome, diffuse endogenous ponsor glioma, multiple osteochondroma, posterior capsule turbidity and cardiac hypertrophy, and common treatment methods have side effects or The problem of limited efficacy.
ALK2 antibodies and their ALK2 binding fragments have been developed for the treatment or prevention of bone diseases, anemia, ectopic ossification, Sjogren's syndrome, diffuse endogenous ponsor glioma, multiple osteochondroma, posterior capsule turbidity and heart Hypertrophy, by binding to the ALK2 receptor to regulate the corresponding physiological processes.
Effective treatment or prevention of the above diseases has been achieved, side effects have been reduced, and therapeutic effects have been improved, especially in osteoporosis, fractures, bone cancer and other bone-related diseases, which have shown significant bone density and bone strength improvement.
Smart Images

Figure CN118955715A_ABST
Abstract
Description
This application is a divisional application of the invention application with an application date of October 23, 2019, Chinese national application number 201980085459.7, and invention name “ALK2 antibodies and methods of use thereof”.
[0001] Sequence Listing This application contains a sequence listing that has been submitted electronically in ASCII form and is hereby incorporated by reference in its entirety. The ASCII copy, created on October 23, 2019, is named 51184-010WO2_Sequence_Listing_10.23.19_ST25 and is 55,259 bytes in size. Background of the Invention Healthy bones undergo constant remodeling, which involves both bone destruction and bone growth. Bone growth is mediated by osteoblastic cell types, while osteoclasts resorb bone. When these systems lose balance through downregulation of anabolic programs, upregulation of catabolic systems, or a combination of the two, pathological conditions occur, resulting in net bone loss. Therefore, controlling the balance of bone remodeling can be used to promote the healing of bone injuries and the treatment of conditions associated with bone loss and bone demineralization, such as osteoporosis.
[0003] Bone damage can be caused by a series of root causes, including age or cancer-related bone loss, genetic conditions or adverse side effects of drug treatment. The World Health Organization estimates that osteoporosis alone has affected 75 million people in the United States, Europe and Japan, and is an important risk factor for bone damage. Generally, the entire bone loss represents a pathological state for which there are few effective treatments. On the contrary, treatment focuses on fixation, exercise and dietary modulation, rather than directly promoting bone growth and increasing bone density. With regard to osteoporosis, estrogen, calcitonin, osteocalcin and vitamin K or high-dose dietary calcium can all be used as therapeutic interventions. Other treatments for osteoporosis include bisphosphonates, parathyroid hormone, parathyroid hormone-related protein (PTHrP), calcimimetic agents, statins, anabolic steroids, lanthanum and strontium salts and sodium fluoride. However, such therapeutic agents are often associated with undesirable side effects.
[0004] Anemia is a global health problem with health implications that affect both morbidity and mortality. Only in the U.S., the prevalence of anemia has almost doubled from 2003 to 2012. The symptoms of anemia include fatigue, weakness, shortness of breath, palpitations and cognitive decline, and it has been found that children, pregnant women, women of childbearing age and the elderly have the highest risk of developing anemia. The most common form of anemia is iron deficiency anemia, but anemia can also be caused by chronic diseases, blood loss and red blood cell destruction. Although iron deficiency anemia can be treated with iron supplements, many other forms of anemia, such as aplastic anemia, chronic disease anemia and hemolytic anemia may require blood transfusion.
[0005] Heterotopic ossification (HO) is the pathological formation of extraskeletal bone in soft tissue. The process occurs in patient populations with severe trauma, including large surface burns, musculoskeletal injuries, orthopedic surgery, and spinal cord injuries, as well as in patient populations with a genetic disease known as fibrodysplasia ossificans progressiva (FOP). FOP is caused by overactivating mutations in the type I bone morphogenetic protein (BMP) receptor activin A receptor type I (ACVR1), and patients with FOP can develop heterotopic bone lesions in muscles, tendons, ligaments, and other connective tissues without any substantial trauma. The clinical sequelae of these pathological heterotopic bone formations, whether in the context of trauma or genetic mutations, include non-healing wounds, chronic pain, and joint sclerosis. In the case of FOP, the formation of heterotopic bone can lead to bony bridges that develop between joints and progressively restrict movement, and progressive ossification may lead to death due to loss of thoracic compliance.
[0006] Treatment options for HO are limited because bone often recurs after surgical resection, and attempts to surgically remove additional bone can result in further bone growth. In addition, some patients may have unresectable HO due to its sensitive location. The risks of surgery may outweigh the benefits of resection, especially in the face of recurrence. There is a need for treatment options that can prevent HO and / or reduce the amount of HO before HO initially occurs in patients at risk, reduce the recurrence of HO, or prevent additional ectopic bone formation in patients with FOP. There is currently no approved treatment for FOP.
[0007] Sjögren's syndrome is a systemic autoimmune disease, which is identified by its two most common symptoms (dry eyes and dry mouth). It can also be characterized by joint pain, swelling and stiffness, salivary gland swelling, rash or dry skin, vaginal dryness, persistent dry cough and long-term fatigue. Sjögren's syndrome can also cause organ dysfunction such as kidney, gastrointestinal system, blood vessels, lungs, liver, pancreas and central nervous system. It is one of the most common autoimmune disorders, wherein more than 4 million Americans suffer from the disease, wherein nine out of ten are women. The dry eyes associated with Sjögren's syndrome can be treated with immunosuppressants and steroid eye drops; however, due to side effects, such as increased intraocular pressure and prone to infection, steroid eye drops should not be used for a long period of time.
[0008] Diffuse intrinsic pontine glioma (DIPG) is a pediatric brain tumor that originates in the pons and accounts for approximately 20% of all pediatric brain tumors. DIPG remains incurable, with a median survival of 10-11 months. The failure to identify successful therapies for DIPG may stem from a lack of biological understanding of the disease, as biopsies were not commonly performed until recently due to the sensitive location of the tumor. As a result, many trials have been based on genetic alterations found in adult glioblastomas, which were recently found to be molecularly distinct from DIPG.
[0009] Multiple osteochondromas (MO), also known as hereditary multiple exostoses, are a rare genetic disorder characterized by the development of multiple benign (non-cancerous) bone tumors called osteochondromas, often on the growth ends (metaphysis) of the legs, arms, and toes and on flat bones, such as the hips and shoulder blades. The number of osteochondromas and the bones in which they are located vary greatly between affected individuals. Osteochondromas do not exist at birth, but approximately 96% of affected individuals develop multiple osteochondromas by the age of 12. These osteochondromas usually continue to grow until shortly after puberty and may cause bone deformities, skeletal abnormalities, limb length differences, short stature, pain, reduced range of motion, and pressure on nerves, blood vessels, spinal cord, and tissues surrounding the osteochondromas. Hereditary multiple osteochondromas are inherited as an autosomal dominant condition and are associated with mutations in the exostosin-1 (EXT1) or exostosin-2 (EXT2) genes. Current treatment options include a "watch and wait" approach (when symptoms are not present), surgical removal of the osteochondroma, corrective osteotomy, growth plate blocks, or limb lengthening surgery.
[0010] Posterior capsule opacification (PCO) is the most common complication associated with decreased vision after cataract surgery and intraocular lens implantation. During cataract surgery, the eye's natural lens is replaced with an artificial intraocular lens that is placed within the lens capsule. PCO occurs when lens epithelial cells migrate to the posterior capsule, proliferate and differentiate, grow on the back of the capsule and cause it to thicken and become slightly opaque. This reduces the amount of light that can reach the retina and can cause problems with blurred or cloudy vision or bright lights and glare. Although PCO can be treated using Nd:YAG laser capsulotomy, the potential complications and high cost of treatment emphasize the importance of identifying new therapies for PCO.
[0011] Cardiac hypertrophy is the abnormal enlargement or thickening of the myocardium caused by the increase of cardiomyocyte size and the change of other myocardial components (such as extracellular matrix). Cardiac hypertrophy can be physiological, occurs in response to exercise or pregnancy, or pathological, occurs in response to stress (for example, hemodynamic stress), such as hypertension or valvular disease. The feature of cardiac fibrosis is also that the abnormal thickening of the heart valve caused by the excessive deposition of extracellular matrix in the inappropriate proliferation of cardiac fibroblasts or myocardium may cause the muscle to be harder, the compliance is reduced, and occurs during the progression to heart failure. Lack of effective therapy to reduce or reverse cardiac fibrosis, and existing cardiac hypertrophy therapy, such as adrenergic antagonists, renin-angiotensin system regulators, such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers may have an upper limit effect, characterized in that lack of efficacy in some patients, and even disappear.
[0012] There is a need for new and effective treatments for bone disease, anemia, HO (eg, HO due to FOP), Sjögren's syndrome (eg, dry eyes associated with Sjögren's syndrome), DIPG, MO, PCO, and cardiac hypertrophy and / or cardiac fibrosis. SUMMARY OF THE INVENTION Described herein are activin receptor-like kinase-2 (ALK2, also known as activin A receptor type I (ACVR1)) antibodies, such as ALK2 neutralizing antibodies and ALK2 binding fragments thereof. The ALK2 antibodies and antigen-binding fragments thereof described herein can be formulated into pharmaceutical compositions for administration to a subject, such as a human subject. The ALK2 antibodies or antigen-binding fragments thereof and compositions described herein can be administered to a subject, such as a human subject, to treat or prevent a bone disease (e.g., a disease or condition involving bone damage, such as primary osteoporosis, secondary osteoporosis, osteopenia, osteosclerosis, bone fractures, bone cancer or cancer metastasis-related bone loss, Paget's disease, renal osteodystrophy, treatment-related bone loss, diet-related bone loss, bone loss associated with obesity treatment, low gravity-related bone loss, or bone loss associated with immobility), low red blood cell levels (e.g., low hemoglobin levels or low red blood cell counts, e.g., anemia), heterotopic ossification (HO), such as heterotopic ossification caused by fibrodysplasia ossificans progressiva (FOP), Sjögren's syndrome (e.g., dry eyes associated with Sjögren's syndrome), diffuse intrinsic pontine glioma (DIPG), multiple osteochondromas (MO), posterior capsule opacification (PCO), or cardiac hypertrophy and / or cardiac fibrosis.
[0014] Exemplary embodiments of the invention are described in the following enumerated paragraphs.
[0015] E1. An isolated antibody or ALK2 binding fragment thereof, comprising: (1) a light chain variable domain, comprising: a light chain complementary determining region (CDR) 1, comprising or consisting of an amino acid sequence selected from the group consisting of SGSSSNIGSNYVS (SEQ ID NO: 1) and SGDX1X2X3X4X5X6X7X8 (SEQ ID NO: 2, wherein X1 is S or N, X2 is I or L, X3 is P, G or R, X4 is S, T or K, X5 is F, K or Y, X6 is F, Y or S, X7 is A or V, and X8 is S, Y or H); a light chain CDR2, comprising or consisting of an amino acid sequence selected from the group consisting of X1X2IYX3X4X5X6RPS (SEQ ID NO:3, wherein X1 is V or L, X2 is V or L, X3 is K, R, G or Y, X4 is N or D, X5 is N or S, and X6 is H, N, D or K); and a light chain CDR3 comprising or consisting of an amino acid sequence selected from the group consisting of ASWDHSDRFYV (SEQ ID NO:4), YVTAPWKSIW (SEQ ID NO:5), YSADAQQMKA (SEQ ID NO:6), QVYASVHRM (SEQ ID NO:7) and QTYDWSHFGW (SEQ ID NO:8); and (2) a heavy chain variable domain comprising: a heavy chain CDR1 comprising or consisting of an amino acid sequence selected from the group consisting of GX1TFX2SX3X4X5X6 (SEQ ID NO:9, wherein X1 is G or F, X2 is S or N, X3 is Y, H, S or A, X4 is G or A, X5 is V, M or I, and X6 is S or H); a heavy chain CDR2 comprising or consisting of an amino acid sequence selected from the group consisting of WMGX1IIPX2FGX3ANYAQKFQG (SEQ ID NO:10, wherein X1 is G or R, X2 is H or D, and X3 is I or T), WVGRIKSKX1DX2X3TTDYAAPVKG (SEQ ID NO:11, wherein X1 is A or R, X2 is S or G, and X3 is G or Y) and WVSVISSDGGSTYYADSVKG (SEQ ID NO:12); and a heavy chain CDR3 comprising or consisting of an amino acid sequence selected from the group consisting of EIGSLDI (SEQ ID NO:13), DYGVAFAY (SEQ ID NO:14), NO:14), DYGGLKFDY (SEQ ID NO:15), GPTQAIHYFAY (SEQ ID NO:16) and AGFILGSLGVAWMDV (SEQ ID NO:17).
[0016] E2. The isolated antibody or ALK2-binding fragment thereof of E1, wherein the light chain CDR1 comprises or consists of the sequence of SEQ ID NO: 2, and X1 is S.
[0017] E3. The isolated antibody or ALK2-binding fragment thereof of E1, wherein the light chain CDR1 comprises or consists of the sequence of SEQ ID NO: 2, and X1 is N.
[0018] E4. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E3, wherein the light chain CDR1 comprises or consists of the sequence of SEQ ID NO: 2, and X2 is 1.
[0019] E5. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E3, wherein the light chain CDR1 comprises or consists of the sequence of SEQ ID NO: 2, and X2 is L.
[0020] E6. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E5, wherein the light chain CDR1 comprises or consists of the sequence of SEQ ID NO: 2, and X3 is P.
[0021] E7. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E5, wherein the light chain CDR1 comprises or consists of the sequence of SEQ ID NO: 2, and X3 is G.
[0022] E8. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E5, wherein the light chain CDR1 comprises or consists of the sequence of SEQ ID NO: 2, and X3 is R.
[0023] E9. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E8, wherein the light chain CDR1 comprises or consists of the sequence of SEQ ID NO: 2, and X4 is S.
[0024] E10. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E8, wherein the light chain CDR1 comprises or consists of the sequence of SEQ ID NO: 2, and X4 is T.
[0025] E11. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E8, wherein the light chain CDR1 comprises or consists of the sequence of SEQ ID NO: 2, and X4 is K.
[0026] E12. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E11, wherein the light chain CDR1 comprises or consists of the sequence of SEQ ID NO: 2, and X5 is F.
[0027] E13. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E11, wherein the light chain CDR1 comprises or consists of the sequence of SEQ ID NO: 2, and X5 is K.
[0028] E14. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E11, wherein the light chain CDR1 comprises or consists of the sequence of SEQ ID NO: 2, and X5 is Y.
[0029] E15. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E14, wherein the light chain CDR1 comprises or consists of the sequence of SEQ ID NO: 2, and X6 is F.
[0030] E16. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E14, wherein the light chain CDR1 comprises or consists of the sequence of SEQ ID NO: 2, and X6 is Y.
[0031] E17. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E14, wherein the light chain CDR1 comprises or consists of the sequence of SEQ ID NO: 2, and X6 is S.
[0032] E18. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E17, wherein the light chain CDR1 comprises or consists of the sequence of SEQ ID NO: 2, and X7 is A.
[0033] E19. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E17, wherein the light chain CDR1 comprises or consists of the sequence of SEQ ID NO: 2, and X7 is V.
[0034] E20. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E19, wherein the light chain CDR1 comprises or consists of the sequence of SEQ ID NO: 2, and X8 is S.
[0035] E21. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E19, wherein the light chain CDR1 comprises or consists of the sequence of SEQ ID NO: 2, and X8 is Y.
[0036] E22. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E19, wherein the light chain CDR1 comprises or consists of the sequence of SEQ ID NO: 2, and X7 is A or V, and X8 is H.
[0037] E23. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E22, wherein the light chain CDR2 comprises or consists of the sequence of SEQ ID NO: 3, and X1 is V.
[0038] E24. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E22, wherein the light chain CDR2 comprises or consists of the sequence of SEQ ID NO:3, and X1 is L.
[0039] E25. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E24, wherein the light chain CDR2 comprises or consists of the sequence of SEQ ID NO: 3, and X2 is V.
[0040] E26. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E24, wherein the light chain CDR2 comprises or consists of the sequence of SEQ ID NO:3, and X2 is L.
[0041] E27. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E26, wherein the light chain CDR2 comprises or consists of the sequence of SEQ ID NO:3, and X3 is K.
[0042] E28. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E26, wherein the light chain CDR2 comprises or consists of the sequence of SEQ ID NO:3, and X3 is R.
[0043] E29. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E26, wherein the light chain CDR2 comprises or consists of the sequence of SEQ ID NO:3, and X3 is G.
[0044] E30. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E26, wherein the light chain CDR2 comprises or consists of the sequence of SEQ ID NO:3, and X3 is Y.
[0045] E31. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E30, wherein the light chain CDR2 comprises or consists of the sequence of SEQ ID NO:3, and X4 is N.
[0046] E32. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E30, wherein the light chain CDR2 comprises or consists of the sequence of SEQ ID NO:3, and X4 is D.
[0047] E33. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E32, wherein the light chain CDR2 comprises or consists of the sequence of SEQ ID NO:3, and X5 is N.
[0048] E34. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E32, wherein the light chain CDR2 comprises or consists of the sequence of SEQ ID NO:3, and X5 is S.
[0049] E35. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E34, wherein the light chain CDR2 comprises or consists of the sequence of SEQ ID NO:3, and X6 is H.
[0050] E36. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E34, wherein the light chain CDR2 comprises or consists of the sequence of SEQ ID NO:3, and X6 is N.
[0051] E37. The isolated antibody or ALK2 binding fragment thereof of any one of E1-E34, wherein the light chain CDR2 comprises or consists of the sequence of SEQ ID NO:3, and X6 is D.
[0052] E38. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E34, wherein the light chain CDR2 comprises or consists of the sequence of SEQ ID NO:3, and X6 is K.
[0053] E39. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E38, wherein the heavy chain CDR1 comprises or consists of the sequence of SEQ ID NO:9, and X1 is G.
[0054] E40. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E38, wherein the heavy chain CDR1 comprises or consists of the sequence of SEQ ID NO:9, and X1 is F.
[0055] E41. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E40, wherein the heavy chain CDR1 comprises or consists of the sequence of SEQ ID NO:9, and X2 is S.
[0056] E42. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E40, wherein the heavy chain CDR1 comprises or consists of the sequence of SEQ ID NO:9, and X2 is N.
[0057] E43. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E42, wherein the heavy chain CDR1 comprises or consists of the sequence of SEQ ID NO:9, and X3 is Y.
[0058] E44. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E42, wherein the heavy chain CDR1 comprises or consists of the sequence of SEQ ID NO:9, and X3 is H.
[0059] E45. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E42, wherein the heavy chain CDR1 comprises or consists of the sequence of SEQ ID NO:9, and X3 is S.
[0060] E46. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E42, wherein the heavy chain CDR1 comprises or consists of the sequence of SEQ ID NO:9, and X3 is A.
[0061] E47. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E46, wherein the heavy chain CDR1 comprises or consists of the sequence of SEQ ID NO:9, and X4 is G.
[0062] E48. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E46, wherein the heavy chain CDR1 comprises or consists of the sequence of SEQ ID NO:9, and X4 is A.
[0063] E49. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E48, wherein the heavy chain CDR1 comprises or consists of the sequence of SEQ ID NO:9, and X5 is V.
[0064] E50. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E48, wherein the heavy chain CDR1 comprises or consists of the sequence of SEQ ID NO:9, and X5 is M.
[0065] E51. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E48, wherein the heavy chain CDR1 comprises or consists of the sequence of SEQ ID NO:9, and X5 is I.
[0066] E52. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E51, wherein the heavy chain CDR1 comprises or consists of the sequence of SEQ ID NO:9, and X6 is S.
[0067] E53. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E51, wherein the heavy chain CDR1 comprises or consists of the sequence of SEQ ID NO:9, and X6 is H.
[0068] E54. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E53, wherein the heavy chain CDR2 comprises or consists of the sequence of SEQ ID NO: 10, and X1 is G.
[0069] E55. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E53, wherein the heavy chain CDR2 comprises or consists of the sequence of SEQ ID NO: 10, and X1 is R.
[0070] E56. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E55, wherein the heavy chain CDR2 comprises or consists of the sequence of SEQ ID NO: 10, and X2 is H.
[0071] E57. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E55, wherein the heavy chain CDR2 comprises or consists of the sequence of SEQ ID NO: 10, and X2 is D.
[0072] E58. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E57, wherein the heavy chain CDR2 comprises or consists of the sequence of SEQ ID NO: 10, and X3 is 1.
[0073] E59. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E57, wherein the heavy chain CDR2 comprises or consists of the sequence of SEQ ID NO: 10, and X3 is T.
[0074] E60. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E53, wherein the heavy chain CDR2 comprises or consists of the sequence of SEQ ID NO:11, and X1 is A.
[0075] E61. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E53, wherein the heavy chain CDR2 comprises or consists of the sequence of SEQ ID NO:11, and X1 is R.
[0076] E62. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E53, E60 and E61, wherein the heavy chain CDR2 comprises or consists of the sequence of SEQ ID NO: 11, and X2 is S.
[0077] E63. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E53, E60 and E61, wherein the heavy chain CDR2 comprises or consists of the sequence of SEQ ID NO: 11, and X2 is G.
[0078] E64. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E53 and E60-E63, wherein the heavy chain CDR2 comprises or consists of the sequence of SEQ ID NO: 11, and X3 is G.
[0079] E65. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E53 and E60-E63, wherein the heavy chain CDR2 comprises or consists of the sequence of SEQ ID NO: 11, and X3 is Y.
[0080] E66. The isolated antibody or ALK2-binding fragment thereof of E1, wherein the light chain CDR1 comprises or consists of the following sequence: SGSSSNIGSNYVS (SEQ ID NO: 1).
[0081] The isolated antibody or ALK2-binding fragment thereof of E67.E1, wherein the light chain CDR1 comprises or consists of the following sequence: SGDSIPSFFAS (SEQ ID NO: 18).
[0082] The isolated antibody or ALK2-binding fragment thereof of E68.E1, wherein the light chain CDR1 comprises or consists of the following sequence: SGDNIGTKYAY (SEQ ID NO: 19).
[0083] The isolated antibody or ALK2-binding fragment thereof of E69.E1, wherein the light chain CDR1 comprises or consists of the following sequence: SGDNLRKYSAH (SEQ ID NO: 20).
[0084] The isolated antibody or ALK2-binding fragment thereof of E70.E1, wherein the light chain CDR1 comprises or consists of the following sequence: SGDSLGSKSVH (SEQ ID NO: 21).
[0085] E71. The isolated antibody or ALK2-binding fragment thereof of any one of E1 and E66-E7, wherein the light chain CDR2 comprises or consists of the following sequence: VLIYKNNHRPS (SEQ ID NO: 24).
[0086] E72. The isolated antibody or ALK2-binding fragment thereof of any one of E1 and E66-E7, wherein the light chain CDR2 comprises or consists of the following sequence: LVIYRDSNRPS (SEQ ID NO: 25).
[0087] E73. The isolated antibody or ALK2-binding fragment thereof of any one of E1 and E66-E7, wherein the light chain CDR2 comprises or consists of the following sequence: LVIYGDSDRPS (SEQ ID NO: 26).
[0088] E74. The isolated antibody or ALK2-binding fragment thereof of any one of E1 and E66-E7, wherein the light chain CDR2 comprises or consists of the following sequence: LVIYYDNKRPS (SEQ ID NO: 27).
[0089] E75. The isolated antibody or ALK2-binding fragment thereof of any one of E1 and E66-E7, wherein the light chain CDR2 comprises or consists of the following sequence: LVIYRDSKRPS (SEQ ID NO: 28).
[0090] E76. The isolated antibody or ALK2-binding fragment thereof of any one of E1 and E66-E75, wherein the light chain CDR3 comprises or consists of the following sequence: ASWDHSDRFYV (SEQ ID NO: 4).
[0091] E77. The isolated antibody or ALK2-binding fragment thereof of any one of E1 and E66-E75, wherein the light chain CDR3 comprises or consists of the following sequence: YVTAPWKSIW (SEQ ID NO: 5).
[0092] E78. The isolated antibody or ALK2-binding fragment thereof of any one of E1 and E66-E75, wherein the light chain CDR3 comprises or consists of the following sequence: YSADAQQMKA (SEQ ID NO: 6).
[0093] E79. The isolated antibody or ALK2-binding fragment thereof of any one of E1 and E66-E75, wherein the light chain CDR3 comprises or consists of the following sequence: QVYASVHRM (SEQ ID NO: 7).
[0094] E80. The isolated antibody or ALK2-binding fragment thereof of any one of E1 and E66-E75, wherein the light chain CDR3 comprises or consists of QTYDWSHFGW (SEQ ID NO: 8).
[0095] E81. The isolated antibody or ALK2-binding fragment thereof of any one of E1 and E66-E80, wherein the heavy chain CDR1 comprises or consists of the following sequence: GGTFSSYGVS (SEQ ID NO: 31).
[0096] E82. The isolated antibody or ALK2-binding fragment thereof of any one of E1 and E66-E80, wherein the heavy chain CDR1 comprises or consists of the following sequence: GFTFSSHAMS (SEQ ID NO: 32).
[0097] E83. The isolated antibody or ALK2-binding fragment thereof of any one of E1 and E66-E80, wherein the heavy chain CDR1 comprises or consists of the following sequence: GFTFNSSAMS (SEQ ID NO: 33).
[0098] E84. The isolated antibody or ALK2-binding fragment thereof of any one of E1 and E66-E80, wherein the heavy chain CDR1 comprises or consists of the following sequence: GGTFSSYAIH (SEQ ID NO: 34).
[0099] E85. The isolated antibody or ALK2-binding fragment thereof of any one of E1 and E66-E80, wherein the heavy chain CDR1 comprises or consists of the following sequence: GFTFSSAAMH (SEQ ID NO: 35).
[0100] E86. The isolated antibody or ALK2-binding fragment thereof of any one of E1 and E66-E85, wherein the heavy chain CDR2 comprises or consists of the following sequence: WMGGIIPHFGIANYAQKFQG (SEQ ID NO: 36).
[0101] E87. The isolated antibody or ALK2-binding fragment thereof of any one of E1 and E66-E85, wherein the heavy chain CDR2 comprises or consists of the following sequence: WVGRIKSKADSGTTDYAAPVKG (SEQ ID NO: 37).
[0102] E88. The isolated antibody or ALK2-binding fragment thereof of any one of E1 and E66-E85, wherein the heavy chain CDR2 comprises or consists of the following sequence: WVGRIKSKRDGYTTDYAAPVKG (SEQ ID NO: 38).
[0103] E89. The isolated antibody or ALK2-binding fragment thereof of any one of E1 and E66-E85, wherein the heavy chain CDR2 comprises or consists of the following sequence: WMGRIIPDFGTANYAQKFQG (SEQ ID NO: 39).
[0104] E90. The isolated antibody or ALK2-binding fragment thereof of any one of E1 and E66-E85, wherein the heavy chain CDR2 comprises or consists of the following sequence: WVSVISSDGGSTYYADSVKG (SEQ ID NO: 12).
[0105] E91. The isolated antibody or ALK2-binding fragment thereof of any one of E1 and E66-E90, wherein the heavy chain CDR3 comprises or consists of the following sequence: EIGSLDI (SEQ ID NO: 13).
[0106] E92. The isolated antibody or ALK2-binding fragment thereof of any one of E1 and E66-E90, wherein the heavy chain CDR3 comprises or consists of the following sequence: DYGVAFAY (SEQ ID NO: 14).
[0107] E93. The isolated antibody or ALK2-binding fragment thereof of any one of E1 and E66-E90, wherein the heavy chain CDR3 comprises or consists of the following sequence: DYGGLKFDY (SEQ ID NO: 15).
[0108] E94. The isolated antibody or ALK2-binding fragment thereof of any one of E1 and E66-E90, wherein the heavy chain CDR3 comprises or consists of the following sequence: GPTQAIHYFAY (SEQ ID NO: 16).
[0109] E95. The isolated antibody or ALK2-binding fragment thereof of any one of E1 and E66-E90, wherein the heavy chain CDR3 comprises or consists of the following sequence: AGFILGSLGVAWMDV (SEQ ID NO: 17).
[0110] The isolated antibody or ALK2-binding fragment thereof of E96.E1, wherein the light chain CDR2 comprises or consists of the following sequence: LVIYX1DX2X3RPS (SEQ ID NO:22, wherein X1 is R, G or Y, X2 is S or N, and X3 is N, D or K).
[0111] E97. The isolated antibody or ALK2-binding fragment thereof of E96, wherein the light chain CDR2 comprises or consists of the sequence of SEQ ID NO:22, and X1 is R.
[0112] E98. The isolated antibody or ALK2-binding fragment thereof of E96, wherein the light chain CDR2 comprises or consists of the sequence of SEQ ID NO:22, and X1 is G.
[0113] E99. The isolated antibody or ALK2-binding fragment thereof of E96, wherein the light chain CDR2 comprises or consists of the sequence of SEQ ID NO:22, and X1 is Y.
[0114] E100. The isolated antibody or ALK2-binding fragment thereof of any one of E96-E99, wherein the light chain CDR2 comprises or consists of the sequence of SEQ ID NO:22, and X2 is S.
[0115] E101. The isolated antibody or ALK2-binding fragment thereof of any one of E96-E99, wherein the light chain CDR2 comprises or consists of the sequence of SEQ ID NO:22, and X2 is N.
[0116] E102. The isolated antibody or ALK2 binding fragment thereof of any one of E96-E101, wherein the light chain CDR2 comprises or consists of the sequence of SEQ ID NO: 22, and X3 is N.
[0117] E103. The isolated antibody or ALK2 binding fragment thereof of any one of E96-E101, wherein the light chain CDR2 comprises or consists of the sequence of SEQ ID NO: 22, and X3 is D.
[0118] E104. The isolated antibody or ALK2 binding fragment thereof of any one of E96-E101, wherein the light chain CDR2 comprises or consists of the sequence of SEQ ID NO:22, and X3 is K.
[0119] E105. The isolated antibody or ALK2-binding fragment thereof of E1, wherein the light chain CDR2 comprises or consists of the following sequence: LVIYRDSX1RPS (SEQ ID NO: 23, wherein X1 is N or K).
[0120] E106. The isolated antibody or ALK2-binding fragment thereof of E105, wherein the light chain CDR2 comprises or consists of the sequence of SEQ ID NO:23, and X1 is N.
[0121] E107. The isolated antibody or ALK2-binding fragment thereof of E105, wherein the light chain CDR2 comprises or consists of the sequence of SEQ ID NO:23, and X1 is K.
[0122] E108. The isolated antibody or ALK2-binding fragment thereof of E108.E1, wherein the heavy chain CDR1 comprises or consists of the following sequence: GFTFSSX1AMX2 (SEQ ID NO: 29, wherein X1 is H or A, and X2 is S or H).
[0123] E109. The isolated antibody or ALK2 binding fragment thereof of E108, wherein the heavy chain CDR1 comprises or consists of the sequence SEQ ID NO:29, and X1 is H.
[0124] E110. The isolated antibody or ALK2 binding fragment thereof of E108, wherein the heavy chain CDR1 comprises or consists of the sequence of SEQ ID NO:29, and X1 is A.
[0125] E111. The isolated antibody or ALK2-binding fragment thereof of any one of E108-E110, wherein the heavy chain CDR1 comprises or consists of the sequence of SEQ ID NO:29, and X2 is S.
[0126] E112. The isolated antibody or ALK2-binding fragment thereof of any one of E108-E110, wherein the heavy chain CDR1 comprises or consists of the sequence of SEQ ID NO: 29, and X2 is H.
[0127] E113. The isolated antibody or ALK2-binding fragment thereof of E1, wherein the heavy chain CDR1 comprises or consists of the following sequence: GFTFX1SX2AMS (SEQ ID NO: 30, wherein X1 is S or N, and X2 is H or S).
[0128] E114. The isolated antibody or ALK2 binding fragment thereof of E113, wherein the heavy chain CDR1 comprises or consists of the sequence SEQ ID NO:30, and X1 is S.
[0129] E115. The isolated antibody or ALK2 binding fragment thereof of E113, wherein the heavy chain CDR1 comprises or consists of the sequence SEQ ID NO:30, and X1 is N.
[0130] E116. The isolated antibody or ALK2-binding fragment thereof of any one of E113-E115, wherein the heavy chain CDR1 comprises or consists of the sequence of SEQ ID NO: 30, and X2 is H.
[0131] E117. The isolated antibody or ALK2-binding fragment thereof of any one of E113-E115, wherein the heavy chain CDR1 comprises or consists of the sequence of SEQ ID NO: 30, and X2 is S.
[0132] An isolated antibody or ALK2-binding fragment thereof of E118.E1, wherein the light chain CDR1 comprises or consists of the following amino acid sequence: SGSSSNIGSNYVS (SEQ ID NO: 1); the light chain CDR2 comprises or consists of the following amino acid sequence: VLIYKNNHRPS (SEQ ID NO: 24); and the light chain CDR3 comprises or consists of the following amino acid sequence: ASWDHSDRFYV (SEQ ID NO: 4).
[0133] An isolated antibody or ALK2-binding fragment thereof of E119.E1, wherein the heavy chain CDR1 comprises or consists of the following amino acid sequence: GGTFSSYGVS (SEQ ID NO:31); the heavy chain CDR2 comprises or consists of the following amino acid sequence: WMGGIIPHFGIANYAQKFQG (SEQ ID NO:36); and the heavy chain CDR3 comprises or consists of the following amino acid sequence: EIGSLDI (SEQ ID NO:13).
[0134] E120.E1 is an isolated antibody or ALK2 binding fragment thereof, wherein the light chain CDR1 comprises or consists of the following amino acid sequence: SGSSSNIGSNYVS (SEQ ID NO: 1); the light chain CDR2 comprises or consists of the following amino acid sequence: VLIYKNNHRPS (SEQ ID NO: 24); the light chain CDR3 comprises or consists of the following amino acid sequence: ASWDHSDRFYV (SEQ ID NO: 4); the heavy chain CDR1 comprises or consists of the following amino acid sequence: GGTFSSYGVS (SEQ ID NO: 31); the heavy chain CDR2 comprises or consists of the following amino acid sequence: WMGGIIPHFGIANYAQKFQG (SEQ ID NO: 36); and the heavy chain CDR3 comprises or consists of the following amino acid sequence: EIGSLDI (SEQ ID NO: 13).
[0135] E121.E1 is an isolated antibody or ALK2 binding fragment thereof, wherein the light chain CDR1 consists of the following amino acid sequence: SGSSSNIGSNYVS (SEQ ID NO: 1); the light chain CDR2 consists of the following amino acid sequence: VLIYKNNHRPS (SEQ ID NO: 24); the light chain CDR3 consists of the following amino acid sequence: ASWDHSDRFYV (SEQ ID NO: 4); the heavy chain CDR1 consists of the following amino acid sequence: GGTFSSYGVS (SEQ ID NO: 31); the heavy chain CDR2 consists of the following amino acid sequence: WMGGIIPHFGIANYAQKFQG (SEQ ID NO: 36); and the heavy chain CDR3 consists of the following amino acid sequence: EIGSLDI (SEQ ID NO: 13).
[0136] An isolated antibody or ALK2-binding fragment thereof of E122.E1, wherein the light chain CDR1 comprises or consists of the following amino acid sequence: SGDSIPSFFAS (SEQ ID NO: 18); the light chain CDR2 comprises or consists of the following amino acid sequence: LVIYRDSNRPS (SEQ ID NO: 25); and the light chain CDR3 comprises or consists of the following amino acid sequence: YVTAPWKSIW (SEQ ID NO: 5).
[0137] An isolated antibody or ALK2-binding fragment thereof of E123.E1, wherein the heavy chain CDR1 comprises or consists of the following amino acid sequence: GFTFSSHAMS (SEQ ID NO:32); the heavy chain CDR2 comprises or consists of the following amino acid sequence: WVGRIKSKADSGTTDYAAPVKG (SEQ ID NO:37); and the heavy chain CDR3 comprises or consists of the following amino acid sequence: DYGVAFAY (SEQ ID NO:14).
[0138] E124.E1 is an isolated antibody or ALK2 binding fragment thereof, wherein the light chain CDR1 comprises or consists of the following amino acid sequence: SGDSIPSFFAS (SEQ ID NO: 18); the light chain CDR2 comprises or consists of the following amino acid sequence: LVIYRDSNRPS (SEQ ID NO: 25); the light chain CDR3 comprises or consists of the following amino acid sequence: YVTAPWKSIW (SEQ ID NO: 5); the heavy chain CDR1 comprises or consists of the following amino acid sequence: GFTFSSHAMS (SEQ ID NO: 32); the heavy chain CDR2 comprises or consists of the following amino acid sequence: WVGRIKSKADSGTTDYAAPVKG (SEQ ID NO: 37); and the heavy chain CDR3 comprises or consists of the following amino acid sequence: DYGVAFAY (SEQ ID NO: 14).
[0139] E125.E1 is an isolated antibody or ALK2 binding fragment thereof, wherein the light chain CDR1 consists of the following amino acid sequence: SGDSIPSFFAS (SEQ ID NO: 18); the light chain CDR2 consists of the following amino acid sequence: LVIYRDSNRPS (SEQ ID NO: 25); the light chain CDR3 consists of the following amino acid sequence: YVTAPWKSIW (SEQ ID NO: 5); the heavy chain CDR1 consists of the following amino acid sequence: GFTFSSHAMS (SEQ ID NO: 32); the heavy chain CDR2 consists of the following amino acid sequence: WVGRIKSKADSGTTDYAAPVKG (SEQ ID NO: 37); and the heavy chain CDR3 consists of the following amino acid sequence: DYGVAFAY (SEQ ID NO: 14).
[0140] An isolated antibody or ALK2-binding fragment thereof of E126.E1, wherein the light chain CDR1 comprises or consists of the following amino acid sequence: SGDNIGTKYAY (SEQ ID NO: 19); the light chain CDR2 comprises or consists of the following amino acid sequence: LVIYGDSDRPS (SEQ ID NO: 26); and the light chain CDR3 comprises or consists of the following amino acid sequence: YSADAQQMKA (SEQ ID NO: 6).
[0141] An isolated antibody or ALK2-binding fragment thereof of E127.E1, wherein the heavy chain CDR1 comprises or consists of the following amino acid sequence: GFTFNSSAMS (SEQ ID NO:33); the heavy chain CDR2 comprises or consists of the following amino acid sequence: WVGRIKSKRDGYTTDYAAPVKG (SEQ ID NO:38); and the heavy chain CDR3 comprises or consists of the following amino acid sequence: DYGGLKFDY (SEQ ID NO:15).
[0142] An isolated antibody or ALK2 binding fragment thereof of E128.E1, wherein the light chain CDR1 comprises or consists of the following amino acid sequence: SGDNIGTKYAY (SEQ ID NO: 19); the light chain CDR2 comprises or consists of the following amino acid sequence: LVIYGDSDRPS (SEQ ID NO: 26); the light chain CDR3 comprises or consists of the following amino acid sequence: YSADAQQMKA (SEQ ID NO: 6); the heavy chain CDR1 comprises or consists of the following amino acid sequence: GFTFNSSAMS (SEQ ID NO: 33); the heavy chain CDR2 comprises or consists of the following amino acid sequence: WVGRIKSKRDGYTTDYAAPVKG (SEQ ID NO: 38); and the heavy chain CDR3 comprises or consists of the following amino acid sequence: DYGGLKFDY (SEQ ID NO: 15).
[0143] An isolated antibody or ALK2-binding fragment thereof of E129.E1, wherein the light chain CDR1 consists of the following amino acid sequence: SGDNIGTKYAY (SEQ ID NO: 19); the light chain CDR2 consists of the following amino acid sequence: LVIYGDSDRPS (SEQ ID NO: 26); the light chain CDR3 consists of the following amino acid sequence: YSADAQQMKA (SEQ ID NO: 6); the heavy chain CDR1 consists of the following amino acid sequence: GFTFNSSAMS (SEQ ID NO: 33); the heavy chain CDR2 consists of the following amino acid sequence: WVGRIKSKRDGYTTDYAAPVKG (SEQ ID NO: 38); and the heavy chain CDR3 consists of the following amino acid sequence: DYGGLKFDY (SEQ ID NO: 15).
[0144] An isolated antibody or ALK2-binding fragment thereof of E130.E1, wherein the light chain CDR1 comprises or consists of the following amino acid sequence: SGDNLRKYSAH (SEQ ID NO:20); the light chain CDR2 comprises or consists of the following amino acid sequence: LVIYYDNKRPS (SEQ ID NO:27); and the light chain CDR3 comprises or consists of the following amino acid sequence: QVYASVHRM (SEQ ID NO:7).
[0145] An isolated antibody or ALK2-binding fragment thereof of E131.E1, wherein the heavy chain CDR1 comprises or consists of the following amino acid sequence: GGTFSSYAIH (SEQ ID NO: 34); the heavy chain CDR2 comprises or consists of the following amino acid sequence: WMGRIIPDFGTANYAQKFQG (SEQ ID NO: 39); and the heavy chain CDR3 comprises or consists of the following amino acid sequence: GPTQAIHYFAY (SEQ ID NO: 16).
[0146] E132.E1 is an isolated antibody or ALK2 binding fragment thereof, wherein the light chain CDR1 comprises or consists of the following amino acid sequence: SGDNLRKYSAH (SEQ ID NO:20); the light chain CDR2 comprises or consists of the following amino acid sequence: LVIYYDNKRPS (SEQ ID NO:27); the light chain CDR3 comprises or consists of the following amino acid sequence: QVYASVHRM (SEQ ID NO:7); the heavy chain CDR1 comprises or consists of the following amino acid sequence: GGTFSSYAIH (SEQ ID NO:34); the heavy chain CDR2 comprises or consists of the following amino acid sequence: WMGRIIPDFGTANYAQKFQG (SEQ ID NO:39); and the heavy chain CDR3 comprises or consists of the following amino acid sequence: GPTQAIHYFAY (SEQ ID NO:16).
[0147] E133.E1 is an isolated antibody or ALK2 binding fragment thereof, wherein the light chain CDR1 consists of the following amino acid sequence: SGDNLRKYSAH (SEQ ID NO: 20); the light chain CDR2 consists of the following amino acid sequence: LVIYYDNKRPS (SEQ ID NO: 27); the light chain CDR3 consists of the following amino acid sequence: QVYASVHRM (SEQ ID NO: 7); the heavy chain CDR1 consists of the following amino acid sequence: GGTFSSYAIH (SEQ ID NO: 34); the heavy chain CDR2 consists of the following amino acid sequence: WMGRIIPDFGTANYAQKFQG (SEQ ID NO: 39); and the heavy chain CDR3 consists of the following amino acid sequence: GPTQAIHYFAY (SEQ ID NO: 16).
[0148] An isolated antibody or ALK2-binding fragment thereof of E134.E1, wherein the light chain CDR1 comprises or consists of the following amino acid sequence: SGDSLGSKSVH (SEQ ID NO:21); the light chain CDR2 comprises or consists of the following amino acid sequence: LVIYRDSKRPS (SEQ ID NO:28); and the light chain CDR3 comprises or consists of the following amino acid sequence: QTYDWSHFGW (SEQ ID NO:8).
[0149] An isolated antibody or ALK2-binding fragment thereof of E135.E1, wherein the heavy chain CDR1 comprises or consists of the following amino acid sequence: GFTFSSAAMH (SEQ ID NO:35); the heavy chain CDR2 comprises or consists of the following amino acid sequence: WVSVISSDGGSTYYADSVKG (SEQ ID NO:12); and the heavy chain CDR3 comprises or consists of the following amino acid sequence: AGFILGSLGVAWMDV (SEQ ID NO:17).
[0150] An isolated antibody or ALK2 binding fragment thereof of E136.E1, wherein the light chain CDR1 comprises or consists of the following amino acid sequence: SGDSLGSKSVH (SEQ ID NO:21); the light chain CDR2 comprises or consists of the following amino acid sequence: LVIYRDSKRPS (SEQ ID NO:28); the light chain CDR3 comprises or consists of the following amino acid sequence: QTYDWSHFGW (SEQ ID NO:8); the heavy chain CDR1 comprises or consists of the following amino acid sequence: GFTFSSAAMH (SEQ ID NO:35); the heavy chain CDR2 comprises or consists of the following amino acid sequence: WVSVISSDGGSTYYADSVKG (SEQ ID NO:12); and the heavy chain CDR3 comprises or consists of the following amino acid sequence: AGFILGSLGVAWMDV (SEQID NO:17).
[0151] An isolated antibody or ALK2-binding fragment thereof of E137.E1, wherein the light chain CDR1 consists of the following amino acid sequence: SGDSLGSKSVH (SEQ ID NO:21); the light chain CDR2 consists of the following amino acid sequence: LVIYRDSKRPS (SEQ ID NO:28); the light chain CDR3 consists of the following amino acid sequence: QTYDWSHFGW (SEQ ID NO:8); the heavy chain CDR1 consists of the following amino acid sequence: GFTFSSAAMH (SEQ ID NO:35); the heavy chain CDR2 consists of the following amino acid sequence: WVSVISSDGGSTYYADSVKG (SEQ ID NO:12); and the heavy chain CDR3 consists of the following amino acid sequence: AGFILGSLGVAWMDV (SEQ ID NO:17).
[0152] An isolated antibody or ALK2 binding fragment thereof of E138.E1, wherein, excluding light chain CDR1, CDR2 and CDR3 and heavy chain CDR1, CDR2 and CDR3, the antibody has at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) sequence identity with amino acids 1 to 331 of the sequence of SEQ ID NO:67, or has at least 95% sequence identity with amino acids 1 to 331 of the sequence of SEQ ID NO:67, or has at least 98% sequence identity with amino acids 1 to 331 of the sequence of SEQ ID NO:67.
[0153] An isolated antibody or ALK2 binding fragment thereof of E139.E1, wherein, excluding light chain CDR1, CDR2 and CDR3 and heavy chain CDR1, CDR2 and CDR3, the antibody has at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) sequence identity with amino acids 1 to 332 of the sequence of SEQ ID NO:68, or has at least 95% sequence identity with amino acids 1 to 332 of the sequence of SEQ ID NO:68, or has at least 98% sequence identity with amino acids 1 to 332 of the sequence of SEQ ID NO:68.
[0154] An isolated antibody or ALK2 binding fragment thereof of E140.E1, wherein, excluding light chain CDR1, CDR2 and CDR3 and heavy chain CDR1, CDR2 and CDR3, the antibody has at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) sequence identity with amino acids 1 to 333 of the sequence of SEQ ID NO:69, or has at least 95% sequence identity with amino acids 1 to 333 of the sequence of SEQ ID NO:69, or has at least 98% sequence identity with amino acids 1 to 333 of the sequence of SEQ ID NO:69.
[0155] An isolated antibody or ALK2 binding fragment thereof of E141.E1, wherein, excluding light chain CDR1, CDR2 and CDR3 and heavy chain CDR1, CDR2 and CDR3, the antibody has at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) sequence identity with amino acids 1 to 332 of the sequence of SEQ ID NO:70, or has at least 95% sequence identity with amino acids 1 to 332 of the sequence of SEQ ID NO:70, or has at least 98% sequence identity with amino acids 1 to 332 of the sequence of SEQ ID NO:70.
[0156] An isolated antibody or ALK2 binding fragment thereof of E142.E1, wherein, excluding light chain CDR1, CDR2 and CDR3 and heavy chain CDR1, CDR2 and CDR3, the antibody has at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) sequence identity with amino acids 1 to 337 of the sequence of SEQ ID NO:71, or has at least 95% sequence identity with amino acids 1 to 337 of the sequence of SEQ ID NO:71, or has at least 98% sequence identity with amino acids 1 to 337 of the sequence of SEQ ID NO:71.
[0157] E143. The isolated antibody or ALK2-binding fragment thereof of E1, wherein the antibody comprises or consists of amino acids 1 to 433 of the sequence of SEQ ID NO:67.
[0158] E144. The isolated antibody or ALK2-binding fragment thereof of E1, wherein the antibody comprises or consists of amino acids 1 to 434 of the sequence of SEQ ID NO:68.
[0159] E145. The isolated antibody or ALK2-binding fragment thereof of E1, wherein the antibody comprises or consists of amino acids 1 to 435 of the sequence of SEQ ID NO:69.
[0160] E146. The isolated antibody or ALK2-binding fragment thereof of E1, wherein the antibody comprises or consists of amino acids 1 to 434 of the sequence of SEQ ID NO:70.
[0161] E147. The isolated antibody or ALK2-binding fragment thereof of E1, wherein the antibody comprises or consists of amino acids 1 to 439 of the sequence of SEQ ID NO:71.
[0162] E148. An isolated antibody or ALK2 binding fragment thereof, comprising: (1) a light chain variable domain, comprising: a light chain complementary determining region (CDR) 1, comprising or consisting of an amino acid sequence selected from the group consisting of RASQGISGNWLT (SEQ ID NO: 40), SGDX1X2RX3X4X5X6H (SEQ ID NO: 64, wherein X1 is N or A, X2 is I or L, X3 is K or Y, X4 is K or Y, X5 is Y or I, and X6 is V or A) and SGSSSNIGQNYVS (SEQ ID NO: 58); a light chain CDR2, comprising or consisting of an amino acid sequence selected from the group consisting of LX1IYX2X3X4X5X6X7S (SEQ ID NO:65, wherein X1 is V or L, X2 is D, R or Y, X3 is A, D or N, X4 is S or N, X5 is K or N, X6 is L or R, and X7 is Q or P); and a light chain CDR3 comprising or consisting of an amino acid sequence selected from the group consisting of: HQSYRGPM (SEQ ID NO:42), SSAGRDNY (SEQ ID NO:48), QSYGPGSV (SEQ ID NO:54), and SSWDLLSKSR (SEQ ID NO:60); and (2) a heavy chain variable domain comprising: a heavy chain CDR1 comprising or consisting of the amino acid sequence: GX1TFX2X3X4X5X6X7 (SEQ ID NO:66, wherein X1 is F or G, X2 is G or S, X3 is R, S, D or T, X4 is F, S, Y or H, X5 is V or A, and X6 is M or I, and X7 is H or S); a heavy chain CDR2 comprising or consisting of an amino acid sequence selected from the group consisting of WVSX1IX2YX3X4SX5TYYADSVKG (SEQ ID NO:76, wherein X1 is V or S, X2 is G, H or F, X3 is S or D, X4 is G or S, and X5 is S, E or N) and WMGLIQPRFGTANYAQKFQR (SEQ ID NO:62); and a heavy chain CDR3 comprising or consisting of an amino acid sequence selected from the group consisting of EPGYYYPSGYYRGPGYWMDV (SEQ ID NO:45), DRYFFDV (SEQ ID NO:51), PKSYASGPFAY (SEQ ID NO:52). NO:57) and DYYGGMAY (SEQ ID NO:63).
[0163] E149. The isolated antibody or ALK2 binding fragment thereof of E148, wherein the light chain CDR1 comprises or consists of the sequence of SEQ ID NO:64, and X1 is N.
[0164] E150. The isolated antibody or ALK2 binding fragment thereof of E148, wherein the light chain CDR1 comprises or consists of the sequence of SEQ ID NO:64, and X1 is A.
[0165] E151. The isolated antibody or ALK2 binding fragment thereof of any one of E148-E150, wherein the light chain CDR1 comprises or consists of the sequence of SEQ ID NO:64, and X2 is 1.
[0166] E152. The isolated antibody or ALK2-binding fragment thereof of any one of E148-E150, wherein the light chain CDR1 comprises or consists of the sequence of SEQ ID NO:64, and X2 is L.
[0167] E153. The isolated antibody or ALK2-binding fragment thereof of any one of E148-E152, wherein the light chain CDR1 comprises or consists of the sequence of SEQ ID NO:64, and X3 is K.
[0168] E154. The isolated antibody or ALK2 binding fragment thereof of any one of E148-E152, wherein the light chain CDR1 comprises or consists of the sequence of SEQ ID NO:64, and X3 is Y.
[0169] E155. The isolated antibody or ALK2 binding fragment thereof of any one of E148-E154, wherein the light chain CDR1 comprises or consists of the sequence of SEQ ID NO:64, and X4 is K.
[0170] E156. The isolated antibody or ALK2 binding fragment thereof of any one of E148-E154, wherein the light chain CDR1 comprises or consists of the sequence of SEQ ID NO:64, and X4 is Y.
[0171] E157. The isolated antibody or ALK2 binding fragment thereof of any one of E148-E156, wherein the light chain CDR1 comprises or consists of the sequence of SEQ ID NO:64, and X5 is Y.
[0172] E158. An isolated antibody or ALK2 binding fragment thereof of any one of E148-E156, wherein the light chain CDR1 comprises or consists of the sequence of SEQ ID NO:64, and X5 is I.
[0173] E159. The isolated antibody or ALK2-binding fragment thereof of any one of E148-E158, wherein the light chain CDR1 comprises or consists of the sequence of SEQ ID NO: 64, and X6 is V.
[0174] E160. The isolated antibody or ALK2 binding fragment thereof of any one of E148-E158, wherein the light chain CDR1 comprises or consists of the sequence of SEQ ID NO:64, and X6 is A.
[0175] E161. The isolated antibody or ALK2-binding fragment thereof of any one of E148-E160, wherein the light chain CDR2 comprises or consists of the sequence of SEQ ID NO:65, and X1 is V.
[0176] E162. The isolated antibody or ALK2-binding fragment thereof of any one of E148-E160, wherein the light chain CDR2 comprises or consists of the sequence of SEQ ID NO:65, and X1 is L.
[0177] E163. The isolated antibody or ALK2 binding fragment thereof of any one of E148-E162, wherein the light chain CDR2 comprises or consists of the sequence of SEQ ID NO:65, and X2 is D.
[0178] E164. The isolated antibody or ALK2 binding fragment thereof of any one of E148-E162, wherein the light chain CDR2 comprises or consists of the sequence of SEQ ID NO:65, and X2 is R.
[0179] E165. The isolated antibody or ALK2 binding fragment thereof of any one of E148-E162, wherein the light chain CDR2 comprises or consists of the sequence of SEQ ID NO:65, and X2 is Y.
[0180] E166. The isolated antibody or ALK2 binding fragment thereof of any one of E148-E165, wherein the light chain CDR2 comprises or consists of the sequence of SEQ ID NO:65, and X3 is A.
[0181] E167. The isolated antibody or ALK2 binding fragment thereof of any one of E148-E165, wherein the light chain CDR2 comprises or consists of the sequence of SEQ ID NO:65, and X3 is D.
[0182] E168. The isolated antibody or ALK2 binding fragment thereof of any one of E148-E165, wherein the light chain CDR2 comprises or consists of the sequence of SEQ ID NO:65, and X3 is N.
[0183] E169. The isolated antibody or ALK2 binding fragment thereof of any one of E148-E168, wherein the light chain CDR2 comprises or consists of the sequence of SEQ ID NO:65, and X4 is S.
[0184] E170. The isolated antibody or ALK2 binding fragment thereof of any one of E148-E168, wherein the light chain CDR2 comprises or consists of the sequence of SEQ ID NO:65, and X4 is N.
[0185] E171. The isolated antibody or ALK2 binding fragment thereof of any one of E148-E170, wherein the light chain CDR2 comprises or consists of the sequence of SEQ ID NO:65, and X5 is K.
[0186] E172. The isolated antibody or ALK2 binding fragment thereof of any one of E148-E170, wherein the light chain CDR2 comprises or consists of the sequence of SEQ ID NO:65, and X5 is N.
[0187] E173. The isolated antibody or ALK2 binding fragment thereof of any one of E148-E172, wherein the light chain CDR2 comprises or consists of the sequence of SEQ ID NO:65, and X6 is L.
[0188] E174. The isolated antibody or ALK2 binding fragment thereof of any one of E148-E172, wherein the light chain CDR2 comprises or consists of the sequence of SEQ ID NO:65, and X6 is R.
[0189] E175. The isolated antibody or ALK2 binding fragment thereof of any one of E148-E174, wherein the light chain CDR2 comprises or consists of the sequence of SEQ ID NO:65, and X7 is Q.
[0190] E176. The isolated antibody or ALK2 binding fragment thereof of any one of E148-E174, wherein the light chain CDR2 comprises or consists of the sequence of SEQ ID NO:65, and X7 is P.
[0191] E177. The isolated antibody or ALK2-binding fragment thereof of any one of E148-E176, wherein the heavy chain CDR1 comprises or consists of the sequence of SEQ ID NO:66, and X1 is F.
[0192] E178. The isolated antibody or ALK2-binding fragment thereof of any one of E148-E176, wherein the heavy chain CDR1 comprises or consists of the sequence of SEQ ID NO:66, and X1 is G.
[0193] E179. The isolated antibody or ALK2-binding fragment thereof of any one of E148-E178, wherein the heavy chain CDR1 comprises or consists of the sequence of SEQ ID NO: 66, and X2 is G.
[0194] E180. The isolated antibody or ALK2-binding fragment thereof of any one of E148-E178, wherein the heavy chain CDR1 comprises or consists of the sequence of SEQ ID NO:66, and X2 is S.
[0195] E181. The isolated antibody or ALK2-binding fragment thereof of any one of E148-E180, wherein the heavy chain CDR1 comprises or consists of the sequence of SEQ ID NO:66, and X3 is R.
[0196] E182. The isolated antibody or ALK2-binding fragment thereof of any one of E148-E180, wherein the heavy chain CDR1 comprises or consists of the sequence of SEQ ID NO:66, and X3 is S.
[0197] E183. The isolated antibody or ALK2 binding fragment thereof of any one of E148-E180, wherein the heavy chain CDR1 comprises or consists of the sequence of SEQ ID NO:66, and X3 is D.
[0198] E184. The isolated antibody or ALK2-binding fragment thereof of any one of E148-E180, wherein the heavy chain CDR1 comprises or consists of the sequence of SEQ ID NO:66, and X3 is T.
[0199] E185. The isolated antibody or ALK2 binding fragment thereof of any one of E148-E184, wherein the heavy chain CDR1 comprises or consists of the sequence of SEQ ID NO:66, and X4 is F.
[0200] E186. The isolated antibody or ALK2 binding fragment thereof of any one of E148-E184, wherein the heavy chain CDR1 comprises or consists of the sequence of SEQ ID NO:66, and X4 is S.
[0201] E187. The isolated antibody or ALK2 binding fragment thereof of any one of E148-E184, wherein the heavy chain CDR1 comprises or consists of the sequence of SEQ ID NO:66, and X4 is Y.
[0202] E188. The isolated antibody or ALK2 binding fragment thereof of any one of E148-E184, wherein the heavy chain CDR1 comprises or consists of the sequence of SEQ ID NO:66, and X4 is H.
[0203] E189. The isolated antibody or ALK2 binding fragment thereof of any one of E148-E188, wherein the heavy chain CDR1 comprises or consists of the sequence of SEQ ID NO: 66, and X5 is V.
[0204] E190. The isolated antibody or ALK2 binding fragment thereof of any one of E148-E188, wherein the heavy chain CDR1 comprises or consists of the sequence of SEQ ID NO:66, and X5 is V or A.
[0205] E191. The isolated antibody or ALK2 binding fragment thereof of any one of E148-E190, wherein the heavy chain CDR1 comprises or consists of the sequence of SEQ ID NO:66, and X6 is M.
[0206] E192. The isolated antibody or ALK2 binding fragment thereof of any one of E148-E190, wherein the heavy chain CDR1 comprises or consists of the sequence of SEQ ID NO:66, and X6 is I.
[0207] E193. The isolated antibody or ALK2 binding fragment thereof of any one of E148-E192, wherein the heavy chain CDR1 comprises or consists of the sequence of SEQ ID NO:66, and X7 is H.
[0208] E194. The isolated antibody or ALK2 binding fragment thereof of any one of E148-E192, wherein the heavy chain CDR1 comprises or consists of the sequence of SEQ ID NO:66, and X7 is S.
[0209] E195. The isolated antibody or ALK2-binding fragment thereof of any one of E148-E194, wherein the heavy chain CDR2 comprises or consists of the sequence of SEQ ID NO: 76, and X1 is V.
[0210] E196. The isolated antibody or ALK2 binding fragment thereof of any one of E148-E194, wherein the heavy chain CDR2 comprises or consists of the sequence of SEQ ID NO:76, and X1 is S.
[0211] E197. The isolated antibody or ALK2-binding fragment thereof of any one of E148-E196, wherein the heavy chain CDR2 comprises or consists of the sequence of SEQ ID NO: 76, and X2 is G.
[0212] E198. The isolated antibody or ALK2 binding fragment thereof of any one of E148-E196, wherein the heavy chain CDR2 comprises or consists of the sequence of SEQ ID NO:76, and X2 is H.
[0213] E199. The isolated antibody or ALK2-binding fragment thereof of any one of E148-E196, wherein the heavy chain CDR2 comprises or consists of the sequence of SEQ ID NO: 76, and X2 is F.
[0214] E200. The isolated antibody or ALK2-binding fragment thereof of any one of E148-E199, wherein the heavy chain CDR2 comprises or consists of the sequence of SEQ ID NO: 76, and X3 is S.
[0215] E201. The isolated antibody or ALK2 binding fragment thereof of any one of E148-E199, wherein the heavy chain CDR2 comprises or consists of the sequence of SEQ ID NO:76, and X3 is D.
[0216] E202. The isolated antibody or ALK2-binding fragment thereof of any one of E148-E201, wherein the heavy chain CDR2 comprises or consists of the sequence of SEQ ID NO: 76, and X4 is G.
[0217] E203. The isolated antibody or ALK2 binding fragment thereof of any one of E148-E201, wherein the heavy chain CDR2 comprises or consists of the sequence of SEQ ID NO:76, and X4 is S.
[0218] E204. The isolated antibody or ALK2-binding fragment thereof of any one of E148-E203, wherein the heavy chain CDR2 comprises or consists of the sequence of SEQ ID NO:76, and X5 is S.
[0219] E205. The isolated antibody or ALK2 binding fragment thereof of any one of E148-E203, wherein the heavy chain CDR2 comprises or consists of the sequence of SEQ ID NO:76, and X5 is E.
[0220] E206. The isolated antibody or ALK2 binding fragment thereof of any one of E148-E203, wherein the heavy chain CDR2 comprises or consists of the sequence of SEQ ID NO: 76, and X5 is N.
[0221] The isolated antibody or ALK2-binding fragment thereof of E207.E148, wherein the light chain CDR1 comprises or consists of the following sequence: RASQGISGNWLT (SEQ ID NO: 40).
[0222] E208. The isolated antibody or ALK2-binding fragment thereof of E148, wherein the light chain CDR1 comprises or consists of the following sequence: SGDNIRKKYVH (SEQ ID NO: 46).
[0223] E209. The isolated antibody or ALK2-binding fragment thereof of E148, wherein the light chain CDR1 comprises or consists of the following sequence: SGDALRYYIAH (SEQ ID NO: 52).
[0224] E210. The isolated antibody or ALK2-binding fragment thereof of E148, wherein the light chain CDR1 comprises or consists of the following sequence: SGSSSNIGQNYVS (SEQ ID NO: 58).
[0225] E211. The isolated antibody or ALK2-binding fragment thereof of any one of E148 and E207-E210, wherein the light chain CDR2 comprises or consists of the following sequence: LLIYDASNLQS (SEQ ID NO: 41).
[0226] E212. The isolated antibody or ALK2-binding fragment thereof of any one of E148 and E207-E210, wherein the light chain CDR2 comprises or consists of the following sequence: LVIYRDSNRPS (SEQ ID NO: 47).
[0227] E213. The isolated antibody or ALK2-binding fragment thereof of any one of E148 and E207-E210, wherein the light chain CDR2 comprises or consists of the following sequence: LVIYYNNNRPS (SEQ ID NO: 53).
[0228] E214. The isolated antibody or ALK2-binding fragment thereof of any one of E148 and E207-E210, wherein the light chain CDR2 comprises or consists of the following sequence: LLIYDNSKRPS (SEQ ID NO: 59).
[0229] E215. The isolated antibody or ALK2-binding fragment thereof of any one of E148 and E207-E214, wherein the light chain CDR3 comprises or consists of the following sequence: HQSYRGPM (SEQ ID NO: 42).
[0230] E216. The isolated antibody or ALK2 binding fragment thereof of any one of E148 and E207-E214, wherein the light chain CDR3 comprises or consists of the following sequence: SSAGRDNY (SEQ ID NO: 48).
[0231] E217. The isolated antibody or ALK2-binding fragment thereof of any one of E148 and E207-E214, wherein the light chain CDR3 comprises or consists of the following sequence: QSYGPGSV (SEQ ID NO: 54).
[0232] E218. The isolated antibody or ALK2-binding fragment thereof of any one of E148 and E207-E214, wherein the light chain CDR3 comprises or consists of the following sequence: SSWDLLSKSR (SEQ ID NO: 60).
[0233] E219. The isolated antibody or ALK2-binding fragment thereof of any one of E148 and E207-E218, wherein the heavy chain CDR1 comprises or consists of the following sequence: GFTFGRFVMH (SEQ ID NO: 43).
[0234] E220. The isolated antibody or ALK2-binding fragment thereof of any one of E148 and E207-E218, wherein the heavy chain CDR1 comprises or consists of the following sequence: GFTFSSSAMH (SEQ ID NO: 49).
[0235] E221. The isolated antibody or ALK2-binding fragment thereof of any one of E148 and E207-E218, wherein the heavy chain CDR1 comprises or consists of the following sequence: GFTFSDYAMH (SEQ ID NO: 55).
[0236] E222. The isolated antibody or ALK2-binding fragment thereof of any one of E148 and E207-E218, wherein the heavy chain CDR1 comprises or consists of the following sequence: GGTFSTHAIS (SEQ ID NO: 61).
[0237] E223. The isolated antibody or ALK2-binding fragment thereof of any one of E148 and E207-E222, wherein the heavy chain CDR2 comprises or consists of the following sequence: WVSVIGYSGSSTYYADSVKG (SEQ ID NO: 44).
[0238] E224. The isolated antibody or ALK2-binding fragment thereof of any one of E148 and E207-E222, wherein the heavy chain CDR2 comprises or consists of the following sequence: WVSVIHYDSSETYYADSVKG (SEQ ID NO: 50).
[0239] E225. The isolated antibody or ALK2-binding fragment thereof of any one of E148 and E207-E222, wherein the heavy chain CDR2 comprises or consists of the following sequence: WVSSIFYSGSNTYYADSVKG (SEQ ID NO: 56).
[0240] E226. The isolated antibody or ALK2-binding fragment thereof of any one of E148 and E207-E222, wherein the heavy chain CDR2 comprises or consists of the following sequence: WMGLIQPRFGTANYAQKFQR (SEQ ID NO: 62).
[0241] E227. The isolated antibody or ALK2-binding fragment thereof of any one of E148 and E207-E226, wherein the heavy chain CDR3 comprises or consists of the following sequence: EPGYYYPSGYYRGPGYWMDV (SEQ ID NO: 45).
[0242] E228. The isolated antibody or ALK2-binding fragment thereof of any one of E148 and E207-E226, wherein the heavy chain CDR3 comprises or consists of the following sequence: DRYFFDV (SEQ ID NO: 51).
[0243] E229. The isolated antibody or ALK2-binding fragment thereof of any one of E148 and E207-E226, wherein the heavy chain CDR3 comprises or consists of the following sequence: PKSYASGPFAY (SEQ ID NO: 57).
[0244] E230. The isolated antibody or ALK2-binding fragment thereof of any one of E148 and E207-E226, wherein the heavy chain CDR3 comprises or consists of the following sequence: DYYGGMAY (SEQ ID NO: 63).
[0245] An isolated antibody or ALK2-binding fragment thereof of E231.E148, wherein the light chain CDR1 comprises or consists of the following amino acid sequence: RASQGISGNWLT (SEQ ID NO:40); the light chain CDR2 comprises or consists of the following amino acid sequence: LLIYDASNLQS (SEQ ID NO:41); and the light chain CDR3 comprises or consists of the following amino acid sequence: HQSYRGPM (SEQ ID NO:42).
[0246] An isolated antibody or ALK2-binding fragment thereof of E232.E148, wherein the heavy chain CDR1 comprises or consists of the following amino acid sequence: GFTFGRFVMH (SEQ ID NO:43); the heavy chain CDR2 comprises or consists of the following amino acid sequence: WVSVIGYSGSSTYYADSVKG (SEQ ID NO:44); and the heavy chain CDR3 comprises or consists of the following amino acid sequence: EPGYYYPSGYYRGPGYWMDV (SEQ ID NO:45).
[0247] An isolated antibody or ALK2 binding fragment thereof of E233.E148, wherein the light chain CDR1 comprises or consists of the following amino acid sequence: RASQGISGNWLT (SEQ ID NO:40); the light chain CDR2 comprises or consists of the following amino acid sequence: LLIYDASNLQS (SEQ ID NO:41); the light chain CDR3 comprises or consists of the following amino acid sequence: HQSYRGPM (SEQ ID NO:42); the heavy chain CDR1 comprises or consists of the following amino acid sequence: GFTFGRFVMH (SEQ ID NO:43); the heavy chain CDR2 comprises or consists of the following amino acid sequence: WVSVIGYSGSSTYYADSVKG (SEQ ID NO:44); and the heavy chain CDR3 comprises or consists of the following amino acid sequence: EPGYYYPSGYYRGPGYWMDV (SEQ ID NO:45).
[0248] The isolated antibody or ALK2 binding fragment thereof of E234.E148, wherein the light chain CDR1 consists of the following amino acid sequence: RASQGISGNWLT (SEQ ID NO:40); the light chain CDR2 consists of the following amino acid sequence: LLIYDASNLQS (SEQ ID NO:41); the light chain CDR3 consists of the following amino acid sequence: HQSYRGPM (SEQ ID NO:42); the heavy chain CDR1 consists of the following amino acid sequence: GFTFGRFVMH (SEQ ID NO:43); the heavy chain CDR2 consists of the following amino acid sequence: WVSVIGYSGSSTYYADSVKG (SEQ ID NO:44); and the heavy chain CDR3 consists of the following amino acid sequence: EPGYYYPSGYYRGPGYWMDV (SEQ ID NO:45).
[0249] An isolated antibody or ALK2-binding fragment thereof of E235.E148, wherein the light chain CDR1 comprises or consists of the following amino acid sequence: SGDNIRKKYVH (SEQ ID NO:46); the light chain CDR2 comprises or consists of the following amino acid sequence: LVIYRDSNRPS (SEQ ID NO:47); and the light chain CDR3 comprises or consists of the following amino acid sequence: SSAGRDNY (SEQ ID NO:48).
[0250] An isolated antibody or ALK2-binding fragment thereof of E236.E148, wherein the heavy chain CDR1 comprises or consists of the following amino acid sequence: GFTFSSSAMH (SEQ ID NO:49); the heavy chain CDR2 comprises or consists of the following amino acid sequence: WVSVIHYDSSETYYADSVKG (SEQ ID NO:50); and the heavy chain CDR3 comprises or consists of the following amino acid sequence: DRYFFDV (SEQ ID NO:51).
[0251] The isolated antibody or ALK2 binding fragment thereof of E237.E148, wherein the light chain CDR1 comprises or consists of the following amino acid sequence: SGDNIRKKYVH (SEQ ID NO:46); the light chain CDR2 comprises or consists of the following amino acid sequence: LVIYRDSNRPS (SEQ ID NO:47); the light chain CDR3 comprises or consists of the following amino acid sequence: SSAGRDNY (SEQ ID NO:48); the heavy chain CDR1 comprises or consists of the following amino acid sequence: GFTFSSSAMH (SEQ ID NO:49); the heavy chain CDR2 comprises or consists of the following amino acid sequence: WVSVIHYDSSETYYADSVKG (SEQ ID NO:50); and the heavy chain CDR3 comprises or consists of the following amino acid sequence: DRYFFDV (SEQ ID NO:51).
[0252] The isolated antibody or ALK2 binding fragment thereof of E238.E148, wherein the light chain CDR1 consists of the following amino acid sequence: SGDNIRKKYVH (SEQ ID NO:46); the light chain CDR2 consists of the following amino acid sequence: LVIYRDSNRPS (SEQ ID NO:47); the light chain CDR3 consists of the following amino acid sequence: SSAGRDNY (SEQ ID NO:48); the heavy chain CDR1 consists of the following amino acid sequence: GFTFSSSAMH (SEQ ID NO:49); the heavy chain CDR2 consists of the following amino acid sequence: WVSVIHYDSSETYYADSVKG (SEQ ID NO:50); and the heavy chain CDR3 consists of the following amino acid sequence: DRYFFDV (SEQ ID NO:51).
[0253] An isolated antibody or ALK2-binding fragment thereof of E239.E148, wherein the light chain CDR1 comprises or consists of the following amino acid sequence: SGDALRYYIAH (SEQ ID NO:52); the light chain CDR2 comprises or consists of the following amino acid sequence: LVIYYNNNRPS (SEQ ID NO:53); and the light chain CDR3 comprises or consists of the following amino acid sequence: QSYGPGSV (SEQ ID NO:54).
[0254] An isolated antibody or ALK2-binding fragment thereof of E240.E148, wherein the heavy chain CDR1 comprises or consists of the following amino acid sequence: GFTFSDYAMH (SEQ ID NO:55); the heavy chain CDR2 comprises or consists of the following amino acid sequence: WVSSIFYSGSNTYYADSVKG (SEQ ID NO:56); and the heavy chain CDR3 comprises or consists of the following amino acid sequence: PKSYASGPFAY (SEQ ID NO:57).
[0255] The isolated antibody or ALK2 binding fragment thereof of E241.E148, wherein the light chain CDR1 comprises or consists of the following amino acid sequence: SGDALRYYIAH (SEQ ID NO:52); the light chain CDR2 comprises or consists of the following amino acid sequence: LVIYYNNNRPS (SEQ ID NO:53); the light chain CDR3 comprises or consists of the following amino acid sequence: QSYGPGSV (SEQ ID NO:54); the heavy chain CDR1 comprises or consists of the following amino acid sequence: GFTFSDYAMH (SEQ ID NO:55); the heavy chain CDR2 comprises or consists of the following amino acid sequence: WVSSIFYSGSNTYYADSVKG (SEQ ID NO:56); and the heavy chain CDR3 comprises or consists of the following amino acid sequence: PKSYASGPFAY (SEQ ID NO:57).
[0256] E242.E148 isolated antibody or ALK2 binding fragment thereof, wherein the light chain CDR1 consists of the following amino acid sequence: SGDALRYYIAH (SEQ ID NO: 52); the light chain CDR2 consists of the following amino acid sequence: LVIYYNNNRPS (SEQ ID NO: 53); the light chain CDR3 consists of the following amino acid sequence: QSYGPGSV (SEQ ID NO: 54); the heavy chain CDR1 consists of the following amino acid sequence: GFTFSDYAMH (SEQ ID NO: 55); the heavy chain CDR2 consists of the following amino acid sequence: WVSSIFYSGSNTYYADSVKG (SEQ ID NO: 56); and the heavy chain CDR3 consists of the following amino acid sequence: PKSYASGPFAY (SEQ ID NO: 57).
[0257] An isolated antibody or ALK2-binding fragment thereof of E243.E148, wherein the light chain CDR1 comprises or consists of the following amino acid sequence: SGSSSNIGQNYVS (SEQ ID NO:58); the light chain CDR2 comprises or consists of the following amino acid sequence: LLIYDNSKRPS (SEQ ID NO:59); and the light chain CDR3 comprises or consists of the following amino acid sequence: SSWDLLSKSR (SEQ ID NO:60).
[0258] An isolated antibody or ALK2-binding fragment thereof of E244.E148, wherein the heavy chain CDR1 comprises or consists of the following amino acid sequence: GGTFSTHAIS (SEQ ID NO:61); the heavy chain CDR2 comprises or consists of the following amino acid sequence: WMGLIQPRFGTANYAQKFQR (SEQ ID NO:62); and the heavy chain CDR3 comprises or consists of the following amino acid sequence: DYYGGMAY (SEQ ID NO:63).
[0259] E245.E148 or an isolated antibody or ALK2 binding fragment thereof, wherein the light chain CDR1 comprises or consists of the following amino acid sequence: SGSSSNIGQNYVS (SEQ ID NO: 58); the light chain CDR2 comprises or consists of the following amino acid sequence: LLIYDNSKRPS (SEQ ID NO: 59); the light chain CDR3 comprises or consists of the following amino acid sequence: SSWDLLSKSR (SEQ ID NO: 60); the heavy chain CDR1 comprises or consists of the following amino acid sequence: GGTFSTHAIS (SEQ ID NO: 61); the heavy chain CDR2 comprises or consists of the following amino acid sequence: WMGLIQPRFGTANYAQKFQR (SEQ ID NO: 62); and the heavy chain CDR3 comprises or consists of the following amino acid sequence: DYYGGMAY (SEQ ID NO: 63).
[0260] E246.E148's isolated antibody or ALK2-binding fragment thereof, wherein the light chain CDR1 consists of the following amino acid sequence: SGSSSNIGQNYVS (SEQ ID NO: 58); the light chain CDR2 consists of the following amino acid sequence: LLIYDNSKRPS (SEQ ID NO: 59); the light chain CDR3 consists of the following amino acid sequence: SSWDLLSKSR (SEQ ID NO: 60); the heavy chain CDR1 consists of the following amino acid sequence: GGTFSTHAIS (SEQ ID NO: 61); the heavy chain CDR2 consists of the following amino acid sequence: WMGLIQPRFGTANYAQKFQR (SEQ ID NO: 62); and the heavy chain CDR3 consists of the following amino acid sequence: DYYGGMAY (SEQ ID NO: 63).
[0261] An isolated antibody or ALK2 binding fragment thereof of E247.E148, wherein, except for the light chain CDR1, CDR2 and CDR3 and the heavy chain CDR1, CDR2 and CDR3, the antibody has at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) sequence identity with amino acids 1 to 344 of the sequence of SEQ ID NO:72, or has at least 95% sequence identity with amino acids 1 to 344 of the sequence of SEQ ID NO:72, or has at least 98% sequence identity with amino acids 1 to 344 of the sequence of SEQ ID NO:72.
[0262] E248. An isolated antibody or ALK2 binding fragment thereof of E148, wherein, except for the light chain CDR1, CDR2 and CDR3 and the heavy chain CDR1, CDR2 and CDR3, the antibody has at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) sequence identity with amino acids 1 to 327 of the sequence of SEQ ID NO:73, or has at least 95% sequence identity with amino acids 1 to 327 of the sequence of SEQ ID NO:73, or has at least 98% sequence identity with amino acids 1 to 327 of the sequence of SEQ ID NO:73.
[0263] An isolated antibody or ALK2 binding fragment thereof of E249.E148, wherein, except for the light chain CDR1, CDR2 and CDR3 and the heavy chain CDR1, CDR2 and CDR3, the antibody has at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) sequence identity with amino acids 1 to 331 of the sequence of SEQ ID NO:74, or has at least 95% sequence identity with amino acids 1 to 331 of the sequence of SEQ ID NO:74, or has at least 98% sequence identity with amino acids 1 to 331 of the sequence of SEQ ID NO:74.
[0264] An isolated antibody or ALK2 binding fragment thereof of E250.E148, wherein, excluding light chain CDR1, CDR2 and CDR3 and heavy chain CDR1, CDR2 and CDR3, the antibody has at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) sequence identity with amino acids 1 to 332 of the sequence of SEQ ID NO:75, or has at least 95% sequence identity with amino acids 1 to 332 of the sequence of SEQ ID NO:75, or has at least 98% sequence identity with amino acids 1 to 332 of the sequence of SEQ ID NO:75.
[0265] E251. The isolated antibody or ALK2-binding fragment thereof of E148, wherein the antibody comprises or consists of amino acids 1 to 446 of the sequence of SEQ ID NO:72.
[0266] E252. The isolated antibody or ALK2-binding fragment thereof of E148, wherein the antibody comprises or consists of amino acids 1 to 429 of the sequence of SEQ ID NO:73.
[0267] E253. The isolated antibody or ALK2 binding fragment thereof of E148, wherein the antibody comprises or consists of amino acids 1 to 433 of the sequence of SEQ ID NO:74.
[0268] E254. The isolated antibody or ALK2 binding fragment thereof of E148, wherein the antibody comprises or consists of amino acids 1 to 434 of the sequence of SEQ ID NO:75.
[0269] E255. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E254, wherein the antibody is a monoclonal antibody.
[0270] E256. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E255, wherein the antibody is a humanized antibody.
[0271] E257. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E256, wherein the ALK2-binding fragment is a Fab.
[0272] E258. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E256, wherein the ALK2-binding fragment is Fab'.
[0273] E259. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E256, wherein the ALK2-binding fragment is F(ab')2.
[0274] E260. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E256, wherein the ALK2-binding fragment is an Fv.
[0275] E261. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E260, wherein the antibody has a K of no more than 14 nM. D Values bind to human ALK2.
[0276] E262. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E261, wherein the antibody has a K of no more than 5 nM. D Values bind to human ALK2.
[0277] E263. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E262, wherein the antibody has a K of no more than 1 nM. D Values bind to human ALK2.
[0278] E264. The isolated antibody or ALK2-binding fragment thereof of any one of E1-E263, wherein the antibody has a K of no more than 0.5 nM. D Values bind to human ALK2.
[0279] E265. A nucleic acid molecule comprising a nucleotide sequence encoding the antibody or ALK2 binding fragment thereof of any one of E1-E264.
[0280] E266. An expression vector comprising the nucleic acid molecule of E265.
[0281] E267. A cell comprising an expression vector of E266.
[0282] E268. A pharmaceutical composition comprising the antibody or ALK2 binding fragment thereof of any one of E1-E264, the nucleic acid molecule of E265 or the expression vector of E266 and one or more pharmaceutically acceptable carriers or excipients.
[0283] E269. The pharmaceutical composition of E268, wherein the antibody or ALK2-binding fragment thereof is in a therapeutically effective amount.
[0284] E270. A method for increasing bone mineral density in a subject by administering to a subject in need thereof a therapeutically effective amount of an antibody or ALK2 binding fragment thereof of any one of E1 to E264, a nucleic acid molecule of E265, an expression vector of E266, or a pharmaceutical composition of E268 or E269.
[0285] E271. A method for reducing bone resorption (e.g., bone loss) in a subject by administering to a subject in need thereof a therapeutically effective amount of an antibody or ALK2 binding fragment thereof of any one of E1 to E264, a nucleic acid molecule of E265, an expression vector of E266, or a pharmaceutical composition of E268 or E269.
[0286] E272. A method of increasing bone formation in a subject by administering to a subject in need thereof a therapeutically effective amount of the antibody or ALK2 binding fragment thereof of any one of E1 to E264, the nucleic acid molecule of E265, the expression vector of E266, or the pharmaceutical composition of E268 or E269.
[0287] E273. A method of increasing bone strength in a subject by administering to a subject in need thereof a therapeutically effective amount of the antibody or ALK2 binding fragment thereof of any one of E1 to E264, the nucleic acid molecule of E265, the expression vector of E266, or the pharmaceutical composition of E268 or E269.
[0288] E274. A method for reducing the risk of bone fracture in a subject by administering to a subject in need thereof a therapeutically effective amount of an antibody or ALK2 binding fragment thereof of any one of E1 to E264, a nucleic acid molecule of E265, an expression vector of E266, or a pharmaceutical composition of E268 or E269.
[0289] E275. The method of any one of E270-E274, wherein the subject has or is at risk of developing primary osteoporosis, secondary osteoporosis, osteopenia, osteosclerosis, bone fracture, bone cancer or cancer metastasis-related bone loss, Paget's disease, renal osteodystrophy, treatment-related bone loss, diet-related bone loss, bone loss associated with obesity treatment, low gravity-related bone loss, or bone loss associated with immobility.
[0290] E276. The method of E275, wherein the subject has primary osteoporosis or is at risk of developing primary osteoporosis.
[0291] E277. The method of E275, wherein the subject has or is at risk of developing secondary osteoporosis.
[0292] E278. The method of E275, wherein the subject has osteopenia or is at risk of developing osteopenia.
[0293] E279. A method of treating a subject having a bone disease or at risk of developing a bone disease by administering to the subject a therapeutically effective amount of an antibody or ALK2 binding fragment thereof of any one of E1 to E264, a nucleic acid molecule of E265, an expression vector of E266, or a pharmaceutical composition of E268 or E269.
[0294] The method of E280.E279, wherein the bone disease is primary osteoporosis, secondary osteoporosis, osteopenia, osteosclerosis, bone fracture, bone cancer or cancer metastasis-related bone loss, Paget's disease, renal osteodystrophy, treatment-related bone loss, diet-related bone loss, bone loss associated with obesity treatment, low gravity-related bone loss, or bone loss associated with immobility.
[0295] E281. The method of E280, wherein the bone disease is primary osteoporosis.
[0296] E282. The method of E280, wherein the bone disease is secondary osteoporosis.
[0297] E283. The method of E280, wherein the bone disease is osteopenia.
[0298] E284. A method of treating a subject having primary osteoporosis or at risk of developing primary osteoporosis by administering to the subject an antibody or ALK2 binding fragment thereof of any one of E1 to E264, a nucleic acid molecule of E265, an expression vector of E266, or a pharmaceutical composition of E268 or E269.
[0299] E285. A method of treating a subject having or at risk of developing secondary osteoporosis by administering to the subject an antibody or ALK2 binding fragment thereof of any one of E1 to E264, a nucleic acid molecule of E265, an expression vector of E266, or a pharmaceutical composition of E268 or E269.
[0300] E286. A method of treating a subject having osteopenia or at risk of developing osteopenia by administering to the subject an antibody or ALK2 binding fragment thereof of any one of E1 to E264, a nucleic acid molecule of E265, an expression vector of E266, or a pharmaceutical composition of E268 or E269.
[0301] E287. A method of treating a subject having a fracture or at risk of developing a fracture by administering to the subject an antibody or ALK2 binding fragment thereof of any one of E1 to E264, a nucleic acid molecule of E265, an expression vector of E266, or a pharmaceutical composition of E268 or E269.
[0302] E288. A method of treating a subject having bone cancer or cancer metastasis-associated bone loss or at risk of developing bone cancer or cancer metastasis-associated bone loss by administering a therapeutically effective amount of an antibody or ALK2-binding fragment thereof of any one of E1 to E264, a nucleic acid molecule of E265, an expression vector of E266, or a pharmaceutical composition of E268 or E269.
[0303] E289. A method of treating a subject having Paget's disease or at risk of developing Paget's disease by administering to the subject a therapeutically effective amount of an antibody or ALK2 binding fragment thereof of any one of E1 to E264, a nucleic acid molecule of E265, an expression vector of E266, or a pharmaceutical composition of E268 or E269.
[0304] E290. A method of treating a subject having renal osteodystrophy or at risk of developing renal osteodystrophy by administering to the subject a therapeutically effective amount of an antibody or ALK2 binding fragment thereof of any one of E1 to E264, a nucleic acid molecule of E265, an expression vector of E266, or a pharmaceutical composition of E268 or E269.
[0305] E291. A method of treating a subject having treatment-related bone loss or at risk of developing treatment-related bone loss by administering a therapeutically effective amount of an antibody or ALK2-binding fragment thereof of any one of E1 to E264, a nucleic acid molecule of E265, an expression vector of E266, or a pharmaceutical composition of E268 or E269.
[0306] E292. A method of treating a subject having diet-related bone loss or at risk of developing diet-related bone loss by administering to the subject a therapeutically effective amount of an antibody or ALK2-binding fragment thereof of any one of E1 to E264, a nucleic acid molecule of E265, an expression vector of E266, or a pharmaceutical composition of E268 or E269.
[0307] E293. A method of treating a subject having low gravity-related bone loss or at risk of developing low gravity-related bone loss by administering to the subject a therapeutically effective amount of an antibody or ALK2-binding fragment thereof of any one of E1 to E264, a nucleic acid molecule of E265, an expression vector of E266, or a pharmaceutical composition of E268 or E269.
[0308] E294. A method of treating a subject having bone loss associated with immobility or at risk of developing bone loss associated with immobility by administering a therapeutically effective amount of an antibody or ALK2 binding fragment thereof of any one of E1 to E264, a nucleic acid molecule of E265, an expression vector of E266, or a pharmaceutical composition of E268 or E269.
[0309] E295. The method of any one of E275, E276, E280, E281 and E284, wherein the primary osteoporosis is age-related osteoporosis or hormone-related osteoporosis.
[0310] E296. The method of any one of E275, E278, E280, E282 and E285, wherein the secondary osteoporosis is immobilization-induced osteoporosis or glucocorticoid-induced osteoporosis.
[0311] E297. The method of any one of E275, E280 and E288, wherein the cancer is multiple myeloma.
[0312] E298. The method of any one of E275, E280 and E291, wherein the treatment is FGF-21 treatment, GLP-1 treatment, cancer therapy, or treatment of obesity or type 2 diabetes.
[0313] E299. The method of any one of E275, E280 and E292, wherein the diet-related bone loss is rickets.
[0314] E300. The method of any one of E270-E299, wherein the subject is at risk for bone fracture.
[0315] E301. The method of any one of E270-E300, wherein the method increases bone formation in the subject.
[0316] E302. The method of any one of E270-E301, wherein the method reduces bone resorption (eg, bone loss) in a subject.
[0317] E303. The method of any one of E270-E302, wherein the method increases osteoblast activity or osteoblastogenesis.
[0318] E304. The method of any one of E270-E303, wherein the method reduces osteoclast activity or reduces osteoclastogenesis.
[0319] E305. The method of any one of E270-E304, wherein the method reduces the risk of bone fracture.
[0320] E306. The method of any one of E270-E305, wherein the method increases bone mineral density.
[0321] E307. The method of any one of E270-E306, wherein the bone is cortical bone.
[0322] E308. The method of any one of E270-E306, wherein the bone is cancellous bone.
[0323] E309. The method of any one of E270-E308, wherein the method further comprises assessing the subject's bone mineral density (e.g., assessing bone mineral density using a standard test such as dual-energy x-ray absorptiometry) prior to administering the antibody or ALK2-binding fragment thereof, nucleic acid molecule, expression vector or pharmaceutical composition.
[0324] E310. The method of any one of E270-E309, wherein the method further comprises assessing the subject's bone mineral density (e.g., assessing bone mineral density using a standard test, such as dual-energy x-ray absorptiometry) after administering the antibody or its ALK2-binding fragment, nucleic acid molecule, expression vector or pharmaceutical composition.
[0325] E311. A method of increasing red blood cell levels in a subject by administering to a subject in need thereof a therapeutically effective amount of an antibody or ALK2 binding fragment thereof of any one of E1 to E264, a nucleic acid molecule of E265, an expression vector of E266, or a pharmaceutical composition of E268 or E269.
[0326] E312. A method for increasing hemoglobin levels (e.g., serum hemoglobin levels) in a subject in need thereof by administering to a subject in need thereof a therapeutically effective amount of an antibody or ALK2 binding fragment thereof of any one of E1 to E264, a nucleic acid molecule of E265, an expression vector of E266, or a pharmaceutical composition of E268 or E269.
[0327] E313. A method of increasing red blood cell count in a subject by administering to a subject in need thereof a therapeutically effective amount of an antibody or ALK2 binding fragment thereof of any one of E1 to E264, a nucleic acid molecule of E265, an expression vector of E266, or a pharmaceutical composition of E268 or E269.
[0328] E314. A method for promoting or increasing red blood cell formation in a subject by administering to a subject in need thereof a therapeutically effective amount of an antibody or ALK2 binding fragment thereof of any one of E1 to E264, a nucleic acid molecule of E265, an expression vector of E266, or a pharmaceutical composition of E268 or E269.
[0329] E315. A method for reducing hepcidin levels (e.g., serum hepcidin concentration) in a subject in need thereof by administering to a subject in need thereof a therapeutically effective amount of an antibody or ALK2 binding fragment thereof of any one of E1 to E264, a nucleic acid molecule of E265, an expression vector of E266, or a pharmaceutical composition of E268 or E269.
[0330] E316. A method for increasing iron levels (e.g., serum iron levels) in a subject in need thereof by administering to a subject in need thereof a therapeutically effective amount of an antibody or ALK2 binding fragment thereof of any one of E1 to E264, a nucleic acid molecule of E265, an expression vector of E266, or a pharmaceutical composition of E268 or E269.
[0331] E317. The method of any one of E311-E316, wherein the subject has anemia or blood loss or is at risk of developing anemia or blood loss.
[0332] E318. The method of E317, wherein the anemia or blood loss is associated with cancer, cancer treatment, kidney disease or failure (e.g., chronic kidney disease or acute kidney disease or failure), myelodysplastic syndrome, thalassemia, nutritional deficiency, adverse reaction to a drug, inflammatory or autoimmune disease, splenomegaly, porphyria, vasculitis, hemolysis, bone marrow defect, bone marrow transplantation, diabetes, liver disease (e.g., acute liver disease or chronic liver disease), bleeding (e.g., acute or chronic bleeding), infection, hemoglobinopathy, drug use, alcohol abuse, advanced age, Churg-Felty syndrome, Felty syndrome, graft-versus-host disease, hematopoietic stem cell transplantation, myelofibrosis, pancytopenia, pure red cell aplasia, Henoch-Schonlein purpura, Schwabmann syndrome (e.g., Schwab-Felty syndrome), contraindications to transfusion, surgery, trauma, wound, ulcer, urinary tract bleeding, gastrointestinal bleeding, frequent blood donation, or excessive menstrual bleeding.
[0333] E319. A method of treating a subject having anemia or at risk of developing anemia by administering to the subject a therapeutically effective amount of an antibody or ALK2 binding fragment thereof of any one of E1 to E264, a nucleic acid molecule of E265, an expression vector of E266, or a pharmaceutical composition of E268 or E269.
[0334] The method of E320.E319, wherein in some embodiments, the anemia is associated with cancer, cancer treatment, kidney disease or failure (e.g., chronic kidney disease or acute kidney disease or failure), myelodysplastic syndrome, thalassemia, nutritional deficiency, adverse reaction to a drug, inflammatory or autoimmune disease, splenomegaly, porphyria, vasculitis, hemolysis, bone marrow defect, bone marrow transplantation, diabetes, liver disease (e.g., acute liver disease or chronic liver disease), bleeding (e.g., acute or chronic bleeding), infection, hemoglobinopathy, drug abuse, alcohol abuse, advanced age, Churg-Fernandez syndrome, Felty syndrome, graft-versus-host disease, hematopoietic stem cell transplantation, myelofibrosis, pancytopenia, pure red cell aplasia, Henoch-Schonlein purpura, Schwabmann syndrome (e.g., Schwab-Fernandez syndrome), contraindications to transfusion, surgery, trauma, wound, ulcer, urinary tract bleeding, gastrointestinal bleeding, frequent blood donation, or excessive menstrual bleeding.
[0335] The method of E321.E317-E320, wherein the anemia is aplastic anemia, iron deficiency anemia, vitamin deficiency anemia, anemia of inflammation (also known as anemia of chronic disease, for example, anemia caused by inflammatory diseases or conditions, such as infection (e.g., chronic infection, such as HIV / AIDS or tuberculosis), autoimmune diseases (e.g., rheumatoid arthritis or lupus), cancer (e.g., cancer or cancer treatment), inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis), and chronic kidney disease), anemia associated with bone marrow disease, hemolytic anemia, sickle cell anemia, microcytic anemia, hypochromic anemia, sideroblastic anemia, DeBouga anemia, Fanconi anemia, or refractory anemia with blastosis.
[0336] E322. The method of E321, wherein the anemia is IRIDA.
[0337] E323. The method of E322, wherein the anemia is anemia of inflammation.
[0338] E324. The method of any one of E311-E323, wherein the anemia is associated with elevated hepcidin levels.
[0339] E325. The method of any one of E311-E324, wherein the subject does not respond well to treatment with erythropoietin (EPO), or is susceptible to adverse effects of EPO.
[0340] E326. The method of any one of E311-E325, wherein the method increases red blood cell formation, red blood cell count, hematocrit, or hemoglobin levels.
[0341] E327. The method of any one of E311-E326, wherein the method prevents or reduces elevated hepcidin levels.
[0342] E328. The method of any one of E311-E327, wherein the method increases iron levels.
[0343] E329. The method of any one of E311-E328, wherein the method reduces the subject's need for blood transfusion.
[0344] E330. The method of any one of E311-E329, wherein the method further comprises assessing the subject's red blood cell level, hemoglobin level, red blood cell count, hepcidin level or iron level (e.g., using standard tests, such as blood tests to assess blood cell level, hemoglobin level, red blood cell count, hepcidin level or iron level) prior to administering the antibody or its ALK2 binding fragment, nucleic acid molecule, expression vector or pharmaceutical composition.
[0345] E331. The method of any one of E311-E330, wherein the method further comprises assessing the subject's red blood cell level, hemoglobin level, red blood cell count, hepcidin level or iron level after administering the antibody or its ALK2 binding fragment, nucleic acid molecule, expression vector or pharmaceutical composition (e.g., using standard tests, such as blood tests to assess blood cell level, hemoglobin level, red blood cell count, hepcidin level or iron level).
[0346] E332. A method for preventing or reducing heterotopic ossification in a subject by administering to a subject in need thereof a therapeutically effective amount of an antibody or ALK2 binding fragment thereof of any one of E1 to E264, a nucleic acid molecule of E265, an expression vector of E266, or a pharmaceutical composition of E268 or E269.
[0347] E333. The method of E332, wherein the subject has fibrodysplasia ossificans progressiva (FOP).
[0348] E334. The method of E333, wherein the FOP is hereditary FOP or sporadic FOP.
[0349] E335. A method of treating a subject having FOP or at risk of developing FOP by administering to the subject a therapeutically effective amount of an antibody or ALK2 binding fragment thereof of any one of E1 to E264, a nucleic acid molecule of E265, an expression vector of E266, or a pharmaceutical composition of E268 or E269.
[0350] E336. The method of E335, wherein the FOP is hereditary FOP or sporadic FOP.
[0351] E337. The method of any one of E332-E336, wherein the method slows or inhibits the progression of FOP.
[0352] E338. The method of any one of E332-E337, wherein the method delays the onset of FOP (eg, delays the onset of heterotopic ossification).
[0353] E339. The method of any one of E332-E338, wherein the method prevents heterotopic ossification (eg, preventing heterotopic ossification in a subject at risk of developing heterotopic ossification, or preventing the recurrence of heterotopic ossification following surgical resection of heterotopic bone).
[0354] E340. The method of any one of E332-E339, wherein the method reduces heterotopic ossification (e.g., reduces the amount of heterotopic ossification in a subject, reduces the occurrence of heterotopic ossification in a subject, or reduces the recurrence of heterotopic ossification after surgical resection of heterotopic bone).
[0355] E341. The method of any one of E332-E340, wherein the method reduces the formation of ectopic bone.
[0356] E342. The method of any one of E332-E341, wherein the method reduces the recurrence of heterotopic bone (eg, after surgical resection).
[0357] E343. The method of any one of E332-E342, wherein the method further comprises assessing heterotopic ossification (e.g., the amount or location of heterotopic bone) in the subject prior to administering the antibody or ALK2 binding fragment thereof, nucleic acid molecule, expression vector or pharmaceutical composition (e.g., assessing heterotopic ossification using standard tests, such as radiographs (e.g., X-rays), CT (computed tomography) and / or MRI (magnetic resonance imaging)).
[0358] E344. The method of any one of E332-E343, wherein the method further comprises assessing heterotopic ossification (e.g., the amount or location of heterotopic bone) in the subject after administration of the antibody or ALK2 binding fragment thereof, nucleic acid molecule, expression vector or pharmaceutical composition (e.g., assessing heterotopic ossification using standard tests, such as radiographs (e.g., X-rays), CT (computed tomography) and / or MRI (magnetic resonance imaging)).
[0359] E345. The method of any one of E332-E344, wherein the method further comprises determining whether the subject carries an activating mutation in ALK2 (ACVR1) prior to administering the antibody or ALK2-binding fragment thereof, nucleic acid molecule, expression vector or pharmaceutical composition.
[0360] E346. A method of treating a subject having Sjögren's syndrome by administering to the subject a therapeutically effective amount of the antibody or ALK2 binding fragment thereof of any one of E1 to E264, the nucleic acid molecule of E265, the expression vector of E266, or the pharmaceutical composition of E268 or E269.
[0361] E347. The method of E346, wherein the method reduces or improves the symptoms of Sjögren's syndrome.
[0362] E348. The method of E347, wherein the symptom is dry eyes, dry mouth, eye irritation, fibrosis of the tear glands, inflammation of the tear glands, blurred vision, systemic inflammation, joint pain or fatigue.
[0363] E349. The method of E348, wherein the symptom is dry eyes.
[0364] E350. A method for treating or reducing dry eye in a subject with Sjögren's syndrome (treating dry eye associated with Sjögren's syndrome) by administering to a subject with Sjögren's syndrome a therapeutically effective amount of an antibody or ALK2 binding fragment thereof of any one of E1 to E264, a nucleic acid molecule of E265, an expression vector of E266, or a pharmaceutical composition of E268 or E269.
[0365] E351. The method of any one of E346-E350, wherein the method increases tear production (eg, increases tear volume production).
[0366] E352. The method of any one of E346-E351, wherein the method reduces eye irritation.
[0367] E353. The method of any one of E346-E352, wherein the method improves vision (e.g., increases visual acuity).
[0368] E354. The method of any one of E346-E353, wherein the method reduces fibrosis of the lacrimal gland.
[0369] E355. The method of any one of E346-E354, wherein the method reduces inflammation of the lacrimal gland.
[0370] E356. The method of any one of E346-E355, wherein the method increases the production of saliva or saliva flow.
[0371] E357. The method of any one of E346-E356, wherein the method reduces systemic inflammation.
[0372] E358. The method of any one of E346-E357, wherein the method reduces joint pain.
[0373] E359. The method of any one of E346-E358, wherein the method reduces fatigue.
[0374] E360. A method for treating a subject having multiple osteochondromas (MO), comprising administering to the subject a therapeutically effective amount of an antibody or ALK2 binding fragment thereof of any one of E1 to E264, a nucleic acid molecule of E265, an expression vector of E266, or a pharmaceutical composition of E268 or E269.
[0375] E361. A method for preventing or reducing the formation of osteochondroma in a subject with MO (e.g., preventing the formation of osteochondroma in a subject with MO who has not yet developed osteochondroma or reducing or preventing the formation of osteochondroma in a subject with MO who has already developed one or more osteochondromas), comprising administering to the subject a therapeutically effective amount of an antibody or ALK2 binding fragment thereof of any one of E1 to E264, a nucleic acid molecule of E265, an expression vector of E266, or a pharmaceutical composition of E268 or E269.
[0376] E362. A method for reducing the size of an osteochondroma in a subject with MO, comprising administering to the subject a therapeutically effective amount of an antibody or ALK2 binding fragment thereof of any one of E1 to E264, a nucleic acid molecule of E265, an expression vector of E266, or a pharmaceutical composition of E268 or E269.
[0377] E363. A method for slowing or inhibiting the growth of osteochondroma in a subject with MO, comprising administering to the subject a therapeutically effective amount of an antibody or ALK2 binding fragment thereof of any one of E1 to E264, a nucleic acid molecule of E265, an expression vector of E266, or a pharmaceutical composition of E268 or E269.
[0378] E364. A method for reducing the number of osteochondromas in a subject with MO, comprising administering to the subject a therapeutically effective amount of an antibody or ALK2 binding fragment thereof of any one of E1 to E264, a nucleic acid molecule of E265, an expression vector of E266, or a pharmaceutical composition of E268 or E269.
[0379] E365. The method of any one of E360-E364, wherein the osteochondroma forms on a long bone.
[0380] E366. The method of any one of E360-E364, wherein the osteochondroma forms on a flat bone.
[0381] E367. The method of any one of E360-E366, wherein the osteochondroma forms on the growing end (metaphysis) of the bone.
[0382] E368. A method for treating a subject having diffuse intrinsic pontine glioma (DIPG), comprising administering to the subject a therapeutically effective amount of an antibody or ALK2 binding fragment thereof of any one of E1 to E264, a nucleic acid molecule of E265, an expression vector of E266, or a pharmaceutical composition of E268 or E269.
[0383] E369. The method of E368, wherein the method increases the survival time (e.g., extends the lifespan) of the subject.
[0384] E370. The method of E368 or E369, wherein the method reduces tumor growth.
[0385] E371. The method of any one of E368-E370, wherein the method reduces tumor volume.
[0386] E372. The method of any one of E368-E371, wherein the method reduces tumor metastasis.
[0387] E373. The method of any one of E368-E372, wherein the method further comprises determining whether the subject carries a mutation in ALK2 (ACVR1) prior to administering the antibody or ALK2-binding fragment thereof, nucleic acid molecule, expression vector or pharmaceutical composition.
[0388] E374. A method for reducing or preventing the development of posterior capsule opacification (PCO) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an antibody or ALK2 binding fragment thereof of any one of E1 to E264, a nucleic acid molecule of E265, an expression vector of E266, or a pharmaceutical composition of E268 or E269.
[0389] E375. A method for treating a subject having PCO or at risk of developing PCO, comprising administering to the subject a therapeutically effective amount of the antibody or ALK2 binding fragment thereof of any one of E1 to E264, the nucleic acid molecule of E265, the expression vector of E266, or the pharmaceutical composition of E268 or E269.
[0390] The method of E376.E374 or E375, wherein the subject has undergone or is about to undergo cataract surgery (e.g., the subject plans to undergo cataract surgery within 6 months, 5 months, 4 months, 3 months, 2 months, 1 month, 2 weeks, 1 week or less).
[0391] E377. The method of any one of E374-E376, wherein the method improves visual acuity.
[0392] E378. The method of any one of E374-E377, wherein the method reduces light sensitivity or glare.
[0393] E379. The method of any one of E374-E378, wherein the method reduces or inhibits fibrosis (e.g., fibrosis on or near the posterior capsule, such as fibrosis near an implanted lens).
[0394] E380. The method of any one of E374-E379, wherein the method reduces or inhibits inflammation in the eye.
[0395] E381. A method for treating a subject having or at risk of developing cardiac hypertrophy, comprising administering to the subject a therapeutically effective amount of an antibody or ALK2 binding fragment thereof of any one of E1 to E264, a nucleic acid molecule of E265, an expression vector of E266, or a pharmaceutical composition of E268 or E269.
[0396] E382. A method for slowing or preventing the development of cardiac hypertrophy, comprising administering to the subject a therapeutically effective amount of an antibody or ALK2 binding fragment thereof of any one of E1 to E264, a nucleic acid molecule of E265, an expression vector of E266, or a pharmaceutical composition of E268 or E269.
[0397] E383. The method of E381 or E382, wherein the subject is identified as having hypertension or valvular disease.
[0398] E384. A method for treating a subject having or at risk of developing cardiac fibrosis, comprising administering to the subject a therapeutically effective amount of an antibody or ALK2 binding fragment thereof of any one of E1 to E264, a nucleic acid molecule of E265, an expression vector of E266, or a pharmaceutical composition of E268 or E269.
[0399] E385. A method for slowing or preventing the development of cardiac fibrosis, comprising administering to the subject a therapeutically effective amount of an antibody or ALK2 binding fragment thereof of any one of E1 to E264, a nucleic acid molecule of E265, an expression vector of E266, or a pharmaceutical composition of E268 or E269.
[0400] E386. The method of E384 or E385, wherein the subject is identified as having hypertension, diabetic hypertrophic cardiomyopathy, or idiopathic dilated cardiomyopathy, or wherein the subject has had a myocardial infarction.
[0401] E387. The method of any one of E381-E386, wherein the method reduces or reverses cardiac fibrosis.
[0402] E388. The method of any one of E381-E387, wherein the method improves one or more symptoms of cardiac hypertrophy or cardiac fibrosis.
[0403] The method of E389.E388, wherein the symptoms of cardiac hypertrophy or cardiac fibrosis are reduced exercise capacity, reduced ejection volume, increased left ventricular end-diastolic pressure, increased pulmonary capillary wedge pressure, reduced cardiac output, reduced cardiac index, increased pulmonary artery pressure, increased left ventricular end-systolic and end-diastolic dimensions, increased left and right ventricular wall stress, increased wall tension and / or wall thickness, reduced myocardial contractility, increased myocardial cell area, or increased extracellular matrix deposition in the myocardium.
[0404] E390. The method of any one of E270-E310, wherein the antibody or ALK2 binding fragment thereof, nucleic acid molecule, expression vector or pharmaceutical composition is administered in an amount sufficient to increase bone mineral density, reduce bone resorption (e.g., reduce bone loss), reduce the risk of fracture, increase bone strength, reduce the rate of bone resorption (e.g., reduce the rate of bone loss), increase bone formation, increase the rate of bone formation, reduce osteoclast activity, increase osteoblast activity or treat bone disease.
[0405] E391. The method of any one of E311-E331, wherein the antibody or ALK2 binding fragment thereof, nucleic acid molecule, expression vector or pharmaceutical composition is administered in an amount sufficient to increase red blood cell levels, increase hemoglobin levels, increase red blood cell formation, increase red blood cell count, increase hematocrit, reduce the need for transfusion, increase iron levels, reduce iron deficiency, reduce elevated hepcidin levels, or treat anemia.
[0406] E392. The method of any one of E332-E345, wherein the antibody or ALK2 binding fragment thereof, nucleic acid molecule, expression vector or pharmaceutical composition is administered in an amount sufficient to treat FOP, slow or stop the progression of FOP, delay the onset of FOP, prevent heterotopic ossification, reduce heterotopic ossification, prevent or reduce heterotopic bone formation, or prevent or reduce the recurrence of heterotopic bone.
[0407] E393. The method of any one of E346-E359, wherein the antibody or ALK2 binding fragment thereof, nucleic acid molecule, expression vector or pharmaceutical composition is administered in an amount sufficient to treat Sjögren's syndrome, treat or reduce dry eye associated with Sjögren's syndrome, reduce or improve symptoms of Sjögren's syndrome, increase tear production, reduce eye irritation, improve vision, reduce fibrosis of the lacrimal gland, reduce inflammation of the lacrimal gland, or increase the production of saliva or saliva flow.
[0408] E394. The method of any one of E360-E367, wherein the antibody or ALK2 binding fragment thereof, nucleic acid molecule, expression vector or pharmaceutical composition is administered in an amount sufficient to treat MO, prevent the formation of osteochondroma, reduce the formation of osteochondroma, reduce the size of osteochondroma, reduce the growth of osteochondroma or reduce the number of osteochondromas.
[0409] E395. The method of any one of E368-E373, wherein the antibody or ALK2 binding fragment thereof, nucleic acid molecule, expression vector or pharmaceutical composition is administered in an amount sufficient to treat DIPG, increase survival time (e.g., prolong life), reduce tumor growth, reduce tumor volume or reduce tumor metastasis.
[0410] E396. The method of any one of E374-E380, wherein the antibody or ALK2 binding fragment thereof, nucleic acid molecule, expression vector or pharmaceutical composition is administered in an amount sufficient to treat PCO, prevent the development of PCO, improve visual acuity, reduce light sensitivity or glare, reduce or inhibit fibrosis, or reduce or inhibit inflammation in the eye.
[0411] E397. The method of any one of E381-E3889, wherein the antibody or ALK2 binding fragment thereof, nucleic acid molecule, expression vector or pharmaceutical composition is administered in an amount sufficient to treat cardiac hypertrophy, treat cardiac fibrosis, slow or prevent the development of cardiac hypertrophy, slow or prevent the development of cardiac fibrosis, or improve the symptoms of cardiac fibrosis.
[0412] definition As used herein, the term "about" refers to a value that is within 10% above or below the stated value.
[0413] As used herein, "administering" refers to providing or administering a therapeutic agent (eg, an ALK2 antibody or antigen-binding fragment thereof described herein (eg, ALK2 binding fragment)) to a subject by any effective route. Exemplary routes of administration are described below.
[0414] The term "antibody" is used in the broadest sense and specifically covers intact monoclonal antibodies, polyclonal antibodies, multispecific antibodies (eg, bispecific antibodies) formed from at least two intact antibodies, and antibody fragments so long as they exhibit the desired biological activity.
[0415] "Antibody fragments" include a portion of an intact antibody, preferably the antigen binding region or variable region of an intact antibody. Examples of antibody fragments include Fab, Fab', F(ab')2, and Fv fragments; diabodies; linear antibodies (Zapata et al. Protein Eng. 8(10): 1057-1062 (1995)); single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.
[0416] As used herein, the term "monoclonal antibody" refers to an antibody obtained from a substantially homogeneous antibody population, i.e., the individual antibodies included in the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site.
[0417] The term "monoclonal antibody" as used herein specifically includes "chimeric" antibodies (in which a portion of the heavy chain and / or light chain is identical or homologous to the corresponding sequence in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain is identical or homologous to the corresponding sequence in antibodies derived from another species or belonging to another antibody class or subclass), as well as fragments of such antibodies, as long as they exhibit the desired biological activity (U.S. Pat. No. 4,816,567; Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)).
[0418] " Humanized " form of non-human (for example, mouse) antibody is chimeric antibody, antibody chain or its fragment (such as Fv, Fab, Fab ', F (ab ') 2 or other antigen binding subsequences of antibody), it contains the minimum sequence derived from non-human antibody.For most part, humanized antibody is people's antibody (acceptor antibody), wherein the residue from the complementary determining region (CDR) of acceptor is replaced by the residue from the CDR of non-human species (donor antibody) (such as mouse, rat or rabbit) with desired specificity, affinity and ability.In some cases, the Fv framework region (FR) residue of people's antibody is replaced by corresponding non-human residue.In addition, humanized antibody can include residues found neither in acceptor antibody nor in CDR or framework sequence of import.
[0419] As used herein, the terms "bone mineral density (BMD)", "bone density" and "bone mass" refer to a measure of the amount of bone mineral (e.g., calcium) in bone tissue. BMD can be measured by well-established clinical techniques known to those skilled in the art (e.g., by single-1 or dual-energy photon or X-ray absorptiometry (DEXA)). The concept of BMD relates to the amount of mineral per volume of bone, although clinically it is measured by proxy according to the optical density per square centimeter of bone surface after imaging. BMD measurements are used as indirect indicators of osteoporosis and fracture risk in clinical medicine. In some embodiments, the BMD test results are provided as T-scores, wherein the T-scores represent the BMD of the subject compared to the ideal or peak bone mineral density of a healthy 30-year-old adult. A score of 0 indicates that BMD is equal to the normal reference value for a healthy young adult. The difference between the measured subject's BMD and the reference value for a healthy young adult is measured in standard deviation units (SD). Thus, a T-score between +1SD and -1SD can indicate normal BMD, a T-score between -1SD and -2.5SD can indicate low bone mass (e.g., osteopenia), and a T-score below -2.5SD can indicate osteoporosis or severe osteoporosis. In some embodiments, an ALK2 antibody or antigen-binding fragment thereof (e.g., ALK2 binding fragment) of the present invention is administered to a subject in need thereof, wherein the patient has low bone mass (e.g., T-score between -1SD and -2.5SD). In some embodiments, an ALK2 antibody or antigen-binding fragment thereof (e.g., ALK2 binding fragment) of the present invention is administered to a subject in need thereof, wherein the patient has osteoporosis (e.g., T-score less than -2.5SD). In some embodiments, administration of an ALK2 antibody or antigen-binding fragment thereof (e.g., ALK2 binding fragment) of the present invention treats the subject by increasing the subject's BMD (e.g., increasing the subject's T-score).
[0420] As used herein, the term "bone strength" refers to a measure of bone determined by bone mass in addition to bone mineral density. Bone mass is affected by bone geometry, microarchitecture, and the properties of the constituent tissues. Bone strength can be used to assess bone fracture risk.
[0421] As used herein, the term "bone disease" refers to a condition characterized by bone damage (e.g., decreased bone mineral density, decreased bone strength, and / or bone loss). Such diseases or conditions may be caused by an imbalance in osteoblast and / or osteoclast activity (e.g., increased bone resorption or decreased bone formation). Bone diseases include primary osteoporosis, secondary osteoporosis, osteopenia, osteosclerosis, bone fractures, bone cancer or cancer metastasis-related bone loss (e.g., bone loss associated with multiple myeloma), Paget's disease, renal osteodystrophy, treatment-related bone loss, diet-related bone loss, bone loss associated with obesity treatment, low gravity-related bone loss, and bone loss associated with immobility.
[0422] As used herein, the term "bone remodeling" or "bone metabolism" refers to the process of maintaining bone strength and ion homeostasis by replacing discrete portions of old bone with newly synthesized protein matrix packets. Bone is resorbed by osteoclasts and deposited by osteoblasts in a process called ossification. Osteocyte activity plays a key role in this process. Conditions that lead to decreased bone mass can be caused by an increase in resorption or a decrease in ossification. In healthy individuals, during childhood, bone formation exceeds resorption. As the aging process occurs, resorption exceeds formation. Bone resorption rates are also typically much higher in older women after menopause due to estrogen deficiency associated with menopause.
[0423] As used herein, the term "bone resorption" or "bone catabolic activity" refers to the process by which osteoclasts break down tissue in the bone and release minerals, resulting in the transfer of minerals (e.g., calcium) from the bone tissue to the blood. An increase in the rate of bone resorption is associated with aging, including postmenopausal women. A high bone resorption rate, or a bone resorption rate that exceeds the ossification rate, is associated with skeletal disorders such as decreased bone mineral density, including osteopenia and osteoporosis, and leads to bone loss. In some embodiments, an ALK2 antibody or antigen-binding fragment thereof (e.g., an ALK2 binding fragment) of the present invention is administered to a subject in need thereof to reduce bone resorption in the subject (e.g., the rate of bone resorption in the subject).
[0424] As used herein, the terms "bone formation," "ossification," "osteogenesis," or "bone anabolic activity" refer to the process by which new bone tissue is formed by osteoblasts. In some embodiments, an ALK2 antibody or antigen-binding fragment thereof (e.g., an ALK2 binding fragment) of the invention is administered to a subject in need thereof to increase bone formation (e.g., to increase the rate of bone formation or osteogenesis in a subject).
[0425] As used herein, the term "cell type" refers to a group of cells that share a phenotype that is statistically separable based on gene expression data. For example, cells of a common cell type may share similar structural and / or functional characteristics, such as similar gene activation patterns and antigen presentation profiles. Cells of a common cell type may include those separated from a common tissue (e.g., epithelial tissue, neural tissue, connective tissue, bone tissue, or muscle tissue) and / or those separated from other structures and / or regions in a common organ, tissue system, blood vessel, or organism.
[0426] As used herein, the terms "conservative mutation", "conservative substitution" and "conservative amino acid substitution" refer to one or more amino acids being substituted with one or more different amino acids that exhibit similar physicochemical properties (such as polarity, electrostatic charge and steric bulk). These properties are summarized in Table 1 below for each of the twenty naturally occurring amino acids. Table 1: Representative physicochemical properties of naturally occurring amino acids
[0427] It will be appreciated from this table that the conservative amino acid family includes (i) G, A, V, L and I; (ii) D and E; (iii) C, S and T; (iv) H, K and R; (v) N and Q; and (vi) F, Y and W. Thus, a conservative mutation or substitution is a substitution of one amino acid for a member of the same amino acid family (e.g., Ser for Thr or Lys for Arg).
[0428] As used herein, the term "isolated antibody" refers to an antibody that is substantially free of other antibodies with different antigenic specificities (e.g., an isolated antibody that binds ALK2 is substantially free of contaminants, such as antibodies that do not bind ALK2). In addition, an "isolated" antibody is an antibody that has been identified and separated and / or recovered from components of its natural environment. Contaminant components of its natural environment are substances that may interfere with the diagnostic or therapeutic use of the antibody, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes.
[0429] As used herein, the terms "increase" and "decrease" refer to modulation of a function, expression, or activity that results in a greater or lesser amount of measurement, respectively, relative to a reference. For example, after administering an ALK2 antibody or antigen-binding fragment thereof (e.g., ALK2 binding fragment) of the invention in the methods described herein, the amount of a marker of a measurement as described herein (e.g., red blood cell levels, bone mineral density, tear production, survival time) in a subject is increased relative to the amount of the marker before administration or relative to an untreated subject, or the amount of a marker of a measurement as described herein (e.g., heterotopic ossification, or osteochondroma size, number, or formation) in a subject is decreased relative to the amount of the marker before administration or relative to an untreated subject. Typically, the measurement is measured at a time after administration at which the administration has achieved the effect, such as at least one week, one month, three months, or six months after the treatment regimen has been initiated.
[0430] As used herein, the terms "increase red blood cell levels" and "promote red blood cell formation" refer to clinically observable metrics such as increases in hematocrit, red blood cell count, and hemoglobin measurements, and are expected to be neutral with respect to the mechanisms by which such changes occur. As used herein, the term "low red blood cell levels" refers to red blood cell counts, hematocrits, and / or hemoglobin measurements that are below the range of values considered normal for the age and sex of the subject. In some embodiments, an ALK2 antibody or antigen-binding fragment thereof (e.g., an ALK2 binding fragment) of the present invention is administered to a subject (e.g., a subject with anemia) to increase red blood cell levels (e.g., increase hemoglobin levels or red blood cell counts).
[0431] As used herein, the terms "erythropoiesis" and "erythropoiesis" refer to the production of red blood cells, such as the process of erythropoiesis in which red blood cells are produced in the bone marrow.
[0432] As used herein, the term "anemia" refers to any abnormality in hemoglobin or red blood cells that results in a decrease in oxygen levels in the blood. Anemia can be associated with abnormal production, processing, or properties of red blood cells and / or hemoglobin. The term anemia refers to any decrease in the number of red blood cells and / or hemoglobin levels in the blood relative to normal blood levels.
[0433] As used herein, the term "anemia of inflammation" refers to a type of anemia that is driven by inflammatory cytokines and is characterized by insufficient iron blood despite adequate iron stores, primarily due to elevated hepcidin. Bone morphogenetic proteins (BMPs) upregulate hepcidin by activating the SMAD signaling pathway via ALK2. Anemia of inflammation is also known as anemia of chronic disease. Chronic conditions that cause anemia of inflammation include infections (e.g., chronic infections such as HIV / AIDS or tuberculosis), autoimmune diseases (e.g., rheumatoid arthritis or lupus), cancer (e.g., cancer or cancer treatment), inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis), and chronic kidney disease.
[0434] As used herein, the terms "iron-refractory iron deficiency anemia" and "IRIDA" refer to a hereditary form of iron deficiency anemia. The main features of IRIDA include lifelong anemia (hemoglobin 6-9g / dL); very low red blood cell size (microcytic), with a mean corpuscular volume (MCV) of 45-65fL; very low iron levels in the blood (transferrin saturation <5%); abnormal oral iron absorption - no response to oral iron supplements or failure of "oral iron challenge"; abnormal iron utilization - slow, incomplete and transient response to parenteral iron (intravenous iron); and other affected family members with an autosomal recessive inheritance pattern. The diagnosis of IRIDA can be confirmed by measuring hepcidin levels in the blood. Mutations in TMPRSS6 have been found to be associated with IRIDA.
[0435] As used herein, the terms "heterotopic ossification," "heterotopic bone formation," and "ectopic bone formation" refer to abnormal growth of bone in non-skeletal tissue, such as muscle, tendon, and other soft tissues. "Ectopic bone" refers to bone formed in non-skeletal tissue. Heterotopic ossification may occur in patients with FOP.
[0436] As used herein, the terms "fibrodysplasia ossificans progressiva" and "FOP" refer to a disorder in which skeletal muscle and connective tissue, such as tendons and ligaments, are gradually replaced by bone (ossification). The condition results in bone formation outside the skeleton (exoskeleton or ectopic bone), which limits movement. The process usually becomes apparent in early childhood, starting in the neck and shoulders, and moving down the body and to the limbs. People with FOP are born with an abnormal big toe (hallus valgus), which may help make the diagnosis. Trauma, such as falls or invasive medical procedures, or viral illnesses may trigger episodes of muscle swelling and inflammation (myositis). These sudden attacks last from days to months and often result in permanent bone growth in the injured area. FOP is caused by mutations in the ACVR1 gene and is inherited in an autosomal dominant manner.
[0437] As used herein, the term "fibrosis" refers to the pathological process of excessive formation of fibrous connective tissue. Fibrosis is characterized by fibroblast accumulation and collagen deposition exceeding the normal deposition in any particular tissue. In response to inflammation or tissue damage, nearby fibroblasts can migrate into the wound, proliferate and produce a large amount of collagen extracellular matrix. When fibrosis occurs in response to damage, the term "scar" can be used as a synonym. Fibrosis can occur in many tissues of the body, including, for example, lungs, skin, liver, kidneys, heart, eyes, lacrimal glands, tendons, cartilage, pancreatic tissue, uterine tissue, neural tissue, testicles, ovaries, adrenal glands, arteries, veins, colon, small and large intestines, bile ducts and intestinal tracts.
[0438] As used herein, the term "cardiac hypertrophy" refers to an abnormal enlargement or thickening of the myocardium caused by a process in which adult cardiomyocytes respond to stress by hypertrophic growth. This growth is characterized by an increase in cell size without cell division, the assembly of additional sarcomeres within the cell to maximize force generation, and the activation of fetal cardiac gene programs. Cardiac hypertrophy is often associated with an increased risk of morbidity and mortality, and has been found to be associated with changes in the extracellular matrix scaffold (e.g., cardiac fibrosis) with fibrous tissue deposition in the cardiac interstitium.
[0439] As used herein, the term "cardiac fibrosis", also known as myocardial fibrosis, refers to myocardial fibrosis and is characterized by wall stiffening, reduced contractility and impaired overall cardiac performance. Cardiac myofibroblasts mediate fibrosis through excessive deposition of connective tissue (e.g., extracellular matrix) in the interstitial space. Cardiac fibrosis is often found to be associated with cardiac hypertrophy.
[0440] As used herein, the term "dry eye" refers to a chronic condition that occurs when the eye does not produce enough tears (eg, decreased tear production or tear volume) or when tears evaporate too quickly. Dry eye can be associated with ocular discomfort and abnormal visual function.
[0441] The term "Sjögren's syndrome" as used herein refers to a systemic inflammatory disorder characterized by dry mouth, decreased tearing and dryness of other mucous membranes. Dry eyes and mouth are the most common symptoms of this syndrome.
[0442] As used herein, "dry eye associated with Sjögren's syndrome" refers to dry eye associated with primary Sjögren's syndrome and dry eye associated with secondary Sjögren's syndrome. Dry eye associated with Sjögren's syndrome is generally classified as dry eye with reduced tear secretion.
[0443] As used herein, the term "multiple osteochondromas" or "MO" refers to a condition or disease associated with the formation of osteochondromas on bones, such as the ends of long bones or flat bones. Subjects with MO often carry loss-of-function mutations in exostosin genes (e.g., EXT1 or EXT2). MO is also known as multiple hereditary exostoses, Bessel-Hagen disease, diaphyseal continuation, multiple cartilaginous exostoses, multiple congenital exostoses, and hereditary multiple osteochondromas.
[0444] As used herein, the term "osteochondroma" refers to a benign (noncancerous) tumor that develops during childhood or adolescence. It is an abnormal overgrowth of cartilage and bone that forms on the surface of bones, usually near the growth plates. Osteochondromas most often form on the long bones of the legs and arms, and on the flat bones, such as the pelvis and scapula (shoulder blade).
[0445] As used herein, the term "diffuse intrinsic pontine glioma" refers to a highly aggressive and difficult to treat brain tumor that originates in the pons and accounts for approximately 20% of all pediatric brain tumors. The median overall survival of children with diffuse intrinsic pontine glioma (DIPG) is 9-11 months, with one-year and two-year survival rates of approximately 30% and less than 10%, respectively. DIPG has been found to be molecularly distinct from adult gliomas and often contains mutations in genes encoding histone variants. Mutations in ALK2 (ACVR1) have also been observed in DIPG.
[0446] As used herein, the term "posterior capsule opacification" refers to the most common postoperative complication of cataract surgery that occurs in 20% to 40% of patients. In posterior capsule opacification (PCO), the posterior capsule undergoes secondary opacification due to migration, proliferation, and differentiation of lens epithelial cells. PCO can cause significant visual symptoms, especially when it involves the central visual axis, and can be identified by the formation of fibrosis (e.g., scar tissue) on the posterior capsule (e.g., behind the lens implant). Symptoms of PCO include gradual decrease in vision, blurred vision, sensitivity to sunlight, and observation of glare or halos around lights.
[0447] "Percent (%) amino acid sequence identity" relative to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues in a reference polypeptide sequence, after aligning the sequences and introducing spaces (if necessary) to achieve maximum percent sequence identity over the comparison length and not considering any conservative substitutions as part of the sequence identity. Alignment for the purpose of determining percent amino acid sequence identity can be achieved in various ways within the skill in the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. In certain embodiments, the amino acid sequence identity is at least 80%, 90%, 95%, 98% or 99%.
[0448] As used herein, the term "affinity" or "binding affinity" refers to the strength of the binding interaction between two molecules. Typically, binding affinity refers to the strength of the sum of non-covalent interactions between a molecule and its binding partner, such as an ALK2 antibody or antigen-binding fragment thereof (e.g., ALK2 binding fragment) and an ALK2 protein. Unless otherwise indicated, binding affinity refers to intrinsic binding affinity, which reflects a 1:1 interaction between members of a binding pair. The binding affinity between two molecules is typically measured by the dissociation constant (K D ) or affinity constant (K A ). Two molecules with low binding affinity for each other typically associate slowly, tend to dissociate easily, and exhibit a large K D Two molecules that have a high affinity for each other generally bind easily, tend to remain bound longer, and exhibit a small K D The K of two interacting molecules can be determined using methods and techniques well known in the art, such as surface plasmon resonance. D . K D Calculated as k off / k on ratio.
[0449] As used herein, the term "specific binding" of an antibody or its ALK2 binding fragment (e.g., Fab, Fab', F(ab')2 or Fv fragment) is binding to a target molecule that is measurably different from binding to a molecule that is not a target molecule. As used herein, specific binding refers to a preference for binding to a specific antigen over background ("nonspecific") binding greater than 95%. "Substantially specific" binding refers to a preference for binding to a specific antigen over background greater than about 80%. Binding can be measured using a variety of methods, including but not limited to Western blotting, immunoblotting, enzyme-linked immunosorbent assay ("ELISA"), radioimmunoassay ("RIA"), immunoprecipitation, surface plasmon resonance, biolayer interferometry, chemiluminescence, fluorescence polarization, phosphorescence, immunohistochemical analysis, matrix-assisted laser desorption / ionization time of flight ("MALDI-TOF") mass spectrometry, microcytometry, microarrays, microscopy, fluorescence activated cell sorting ("FACS"), and flow cytometry. In certain embodiments, an antibody that specifically binds to a target (e.g., ALK2) has a dissociation constant (K) of no more than 0.1 nM, 0.15 nM, 0.2 nM, 0.3 nM, 0.5 nM, 0.7 nM, 1.0 nM, 2.0 nM, 4.0 nM, 5.0 nM, 7.0 nM, 10.0 nM, 14.0 nM, or 15.0 nM. D ).
[0450] As used herein, the term "polypeptide" describes a single polymer in which monomers are amino acid residues covalently joined together by amide bonds. Polypeptide is intended to encompass any amino acid sequence occurring naturally, recombinantly, or synthetically produced.
[0451] As used herein, the terms "effective amount," "therapeutically effective amount," and "sufficient amount" of a composition described herein or an ALK2 antibody or antigen-binding fragment thereof (e.g., ALK2 binding fragment) refer to an amount sufficient to achieve beneficial or desired results, including clinical results, when administered to a subject, and therefore, "effective amount" or its synonyms depend on the context in which it is used. For example, in the context of treating a patient who has a disease, such as a bone disease (e.g., osteoporosis, or a condition involving bone damage, e.g., primary osteoporosis, secondary osteoporosis, osteopenia, osteosclerosis, bone fracture, bone cancer or cancer metastasis-related bone loss, Paget's disease, renal osteodystrophy, treatment-related bone loss, diet-related bone loss, bone loss associated with obesity treatment, low gravity-related bone loss, or bone loss associated with immobility), a disease or condition involving low red blood cell levels (e.g., anemia or blood loss), heterotopic ossification (e.g., heterotopic ossification caused by FOP), Sjögren's syndrome (e.g., dry eyes associated with Sjögren's syndrome), DIPG, MO, PCO, or cardiac hypertrophy and / or fibrosis, or who is at risk of developing such a disease, it is an amount of the composition or ALK2 antibody or antigen-binding fragment thereof (e.g., ALK2 binding fragment) sufficient to achieve a therapeutic response as compared to the response obtained without administration of the composition or ALK2 antibody or antigen-binding fragment thereof (e.g., ALK2 binding fragment). The amount of a given composition described herein that will respond to such an amount will vary depending on factors such as a given medicament, pharmaceutical formulation, route of administration, type of disease or condition, identity of the subject (e.g., age, sex, weight) or host being treated, etc., but can still be routinely determined by those skilled in the art by conventional methods known in the art. Dosage regimens can be adjusted to provide the optimal therapeutic response.
[0452] As used herein, "topical" or "local administration" means administration at a specific site of the body, intended to achieve a local effect rather than a systemic effect. Examples of local administration are epidermal, inhalation, intra-articular, intrathecal, intravaginal, intravitreal, intrauterine, intralesional administration, lymph node administration, intratumoral administration, and mucosal administration to a subject, where the administration is intended to have a local effect rather than a systemic effect.
[0453] As used herein, the term "pharmaceutical composition" refers to a mixture containing a therapeutic agent, optionally in combination with one or more pharmaceutically acceptable excipients, diluents and / or carriers, to be administered to a subject to prevent, treat or control a specific disease or condition that affects or may affect the subject. The pharmaceutical composition may be in the form of tablets or capsules for oral administration, or in aqueous form for intravenous or subcutaneous administration.
[0454] As used herein, the term "pharmaceutically acceptable carrier or excipient" refers to an excipient or diluent in a pharmaceutical composition. A pharmaceutically acceptable carrier must be compatible with the other ingredients of the formulation and suitable for contact with the tissues of the subject without excessive toxicity, irritation, allergic response, and other problematic complications commensurate with a reasonable benefit / risk ratio. In the present invention, a pharmaceutically acceptable carrier or excipient must provide sufficient drug stability for the ALK2 antibody or antigen-binding fragment thereof (e.g., ALK2 binding fragment) of the present invention. The nature of the carrier or excipient varies with the mode of administration. For example, for intravenous administration, an aqueous solution carrier is generally used; for oral administration, a solid carrier is preferred.
[0455] As used herein, the term "sample" refers to a specimen isolated from a subject (e.g., blood, blood components (e.g., serum or plasma), urine, saliva, amniotic fluid, cerebrospinal fluid, tissue (e.g., neural tissue, placental tissue or dermal tissue), pancreatic juice, chorionic villus sample, and cells (e.g., blood cells or bone cells)).
[0456] As used herein, "treatment" and "treating" with respect to a disease or condition refer to methods for obtaining a beneficial or desired result, such as a clinical result. Beneficial or desired results may include, but are not limited to, alleviating or improving one or more symptoms or conditions; reducing the extent of a disease or condition; stabilizing (i.e., not worsening) the state of a disease, disorder, or condition; preventing the spread of a disease or condition; delaying or slowing the progression of a disease or condition; improving or alleviating a disease or condition; and alleviating (whether partial or complete), whether detectable or undetectable. "Improving" or "alleviating" a disease or condition means that the extent of a disease, disorder, or condition and / or the time course of undesirable clinical manifestations are alleviated and / or the progression is slowed or prolonged compared to the extent or time course in the absence of treatment. "Treatment" may also mean extending survival compared to the expected survival without treatment. Those in need of treatment include those who already have the condition or condition, as well as those who are prone to the condition or condition or those in which the condition or condition is to be prevented.
[0457] As used herein, the terms "subject" and "patient" refer to mammals, such as humans. Mammals include, but are not limited to, humans and domestic and farm animals, such as monkeys (e.g., cynomolgus monkeys), mice, dogs, cats, horses, and cattle. Subjects to be treated according to the methods described herein are subjects who have been diagnosed with bone diseases (e.g., diseases or conditions involving bone damage, such as osteoporosis, osteopenia, osteosclerosis, bone fractures, bone loss associated with bone cancer or cancer metastasis, Paget's disease, renal osteodystrophy, bone loss associated with treatment, bone loss associated with diet, bone loss associated with obesity treatment, bone loss associated with low gravity, or bone loss associated with immobility), diseases involving low red blood cell levels (e.g., anemia or blood loss), heterotopic ossification (e.g., heterotopic ossification caused by FOP), Sjögren's syndrome (e.g., dry eyes associated with Sjögren's syndrome), DIPG, MO, PCO, or cardiac hypertrophy and / or fibrosis, or subjects who are developing these conditions. Diagnosis can be performed by any method or technique known in the art. One skilled in the art will appreciate that a subject to be treated in accordance with the present disclosure may have undergone standard testing, or may have been identified without examination as a subject at risk due to the presence of one or more risk factors associated with the disease or condition.
[0458] Description of the drawings Figure 1A-1B is a series of graphs showing dose response curves of BMP6 inhibition of anti-ALK2 fABs in C2C12 cells using a SMAD1 luciferase reporter. The 50% inhibition values (IC50) from three- and four-parameter curve fits in Graphpad Prism are shown next to each graph. Figure 1A is a graph of dose response curves from the first four fABs generated. Figure 1B is a graph of dose response curves from five second round fABs generated from rapid pool maturation.
[0459] Figure 2 is a graph showing the effect of treatment with ALK2 antibody on hemoglobin levels in a mouse model of IRIDA. Treatment with ALK2 antibody prevented the hemoglobin reduction associated with TMPRSS6 deficiency (* = p < 0.05; ** = p < 0.01).
[0460] Figures 3A-3C is a series of graphs showing the effects of treatment with ALK2 antibody on hemoglobin levels, hepcidin concentrations, and iron levels in a mouse model of IRIDA. Treatment with ALK2 antibody reversed the hemoglobin reduction associated with TMPRSS6 deficiency (* = p < 0.05; ** = p < 0.01, Figure 3A ), increased serum hepcidin associated with TMPRSS6 deficiency (** = p < 0.01, Figure 3B ), and decreased serum iron associated with TMPRSS6 deficiency (* = p < 0.05; ** = p < 0.01).
[0461] Figure 4 is a graph showing the effect of treatment with ALK2 antibody on bone mineral density in a mouse model of osteoporosis. Treatment with ALK2 antibody increases bone mineral density (reduces bone loss) associated with orchiectomy (* = p < 0.05; **** = p < 0.0001).
[0462] Figure 5 The amino acid sequence of Antibody 1 is shown (SEQ ID NO: 67), with the light and heavy chain CDR1, CDR2 and CDR3 domains highlighted and the amino acid positions provided. The start and end amino acids of the variable light chain, constant light chain, variable heavy chain, CH1 domain, EcoRI linker, Flag tag, tag linker and six amino acid histidine tag are also provided.
[0463] Figure 6 The amino acid sequence of Antibody 2 is shown (SEQ ID NO: 68), with the light and heavy chain CDR1, CDR2 and CDR3 domains highlighted and the amino acid positions provided. The start and end amino acids of the variable light chain, constant light chain, variable heavy chain, CH1 domain, EcoRI linker, Flag tag, tag linker and six amino acid histidine tag are also provided.
[0464] Figure 7 The amino acid sequence of Antibody 3 is shown (SEQ ID NO: 69), with the light and heavy chain CDR1, CDR2 and CDR3 domains highlighted and the amino acid positions provided. The start and end amino acids of the variable light chain, constant light chain, variable heavy chain, CH1 domain, EcoRI linker, Flag tag, tag linker and six amino acid histidine tag are also provided.
[0465] Figure 8 The amino acid sequence of Antibody 4 is shown (SEQ ID NO: 70), with the light and heavy chain CDR1, CDR2 and CDR3 domains highlighted and the amino acid positions provided. The start and end amino acids of the variable light chain, constant light chain, variable heavy chain, CH1 domain, EcoRI linker, Flag tag, tag linker and six amino acid histidine tag are also provided.
[0466] Fig. 9 The amino acid sequence of antibody 5 is shown (SEQ ID NO: 71), with the light and heavy chain CDR1, CDR2 and CDR3 domains highlighted and the amino acid positions provided. The start and end amino acids of the variable light chain, constant light chain, variable heavy chain, CH1 domain, EcoRI linker, Flag tag, tag linker and six amino acid histidine tag are also provided.
[0467] Fig.10 The amino acid sequence of antibody 6 is shown (SEQ ID NO: 72), with the light and heavy chain CDR1, CDR2 and CDR3 domains highlighted and the amino acid positions provided. The variable light chain, constant light chain, variable heavy chain, CH1 domain, EcoRI linker, Flag tag, tag linker and the start and end amino acids of the six amino acid histidine tag are also provided.
[0468] Fig.11 The amino acid sequence of antibody 7 is shown (SEQ ID NO: 73), with the light and heavy chain CDR1, CDR2 and CDR3 domains highlighted and the amino acid positions provided. The variable light chain, constant light chain, variable heavy chain, CH1 domain, EcoRI linker, Flag tag, tag linker and the start and end amino acids of the six amino acid histidine tag are also provided.
[0469] Fig.12 The amino acid sequence of antibody 8 is shown (SEQ ID NO: 74), with the light and heavy chain CDR1, CDR2 and CDR3 domains highlighted and the amino acid positions provided. The variable light chain, constant light chain, variable heavy chain, CH1 domain, EcoRI linker, Flag tag, tag linker and the start and end amino acids of the six amino acid histidine tag are also provided.
[0470] Fig.13 The amino acid sequence of antibody 9 is shown (SEQ ID NO: 75), with the light and heavy chain CDR1, CDR2 and CDR3 domains highlighted and the amino acid positions provided. The variable light chain, constant light chain, variable heavy chain, CH1 domain, EcoRI linker, Flag tag, tag linker and the start and end amino acids of the six amino acid histidine tag are also provided. DETAILED DESCRIPTION OF THE INVENTION Described herein are methods for treating bone disease, anemia, heterotopic ossification (e.g., heterotopic ossification caused by FOP), Sjögren's syndrome (e.g., dry eye associated with Sjögren's syndrome), DIPG, MO, PCO, or cardiac hypertrophy and / or cardiac fibrosis. The invention features ALK2 antibodies (e.g., neutralizing antibodies) and antigen-binding fragments thereof (e.g., ALK2 binding fragments), as well as nucleic acid molecules containing nucleotide sequences encoding the antibodies or ALK2 binding fragments thereof, and expression vectors comprising nucleic acid molecules containing nucleotide sequences encoding the antibodies or ALK2 binding fragments thereof. The invention also features the use of the ALK2 antibodies or antigen-binding fragments thereof, nucleic acid molecules, expression vectors and compositions described herein to treat or prevent bone diseases (e.g., diseases or conditions involving bone damage, such as primary osteoporosis, secondary osteoporosis, osteopenia, osteosclerosis, fractures, bone cancer or cancer metastasis-related bone loss, Paget's disease, renal osteodystrophy, treatment-related bone loss, diet-related bone loss, bone loss associated with obesity treatment, low gravity-related bone loss, or bone loss associated with immobility), low red blood cell levels (e.g., low hemoglobin levels or low red blood cell counts, such as anemia), heterotopic ossification (e.g., heterotopic ossification caused by FOP), Sjögren's syndrome (e.g., dry eyes associated with Sjögren's syndrome), DIPG, MO, PCO, or cardiac hypertrophy and / or cardiac fibrosis in a subject, such as a human subject.
[0472] ALK2 antibody ALK2 (also known as ACVR1) is a bone morphogenetic protein (BMP) receptor in the transforming growth factor beta (TGF-β) superfamily. ALK2 is widely expressed in many tissues during embryonic development and highly expressed in bone during postnatal development and is thought to have an important role in both osteogenesis and chondrogenesis. Gain-of-function mutations in ALK2 have been found in subjects with FOP, including c.617G>A (p.R206H), c.619C>G (p.Q207E), c.1067G>A (p.G356D), c.982G>T (p.G328W), c.983G>A (p.G328E), c.982G>A (p.G328R), c.774G>C / c.774G>T (p.R258S), c.1124G>C (p.R375P), c.587T>C (p.L196P), c.590–592delCTT (p.P197_F198delinsL), and c.605G>T (p.R202I). R206HStudies with mutant mice have shown that ALK2 regulates osteogenic differentiation of mesenchymal stem cells. Activating mutations in ALK2 have also been observed in approximately 25% of DIPG patients, and small molecule ALK2 inhibitors have been found to prolong survival and reduce cell number in an orthotopic DIPG xenograft model. ALK2 may also play a role in anemia, as the SMAD signaling pathway induces upregulation of hepcidin through BMP activation of ALK2, which is a major regulator of iron homeostasis involved in anemia of inflammation (also known as anemia of chronic disease) and iron-refractory iron deficiency anemia (IRIDA). ALK2 also promotes the proliferation of lens epithelial cells during development; therefore, inhibition of ALK2 can prevent or reduce the abnormal proliferation of lens epithelial cells that leads to PCO. In addition, small molecule ALK2 inhibitors have been found to reduce inflammation and treat symptoms of Sjögren's syndrome in established mouse models, and to reduce osteochondroma formation, growth, and size in multiple studies using mouse models of MO. Furthermore, treatment with a small molecule ALK2 inhibitor and cardiomyocyte-specific deletion of ALK2 both reduced cardiac hypertrophy and left ventricular fibrosis in mice. Furthermore, the role of ALK2 ligands in promoting fibrosis suggests that inhibition of ALK2 can be used to treat diseases or conditions in which fibrosis promotes pathology (e.g., fibrosis of the posterior capsule in PCO, fibrosis of the lacrimal gland in Sjögren's syndrome, and fibrosis in cardiac fibrosis and / or cardiac hypertrophy).
[0473] The present invention is based in part on the discovery that the ALK2 antibodies described herein restore hemoglobin levels, hepcidin concentrations, and iron levels in a mouse model of IRIDA, and increase bone density (e.g., reduce bone loss) in a mouse model of osteoporosis. Without wishing to be bound by theory, the finding that the ALK2 antibodies restore hemoglobin levels in the TMPRSS6 knockdown model of IRIDA suggests that the ALK2 antibodies described herein may be used to treat inflammatory anemias, because TMPRSS6 is used to inhibit hepcidin secretion and inflammatory anemias are often characterized by elevated hepcidin levels. In view of the ALK2 gain-of-function mutations that have been identified in patients with FOP and DIPG, the ALK2 antibodies or antigen-binding fragments thereof described herein may also be used for FOP treatment and / or for the prevention or treatment of heterotopic ossification and for the treatment of DIPG or for prolonging the survival of subjects with DIPG. Previous studies have also shown that small molecule ALK2 inhibitors can be used to treat symptoms of Sjögren's syndrome, MO (e.g., reducing the formation, growth, or size of osteochondromas), and cardiac hypertrophy and cardiac fibrosis, and therefore, the ALK2 antibodies or antigen-binding fragments thereof described herein can also be used to treat these conditions. Finally, the necessity of ALK2 for promoting lens epithelial cell proliferation suggests that inhibition of ALK2 may be effective in treating PCO. Thus, the ALK2 antibodies or antigen-binding fragments thereof), nucleic acid molecules, expression vectors and compositions described herein can be administered to a subject, such as a human subject, to treat or prevent a bone disease (e.g., a disease or condition involving bone damage, such as primary osteoporosis, secondary osteoporosis, osteopenia, osteosclerosis, fracture, bone cancer or cancer metastasis-related bone loss, Paget's disease, renal osteodystrophy, treatment-related bone loss, diet-related bone loss, bone loss associated with obesity treatment, low gravity-related bone loss, or bone loss associated with immobility), anemia (e.g., IRIDA, anemia of inflammation), heterotopic ossification (e.g., heterotopic ossification caused by FOP), Sjögren's syndrome (e.g., dry eye associated with Sjögren's syndrome), DIPG, MO, PCO, or cardiac hypertrophy and / or cardiac fibrosis.
[0474] Vectors, host cells, and protein production The ALK2 antibodies and antigen-binding fragments thereof described herein (e.g., ALK2 binding fragments) can be produced from host cells. A host cell refers to a medium containing the necessary cellular components (e.g., organelles) required to express the antibodies and antigen-binding fragments thereof described herein from their corresponding nucleic acids. The nucleic acid can be included in a nucleic acid vector, which can be introduced into a host cell by conventional techniques known in the art (e.g., transformation, transfection, electroporation, calcium phosphate precipitation, direct microinjection, injection, etc.). The selection of the nucleic acid vector depends in part on the host cell to be used. Typically, preferred host cells are of eukaryotic (e.g., mammalian) or prokaryotic (e.g., bacterial) origin.
[0475] Nucleic acid vector construction and host cells Nucleic acid sequences encoding the amino acid sequences of the ALK2 antibodies or antigen-binding fragments thereof described herein (e.g., ALK2 binding fragments) can be prepared by various methods known in the art. These methods include, but are not limited to, oligonucleotide-mediated (or site-directed) mutagenesis and PCR mutagenesis. Nucleic acid molecules encoding the ALK2 antibodies or antigen-binding fragments thereof described herein can be obtained using standard techniques (e.g., gene synthesis). Alternatively, standard techniques in the art (e.g., QuikChange TM Mutagenesis) Mutates nucleic acid molecules encoding ALK2 antibodies or antigen-binding fragments thereof described herein to include specific amino acid substitutions. Nucleic acid molecules can be synthesized using a nucleotide synthesizer or PCR technology.
[0476] The nucleic acid sequence encoding the ALK2 antibody or antigen-binding fragment thereof described herein (e.g., ALK2 binding fragment) can be inserted into a vector capable of replicating and expressing the nucleic acid molecule in a prokaryotic or eukaryotic host cell. Many vectors are available in the art and can be used for the purposes of the present invention. Each vector may include various components that can be adjusted and optimized for compatibility with a particular host cell. For example, vector components may include, but are not limited to, an origin of replication, a selectable marker gene, a promoter, a ribosome binding site, a signal sequence, a nucleic acid sequence encoding a target protein, and a transcription termination sequence.
[0477] In some embodiments, mammalian cells can be used as host cells of the present invention. Examples of mammalian cell types include, but are not limited to, human embryonic kidney (HEK) (e.g., HEK293, HEK 293F), Chinese hamster ovary (CHO), HeLa, COS, PC3, Vero, MC3T3, NSO, Sp2 / 0, VERY, BHK, MDCK, W138, BT483, Hs578T, HTB2, BT20, T47D, NSO (a mouse myeloma cell line that does not endogenously produce any immunoglobulin chains), CRL7030, and HsS78Bst cells. In some embodiments, E. coli cells can also be used as host cells of the present invention. Examples of E. coli strains include, but are not limited to, E. coli 294 ( 31,446), Escherichia coli λ1776( 31,537, Escherichia coli BL21(DE3) ( BAA-1025), and Escherichia coli RV308 ( 31,608). Different host cells have characteristics and specific mechanisms for post-transcriptional processing and modification of protein products (e.g., glycosylation). Appropriate cell lines or host systems can be selected to ensure the correct modification and processing of the expressed polypeptide. The above expression vectors can be introduced into appropriate host cells using conventional techniques in the art (e.g., transformation, transfection, electroporation, calcium phosphate precipitation, and direct microinjection). Once the vector is introduced into the host cell for protein production, the host cell is cultured in a conventional nutrient medium appropriately modified for inducing promoters, selecting transformants, or amplifying genes encoding the desired sequence. Methods for expressing therapeutic proteins are known in the art, see, for example, Paulina Balbas, Argelia Lorence (eds.) Recombinant Gene Expression: Reviews and Protocols (Methods in Molecular Biology), Humana Press; 2nd edition 2004 and Vladimir Voynov and Justin A. Caravella (eds.) Therapeutic Proteins: Methods and Protocols (Methods in Molecular Biology) Humana Press; 2nd edition 2012.
[0478] Protein production, recovery and purification Host cells used to produce the ALK2 antibodies or antigen-binding fragments described herein (e.g., ALK2 binding fragments) can be grown in a culture medium known in the art and suitable for culturing the selected host cell. Examples of suitable culture media for mammalian host cells include Minimal Essential Medium (MEM), Dulbecco's Modified Eagle's Medium (DMEM), Expi293 TM Expression medium, DMEM and RPMI-1640 supplemented with fetal bovine serum (FBS). Examples of suitable culture media for bacterial host cells include Luria broth (LB) plus necessary supplements, such as selection agents, such as ampicillin. Host cells are cultured at a suitable temperature such as about 20°C to about 39°C, for example 25°C to about 37°C, preferably 37°C, and CO2 levels, such as 5 to 10%. The pH of the culture medium is generally about 6.8 to 7.4, for example 7.0, depending primarily on the host organism. If an inducible promoter is used in the expression vector of the present invention, protein expression is induced under conditions suitable for activating the promoter.
[0479] In some embodiments, depending on the expression vector and host cell used, the expressed protein can be secreted from the host cell (e.g., a mammalian host cell) into the cell culture medium. Protein recovery can involve filtering the cell culture medium to remove cell debris. The protein can be further purified. The ALK2 antibody or its antigen-binding fragment described herein (e.g., ALK2 binding fragment) can be purified by any method known in the field of protein purification, for example, by chromatography (e.g., ion exchange, affinity and size exclusion column chromatography), centrifugation, differential solubility, or by any other standard technique for protein purification. For example, the protein can be separated and purified by appropriately selecting and combining affinity columns, such as protein A columns (e.g., POROS protein A chromatography)) and chromatographic columns (e.g., POROS HS-50 cation exchange chromatography), filtration, ultrafiltration, salting out, and dialysis procedures.
[0480] In other embodiments, the host cells can be destroyed, for example, by osmotic shock, ultrasonic treatment or lysis to destroy the host cells to recover the expressed protein. Once the cells are destroyed, the cell debris can be removed by centrifugation or filtration. In some cases, the polypeptide can be conjugated to a marker sequence (such as a peptide) to facilitate purification. An example of a marker amino acid sequence is a six-histidine peptide (His-tag), which binds to a nickel-functionalized agarose affinity column with micromolar affinity. Other peptide tags that can be used for purification include, but are not limited to, hemagglutinin "HA" tags, which correspond to epitopes derived from influenza hemagglutinin proteins (Wilson et al., Cell 37:767, 1984).
[0481] Alternatively, the ALK2 antibodies or antigen-binding fragments thereof described herein (e.g., ALK2 binding fragments) can be produced by cells of a subject (e.g., a human), for example, in the context of gene therapy, by administering a vector (such as a viral vector (e.g., a retroviral vector, an adenoviral vector, a poxvirus vector (e.g., a vaccinia virus vector, such as modified vaccinia virus Ankara (MVA)), an adeno-associated virus vector, and an alphavirus vector)) containing a nucleic acid molecule encoding the antibody or antigen-binding fragment thereof described herein. The vector, once within the cells of the subject (e.g., by transformation, transfection, electroporation, calcium phosphate precipitation, direct microinjection, infection, etc.), will promote expression of the antibody or antigen-binding fragment thereof, and the polypeptide is then secreted from the cells. If treatment of the disease or condition is the desired outcome, no further action may be required. If it is desired to collect the protein, blood can be collected from the subject and the protein purified from the blood by methods known in the art.
[0482] Pharmaceutical compositions and preparations The ALK2 antibodies or antigen-binding fragments thereof (e.g., ALK2 binding fragments) described herein can be incorporated into a vehicle for administration to a patient, such as a human patient, who suffers from bone disease, low red blood cell levels (e.g., low hemoglobin levels) or low red blood cell counts, such as anemia), heterotopic ossification (e.g., heterotopic ossification caused by FOP), Sjögren's syndrome (e.g., dry eyes associated with Sjögren's syndrome), MO, DIPG, PCO, or cardiac hypertrophy and / or cardiac fibrosis. In some embodiments, in therapy, pharmaceutical compositions comprising ALK2 antibodies or antigen-binding fragments thereof (e.g., ALK2 binding fragments) described herein can be used in combination with other agents (e.g., therapeutic biologics and / or small molecules) or compositions. Pharmaceutical compositions containing ALK2 antibodies or antigen-binding fragments thereof can be prepared using methods known in the art. For example, such compositions can be prepared using, for example, physiologically acceptable carriers, excipients, or stabilizers (Remington: The Science and Practice of Pharmacology 22nd Edition Allen, L. Ed. (2013); which is incorporated herein by reference), and in a desired form, for example, in the form of a lyophilized formulation or an aqueous solution. In some embodiments, the pharmaceutical compositions of the present invention comprise a nucleic acid molecule (DNA or RNA, such as mRNA) encoding an antibody or ALK binding fragment thereof described herein, or a vector containing such a nucleic acid molecule.
[0483] Acceptable carriers and excipients in the pharmaceutical composition are nontoxic to the receptor at the dosage and concentration used. Acceptable carriers and excipients can include buffers, such as phosphate, citrate, HEPES and TAE, antioxidants, such as ascorbic acid and methionine, preservatives, such as hexamethylammonium chloride, octadecyl dimethyl benzyl ammonium chloride, resorcinol and benzalkonium chloride, proteins, such as human serum albumin, gelatin, dextran and immunoglobulin, hydrophilic polymers, such as polyvinyl pyrrolidone, amino acids, such as glycine, glutamine, histidine and lysine, and carbohydrates, such as glucose, mannose, sucrose and sorbitol. The pharmaceutical composition of the present invention can be administered parenterally in the form of an injectable preparation. Sterile solutions or any pharmaceutically acceptable liquids can be used as vehicles to prepare pharmaceutical compositions for injection. Pharmaceutically acceptable vehicles include, but are not limited to, sterile water, physiological saline and cell culture medium (e.g., Dulbecco's modified Eagle medium (DMEM), α-modified Eagles medium (α-MEMI).
[0484] A mixture of ALK2 antibodies or antigen-binding fragments thereof (e.g., ALK2 binding fragments) can be prepared in water suitably mixed with one or more excipients, carriers or diluents. Dispersions can also be prepared in glycerol, liquid polyethylene glycol, mixtures thereof and oils. Under normal conditions of storage and use, these preparations may contain preservatives to prevent the growth of microorganisms. Pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions (described in US 5,466,468, the disclosure of which is incorporated herein by reference). In any case, the preparation can be sterile and can be a fluid with a degree of easy injectability. The preparation can be stable under manufacturing and storage conditions and can be preserved against the contaminating effects of microorganisms, such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, a polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol, etc.), a suitable mixture thereof and / or a vegetable oil. For example, appropriate fluidity can be maintained by using a coating, such as lecithin, by maintaining the desired particle size in the case of dispersion, and by using a surfactant. The prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be achieved by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
[0485] For example, if necessary, a solution containing a pharmaceutical composition as described herein can be suitably buffered and the liquid diluent first made isotonic with sufficient saline or glucose. These specific aqueous solutions are particularly suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. In this regard, in view of the present disclosure, those skilled in the art will know the sterile aqueous media that can be used. For example, a dose can be dissolved in 1 ml of isotonic NaCl solution and added to 1000 ml of subcutaneous lysate or injected at a proposed infusion site. Depending on the condition of the subject being treated, some changes in dosage will certainly occur.
[0486] The pharmaceutical composition of the present invention can be prepared in microcapsules, such as hydroxymethylcellulose or gelatin-microcapsules and poly-(methyl methacrylate) microcapsules. The pharmaceutical composition of the present invention can also be prepared in other drug delivery systems, such as liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules. Such technology is described in Remington: The Science and Practice of Pharmacology 22nd edition, Allen, L. (2013). The pharmaceutical composition to be used for in vivo administration must be sterile. This can be easily accomplished by filtering through a sterile filtration membrane.
[0487] The pharmaceutical composition of the present invention can also be prepared as a sustained release formulation. Suitable examples of sustained release formulations include semipermeable matrices of solid hydrophobic polymers containing the polypeptide of the present invention. Examples of sustained release matrices include polyesters, hydrogels, polylactides, copolymers of L-glutamic acid and γ-ethyl-L-glutamic acid, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as LUPRON DEPOT TM Some sustained release formulations enable release of the molecule over several months, for example one to six months, while other formulations release the pharmaceutical composition of the invention for shorter periods of time, for example days to weeks.
[0488] The pharmaceutical composition can be formed in a unit dosage form as desired. The amount of active ingredient (e.g., an ALK2 antibody or antigen-binding fragment thereof (e.g., ALK2 binding fragment) described herein) included in the pharmaceutical preparation is such that a suitable dose within a specified range is provided (e.g., a dose within a range of 0.01-100 mg / kg body weight).
[0489] The pharmaceutical composition for gene therapy can be in an acceptable diluent, or can include a sustained-release matrix in which a gene delivery vector is embedded. If hydrodynamic injection is used as a delivery method, a pharmaceutical composition containing a nucleic acid molecule encoding an antibody or its ALK2 binding fragment described herein or a vector (e.g., a viral vector) containing the nucleic acid molecule is delivered rapidly intravenously with a large fluid volume. Vectors that can be used as in vivo gene delivery vehicles include, but are not limited to, retroviral vectors, adenoviral vectors, poxvirus vectors (e.g., vaccinia virus vectors, such as modified vaccinia virus Ankara), adeno-associated virus vectors, and alphavirus vectors.
[0490] Route, Dosage and Administration Pharmaceutical compositions comprising the ALK2 antibodies of the present invention or antigen-binding fragments thereof (e.g., ALK2 binding fragments) as therapeutic agents can be administered by various routes, such as intravenous, parenteral, intradermal, transdermal, intramuscular, intranasal, subcutaneous, transdermal, topical, intratracheal, intraperitoneal, intraarterial, intravascular, intrathecal, intraventricular, inhalation, perfusion, lavage, and oral administration. The pharmaceutical compositions can also be formulated for oral, ocular, nasal, spray, aerosol, rectal or vaginal administration or administered via oral, ocular, nasal, spray, aerosol, rectal or vaginal administration. For injectable formulations, various effective drug carriers are known in the art. See, for example, ASHP Handbook on Injectable Drugs, Toissel, 18th Edition (2014). For ocular administration, the formulation can be delivered systemically by injection (e.g., intraocular injection) or locally (e.g., as a solution, suspension or ointment, such as by instillation (e.g., eye drops)).
[0491] In some embodiments, a pharmaceutical composition comprising a nucleic acid molecule encoding an antibody or ALK2 binding fragment thereof described herein or a vector containing such a nucleic acid molecule can be administered by gene delivery. Methods of gene delivery are well known to those skilled in the art. Vectors that can be used for in vivo gene delivery and expression include, but are not limited to, retroviral vectors, adenoviral vectors, poxvirus vectors (e.g., vaccinia virus vectors, such as modified vaccinia virus Ankara (MVA)), adeno-associated virus vectors, and alphavirus vectors. In some embodiments, mRNA molecules encoding polypeptides of the present invention can be directly administered to a subject.
[0492] In some embodiments of the present invention, a nucleic acid molecule encoding a polypeptide described herein or a vector containing such a nucleic acid molecule can be administered using a hydrodynamic injection platform. In the hydrodynamic injection method, a nucleic acid molecule encoding an antibody or its ALK2 binding fragment described herein is placed under the control of a strong promoter in an engineered plasmid (e.g., a viral plasmid). Plasmids are often delivered rapidly intravenously with large fluid volumes. Hydrodynamic injection uses controlled hydrodynamic pressure in the vein to enhance cell permeability so that the increased pressure from the rapid injection of a large fluid volume causes fluid and plasmids to extravasate from the vein. The expression of nucleic acid molecules is mainly driven by the liver. In mice, hydrodynamic injection is often performed by injecting plasmids into the tail vein. In certain embodiments, mRNA molecules encoding antibodies or their ALK2 binding fragments described herein can be administered using hydrodynamic injection.
[0493] In any given case, the most appropriate route of administration and dosage will depend on the specific composition being administered, the patient, the method of drug formulation, the method of administration (e.g., time of administration and route of administration), the patient's age, weight, sex, severity of the disease being treated, the patient's diet, and the patient's excretion rate. The pharmaceutical compositions of the present invention may include a dosage of an ALK2 antibody or antigen-binding fragment thereof (e.g., ALK2 binding fragment) of the present invention ranging from 0.01 to 500 mg / kg (e.g., 0.01, 0.1, 0.2, 0.3, 0.4, 0.5, 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg / kg), and in a more specific embodiment, about 0.1 to about 30 mg / kg, and in a more specific embodiment, about 0.3 to about 30 mg / kg. The dosage can be adjusted by the physician according to conventional factors, such as the extent of the disease and the individual parameters of the subject.
[0494] The pharmaceutical composition is administered in a manner compatible with the dosage formulation and in a therapeutically effective amount that results in improvement or remedy of symptoms. The pharmaceutical composition is administered in various dosage forms, such as intravenous dosage forms, subcutaneous dosage forms, and oral dosage forms (e.g., ingestible solutions, drug release capsules). Typically, therapeutic antibodies are administered at 0.1-100 mg / kg, for example, 1-50 mg / kg. A pharmaceutical composition comprising an ALK2 antibody or an antigen-binding fragment thereof (e.g., an ALK2 binding fragment) of the present invention can be administered to a subject in need thereof, for example, once or more (e.g., 1-10 times or more) every day, every week, every two weeks, every month, every two months, every quarter, every two years, every year, or when medically necessary. In some embodiments, a pharmaceutical composition comprising an ALK2 antibody or an antigen-binding fragment thereof (e.g., an ALK2 binding fragment) of the present invention can be administered to a subject in need thereof weekly, every two weeks, every month, every two months, or every quarter. The dosage can be provided in a single dose or multiple dose regimen. As the patient's health condition declines, as medical conditions improve or increase, the timing between administrations can be reduced.
[0495] Treatment The compositions and methods described herein can be used to treat and / or prevent (e.g., prevent the development of or treat a subject diagnosed with) a medical condition such as bone disease, anemia or low red blood cell levels (e.g., low hemoglobin levels or low red blood cell counts), heterotopic ossification (e.g., heterotopic ossification caused by FOP), Sjögren's syndrome (e.g., dry eyes associated with Sjögren's syndrome), DIPG, MO, PCO, or cardiac hypertrophy and / or cardiac fibrosis. In some embodiments, an ALK2 antibody (e.g., a neutralizing antibody) or an antigen-binding fragment thereof (e.g., an ALK2 binding fragment) described herein is administered to increase bone mineral density, increase bone formation, increase bone strength, reduce bone resorption (e.g., bone loss), or reduce the risk of fractures in a subject in need thereof. Compared to the measured values obtained before treatment or compared to the risk of bone mineral density, bone strength, bone formation, bone resorption or fractures generally observed in untreated subjects, the ALK2 antibodies or antigen-binding fragments thereof described herein (e.g., ALK2 binding fragments) can increase bone mineral density, increase bone formation, increase bone strength, reduce bone resorption (e.g., bone loss), or reduce the risk of fractures. In some embodiments, the subject may have a disease that causes bone damage (e.g., osteoporosis or osteopenia) or be at risk of developing it. In some embodiments of the methods described herein, the subject has a disease or condition involving bone damage (e.g., primary osteoporosis, secondary osteoporosis, osteopenia, osteosclerosis, fracture, bone cancer or cancer metastasis-related bone loss, Paget's disease, renal osteodystrophy, treatment-related bone loss, diet-related bone loss, bone loss associated with obesity treatment, low gravity-related bone loss, or bone loss associated with immobility) or is at risk of developing it. The present invention also includes methods of treating a subject having or at risk of developing primary osteoporosis, secondary osteoporosis, osteopenia, osteosclerosis, bone fractures, bone cancer or cancer metastasis-related bone loss, Paget's disease, renal osteodystrophy, treatment-related bone loss, diet-related bone loss, obesity treatment-related bone loss, low gravity-related bone loss, or immobility-related bone loss by administering to the subject an effective amount of an ALK2 antibody or antigen-binding fragment thereof described herein (e.g., ALK2 binding fragment).
[0496] In any of the methods described herein, a subject having a bone disease (e.g., bone injury) or being at risk of developing a bone disease (e.g., bone injury) has a disease or condition or is at risk of developing a disease or condition, including primary osteoporosis, secondary osteoporosis, osteopenia, osteosclerosis, fracture, bone cancer or cancer metastasis-related bone loss, Paget's disease, renal osteodystrophy, treatment-related bone loss, diet-related bone loss, bone loss associated with obesity treatment, low gravity-related bone loss, or bone loss associated with immobility. In some embodiments, the primary osteoporosis is age-related or hormone-related osteoporosis (e.g., associated with estrogen decline). In some embodiments, the secondary osteoporosis is immobilization-induced or glucocorticoid-induced osteoporosis. In some embodiments, the bone cancer is multiple myeloma or the bone loss associated with cancer metastasis is caused by multiple myeloma. In some embodiments, the bone loss associated with the treatment is due to treatment with FGF-21 or GLP-1, due to treatment with a therapeutic agent containing FGF-21 or GLP-1, or due to treatment of type 2 diabetes and / or obesity, or due to cancer therapy (e.g., chemotherapy or radiation). In some embodiments, the diet-related bone loss is rickets (e.g., vitamin D deficiency). In some embodiments, the low gravity-related bone loss lacks load-related bone loss. In some embodiments, the methods described herein increase bone mineral density (e.g., increase bone mass). In some embodiments, compared to the measured values obtained before treatment or compared to the bone resorption usually observed in untreated subjects, the methods described herein reduce bone resorption (e.g., reduce bone decomposition activity or reduce bone loss), such as reducing bone resorption. In some embodiments, compared to the measured values obtained before treatment or compared to the bone formation usually observed in untreated subjects, the methods described herein increase bone formation (e.g., increase bone anabolic activity or increase osteogenesis), such as increasing bone formation. In some embodiments, the methods described herein increase osteoblast activity or osteoblast generation, such as increasing osteoblast activity or osteoblast generation, compared to the measured values obtained before treatment or compared to the osteoblast activity or osteoblast generation typically observed in untreated subjects. In some embodiments, the methods described herein reduce osteoclast activity or osteoclast generation, such as reducing osteoclast activity or osteoclast generation, compared to the measured values obtained before treatment or compared to the osteoclast activity or osteoclast generation typically observed in untreated subjects. In some embodiments, the bone is cortical bone or cancellous bone.
[0497] In some embodiments, an ALK2 antibody or antigen-binding fragment thereof (e.g., ALK2 binding fragment) described herein is administered to increase red blood cell levels (e.g., increase hemoglobin levels, increase red blood cell counts, or increase red blood cell formation or production) in a subject in need thereof. The ALK2 antibody or antigen-binding fragment thereof (e.g., ALK2 binding fragment) described herein can increase red blood cell levels (e.g., increase hemoglobin levels, red blood cell counts, or red blood cell formation) compared to measurements obtained before treatment or compared to red blood cell levels typically observed in untreated subjects. In some embodiments, the subject may have a disease or condition associated with low red blood cell levels (e.g., anemia or blood loss). In some embodiments of the methods described herein, the subject has a disease or condition involving low red blood cell levels (e.g., anemia or blood loss, such as aplastic anemia, iron deficiency anemia, iron-refractory iron deficiency anemia (IRIDA), anemia of inflammation (also known as anemia of chronic disease, such as anemia caused by inflammatory diseases or conditions (such as infection (e.g., chronic infection, such as HIV / AIDS or tuberculosis), autoimmune disease (e.g., rheumatoid arthritis or lupus), cancer (e.g., cancer or cancer treatment), inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis), and chronic kidney disease). The present invention also includes treating the subject with an effective amount of an ALK2 antibody described herein. Methods for treating subjects with low red blood cell levels (e.g., low hemoglobin levels or low red blood cell counts, such as anemia) or at risk of developing low red blood cell levels (e.g., low hemoglobin levels or low red blood cell counts, such as anemia) using a combination of an antibody or an antigen-binding fragment thereof (e.g., an ALK2 binding fragment). The methods described herein may include the step of screening subjects for one or more mutations in genes known to be associated with anemia (e.g., mutations in TMPRSS6 associated with IRIDA) prior to treatment with a composition described herein or administration of a composition described herein. Subjects may be screened for gene mutations using standard methods known to those skilled in the art (e.g., genetic testing).
[0498] The present invention also includes methods of treating a subject having anemia or blood loss or at risk of developing anemia or blood loss by administering to the subject an effective amount of an ALK2 antibody or antigen-binding fragment thereof described herein (e.g., ALK2 binding fragment). In any of the methods described herein, a subject having low red blood cell levels (e.g., low hemoglobin levels or low red blood cell counts) or at risk of developing low red blood cell levels (e.g., low hemoglobin levels or low red blood cell counts) has anemia or blood loss or is at risk of developing anemia or blood loss. In some embodiments, anemia is associated with or caused by nutritional deficiencies (e.g., vitamin deficiencies), bone marrow defects (e.g., paroxysmal nocturnal hemoglobinuria), adverse reactions to drug therapy (e.g., antiretroviral HIV drugs), myelodysplastic syndrome, bone marrow transplantation, cancer (e.g., solid tumors such as breast cancer, lung cancer, colon cancer; lymphatic system tumors such as chronic lymphocytic leukemia, non-Hodgkin's lymphoma, Hodgkin's lymphoma; or hematopoietic system tumors such as leukemia or multiple myeloma), cancer treatment (e.g., radiation or chemotherapy, such as chemotherapy with platinum-containing agents), inflammatory or autoimmune diseases (e.g., rheumatoid arthritis, other inflammatory arthritis, systemic lupus erythematosus (SLE), acute or chronic skin diseases (e.g., psoriasis), or inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis). enteritis), cystitis, gastritis), acute or chronic renal disease or failure (e.g., chronic kidney disease) including idiopathic or congenital conditions, acute or chronic liver disease, acute or chronic bleeding, infection (e.g., malaria, osteomyelitis), splenomegaly, porphyria, vasculitis, hemolysis, urinary tract infection, hemoglobinopathies (e.g., sickle cell disease), thalassemia, Churg-Fernandez syndrome, Felty syndrome, graft-versus-host disease, hematopoietic stem cell transplantation, myelofibrosis, pancytopenia, pure red cell aplasia, Henoch-Schonlein purpura, Schwabmann syndrome (e.g., Schwartz-Diesel syndrome), drug abuse or misuse (e.g., alcohol abuse), or contraindications to transfusion (e.g., elderly patients, patients with allo- or autoantibodies, pediatric patients, patients with cardiopulmonary disease, patients who object to transfusion for religious reasons (e.g., some Jehovah's Witnesses).In some embodiments, the anemia is aplastic anemia, iron deficiency anemia, iron refractory iron deficiency anemia (IRIDA), vitamin deficiency anemia, anemia of inflammation (also known as anemia of chronic disease, e.g., anemia caused by inflammatory diseases or conditions such as infection (e.g., chronic infection, such as HIV / AIDS or tuberculosis), autoimmune diseases (e.g., rheumatoid arthritis or lupus), cancer, inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis), and chronic kidney disease), anemia associated with bone marrow disease, hemolytic anemia, sickle cell anemia, microcytic anemia, hypochromic anemia, sideroblastic anemia, DeBoudet's anemia, Fanconi anemia, or refractory anemia with blastosis. In some embodiments, the anemia is associated with elevated hepcidin levels (e.g., elevated compared to hepcidin levels in subjects without anemia). Compositions and methods described herein can also be used to treat subjects who do not respond well to erythropoietin (EPO), or are susceptible to adverse effects of EPO (e.g., hypertension, headache, vascular thrombosis, flu-like syndrome, shunt obstruction, and myocardial infarction). In some embodiments, blood loss is due to surgery, trauma, wounds, ulcers, urinary tract bleeding, gastrointestinal bleeding, frequent blood donations, or excessive menstrual bleeding (e.g., menorrhagia). In some embodiments, compared to the measured values obtained before treatment or compared to the red blood cell levels usually observed in untreated subjects, the methods described herein increase red blood cell levels (e.g., hemoglobin levels or red blood cell counts). In some embodiments, compared to the measured values obtained before treatment or compared to the red blood cell levels usually observed in untreated subjects, the methods described herein increase or induce red blood cell formation. In some embodiments, compositions and methods described herein reduce the need for subject transfusion (e.g., subject no longer needs transfusion, or subject needs less frequent transfusion than before treatment with compositions and methods described herein). Subjects with normal red blood cell levels can also be treated using the methods and compositions described herein to increase red blood cell levels so that blood can be drawn and stored for use in a later transfusion.
[0499] In some embodiments, the ALK2 antibodies or antigen-binding fragments thereof described herein (e.g., ALK2 binding fragments) can be administered to a subject to treat FOP, slow or stop the progression of FOP, delay the onset of FOP (e.g., delay the development of heterotopic ossification), or prevent or reduce heterotopic ossification (e.g., the formation of bone in muscle, tendon, ligament or other connective tissue, e.g., preventing or reducing heterotopic ossification in a subject with FOP who has already experienced heterotopic ossification, or preventing the development of heterotopic ossification in a subject who has not yet exhibited heterotopic ossification), such as heterotopic ossification in a subject with FOP. The FOP can be hereditary FOP (e.g., FOP associated with germline transmission of a mutation, such as an autosomal dominant mutation) or sporadic FOP (e.g., FOP associated with a spontaneous, non-inherited mutation). The ALK2 antibodies or antigen-binding fragments thereof described herein (e.g., ALK2 binding fragments) can reduce the amount of heterotopic bone, reduce the formation of heterotopic bone, or reduce the recurrence of heterotopic bone (e.g., recurrence after surgical resection) compared to the amount of heterotopic bone, the formation of heterotopic bone, or the recurrence of heterotopic bone observed in untreated or control-treated subjects. The ALK2 antibodies or antigen-binding fragments thereof described herein (e.g., ALK2 binding fragments) can prevent the formation of heterotopic bone (e.g., in subjects at risk of developing heterotopic ossification, such as subjects with FOP, or prevent the recurrence of heterotopic bone, such as recurrence after surgical resection). In some embodiments, the subject is at risk of developing heterotopic ossification (e.g., the subject has a genetic mutation associated with FOP, but has not yet shown symptoms of FOP, such as heterotopic ossification). The methods described herein may include a step of screening the subject for one or more mutations in a gene known to be associated with FOP (e.g., mutations in ALK2, also known as activin type A I receptor (ACVR1)) prior to treating with a composition described herein or administering a composition described herein. Subjects can be screened for genetic mutations using standard methods known to those of skill in the art (eg, genetic testing).
[0500] In some embodiments, the ALK2 antibodies or antigen-binding fragments thereof described herein (e.g., ALK2 binding fragments) can be administered to a subject to treat Sjögren's syndrome (e.g., treat dry eyes associated with Sjögren's syndrome) or reduce one or more symptoms of Sjögren's syndrome (e.g., reduce dry eyes or dry mouth associated with Sjögren's syndrome). The ALK2 antibodies or antigen-binding fragments thereof described herein (e.g., ALK2 binding fragments) can reduce eye irritation, reduce fibrosis of the tear glands, reduce inflammation of the tear glands, improve vision, increase saliva production, increase tear production (e.g., increase tear volume production), reduce systemic inflammation, reduce joint pain or reduce fatigue in a subject with Sjögren's syndrome, or reduce the severity or incidence of one or more symptoms of Sjögren's syndrome (e.g., reduce dry eyes, dry mouth, or joint pain associated with Sjögren's syndrome) compared to the severity or incidence of eye irritation, vision, inflammation or fibrosis of the tear glands, saliva production, tear production, systemic inflammation, joint pain, fatigue, or symptoms of Sjögren's syndrome in a subject before treatment or in an untreated subject with Sjögren's syndrome.
[0501] In some embodiments, the ALK2 antibodies or antigen-binding fragments thereof described herein (e.g., ALK2 binding fragments) can be administered to a subject to treat DIPG, increase the survival (e.g., survival time, e.g., lifespan) of a subject with DIPG, increase the progression-free survival of a subject with DIPG, reduce DIPG tumor growth, reduce DIPG tumor size or volume, or prevent or reduce DIPG tumor metastasis. The ALK2 antibodies or antigen-binding fragments thereof described herein (e.g., ALK2 binding fragments) can increase the survival (e.g., survival time, e.g., lifespan) of a subject with DIPG, increase the progression-free survival of a subject with DIPG, reduce DIPG tumor growth, reduce DIPG tumor size or volume, or prevent or reduce DIPG tumor metastasis, compared to untreated or control treated subjects or compared to tumor growth, tumor size or volume in subjects before treatment. In some embodiments, the subject has an activating mutation in ALK2 (ACVR1). The methods described herein may include the step of screening a subject for a mutation in ALK2 (ACVR1) prior to treating with a composition described herein or administering a composition described herein. Subjects can be screened for genetic mutations using standard methods known to those of skill in the art (eg, genetic testing).
[0502] In some embodiments, an ALK2 antibody or antigen-binding fragment thereof described herein (e.g., an ALK2 binding fragment) can be administered to a subject to treat MO, reduce or prevent the formation of osteochondromas in a subject with MO, reduce the number of osteochondromas in a subject with MO, reduce the size of an osteochondroma in a subject with MO, or slow the growth of an osteochondroma in a subject with MO. Osteochondromas can form on the growing ends (metaphysis) of bones, on long bones (e.g., long bones of the legs, arms, or toes), and / or on flat bones (e.g., hip bones (pelvic bones), ribs, or shoulder blades). The ALK2 antibodies or antigen-binding fragments thereof described herein (e.g., ALK2 binding fragments) can reduce or prevent the formation of osteochondromas (e.g., prevent the formation of osteochondromas in subjects with MO who have not yet developed osteochondromas or reduce or prevent the formation of osteochondromas in subjects with MO who have developed one or more osteochondromas, reduce the number of osteochondromas, reduce the size of osteochondromas, or slow the growth of osteochondromas, compared to the formation of osteochondromas in subjects before treatment or in untreated subjects with MO. The methods described herein may include a step of screening subjects for mutations in EXT1 or EXT2 prior to treatment with a composition described herein or administration of a composition described herein. Subjects can be screened for genetic mutations using standard methods known to those skilled in the art (e.g., genetic testing).
[0503] In some embodiments, the ALK2 antibodies or antigen-binding fragments thereof described herein (e.g., ALK2 binding fragments) can be administered to a subject to treat PCO, reduce or prevent the development of PCO (e.g., prevent the development of PCO in a subject who has undergone cataract surgery but has not yet developed PCO or in a subject who is about to undergo cataract surgery, e.g., will undergo cataract surgery within 6 months, 5 months, 4 months, 3 months, 2 months, 1 month, 2 weeks, 1 week or less, e.g., a subject who is at risk of developing PCO), improve visual acuity in a subject with PCO (e.g., reduce The invention relates to reducing or inhibiting ocular inflammation in a subject with PCO (e.g., reducing blurred or cloudy vision), reducing light sensitivity or glare in a subject with PCO, reducing or preventing fibrosis (e.g., fibrosis near an implanted lens, such as fibrosis on or near the posterior capsule), reducing or inhibiting lens epithelial cell proliferation, reducing or preventing lens fiber differentiation, or reducing or preventing ocular inflammation in a subject with PCO or at risk of developing PCO (e.g., in a subject who has undergone or is about to undergo cataract surgery, e.g., in a subject who will undergo cataract surgery within 6 months, 5 months, 4 months, 3 months, 2 months, 1 month, 2 weeks, 1 week or less). The ALK2 antibodies or antigen-binding fragments thereof described herein (e.g., ALK2 binding fragments) can reduce or prevent the development of PCO, reduce or prevent fibrosis (e.g., fibrosis near an implanted lens, e.g., fibrosis on or near the posterior capsule), reduce or prevent lens fiber differentiation, reduce or inhibit lens epithelial cell proliferation, or reduce or prevent ocular inflammation in a subject at risk of developing PCO, compared to the development of PCO, fibrosis (e.g., fibrosis near an implanted lens, e.g., fibrosis on or near the posterior capsule), lens fiber differentiation, lens epithelial cell proliferation, or reduce or prevent ocular inflammation in an untreated subject, or can improve visual acuity (e.g., reduce blurred or cloudy vision) or reduce light sensitivity or glare, reduce fibrosis, reduce ocular inflammation, reduce lens epithelial cell proliferation, or reduce lens fiber differentiation in a subject before treatment.
[0504] In some embodiments, the ALK2 antibodies or antigen-binding fragments thereof described herein (e.g., ALK2 binding fragments) can be administered to a subject to treat cardiac hypertrophy, treat cardiac fibrosis, slow down or prevent the development of cardiac hypertrophy (e.g., in a subject at risk of developing cardiac hypertrophy, such as a subject with hypertension or valvular disease), slow down or prevent the development of cardiac fibrosis (e.g., in a subject at risk of developing cardiac fibrosis, such as a subject with hypertension, a subject who has had a myocardial infarction, a subject with diabetic hypertrophic cardiomyopathy, or a subject with idiopathic dilated cardiomyopathy). of left ventricular wall stress, wall tension and / or wall thickness, increase myocardial contractility, decrease myocardial cell area, decrease extracellular matrix deposition in the myocardium, improve quality of life, and / or reduce disease-related morbidity and mortality). The ALK2 antibodies or antigen-binding fragments thereof described herein (e.g., ALK2 binding fragments) slow or prevent the development of cardiac hypertrophy, slow or prevent the development of cardiac fibrosis, reverse cardiac fibrosis, reduce or inhibit cardiac scarring, increase or induce cardiac regeneration, or improve one or more symptoms of cardiac hypertrophy or cardiac fibrosis in subjects having cardiac hypertrophy or cardiac fibrosis or at risk of developing cardiac hypertrophy or cardiac fibrosis, compared to the development of cardiac hypertrophy, development of cardiac fibrosis, extent of cardiac fibrosis, cardiac scarring, cardiac regeneration, or one or more symptoms of cardiac hypertrophy or cardiac fibrosis in subjects before treatment or in untreated or control-treated subjects.
[0505] The compositions described herein are administered in an amount sufficient to increase bone mineral density, increase bone strength, density, reduce bone resorption (e.g., bone loss), reduce the rate of bone resorption (e.g., bone loss), increase bone formation, increase the rate of bone formation, reduce osteoclast activity, increase osteoblast activity, reduce the risk of bone fractures, increase red blood cell levels, increase hemoglobin levels, reduce the need for blood transfusions, increase red blood cell formation, or increase red blood cell counts, treat anemia, increase iron levels, reduce iron deficiency, reduce elevated hepcidin levels, treat FOP, prevent heterotopic ossification (e.g., prevent the initial formation of heterotopic bone in a subject or prevent the recurrence of heterotopic bone after surgical resection), slow or stop the progression of FOP, delay the onset of FOP (e.g., delay the onset of heterotopic bone The invention relates to a method for treating a subject with DIPG, wherein the present invention provides an agent for treating a subject with DIPG, wherein the present invention provides an agent for treating a subject with DIPG, wherein the present invention provides an agent for treating a subject with DIPG, wherein the present invention provides an agent for treating a subject with DIPG, wherein the present invention provides an agent for treating a subject with DIPG, wherein the present invention provides an agent for treating a subject with DIPG, wherein the present invention provides an agent for treating a subject with DIPG, wherein the present invention provides an agent for treating a subject with DIPG, wherein the present invention provides an agent for treating a subject with DIPG, wherein the present invention provides an agent for treating a subject with DIPG, wherein the present invention provides an agent for treating a subject with DIPG, wherein the present invention provides an agent for treating a subject with DIPG, wherein the present invention provides an agent for treating a subject with DIPG, wherein the present The invention relates to the present invention to reduce or inhibit the growth of a DIPG tumor, reduce the size or volume of a DIPG tumor, prevent or reduce DIPG tumor metastasis, treat MO, reduce or prevent the formation of an osteochondroma in a subject with MO, reduce the number of osteochondromas in a subject with MO, reduce the size of an osteochondroma in a subject with MO, slow the growth of an osteochondroma in a subject with MO, reduce or prevent the development of PCO, improve visual acuity (e.g., reduce blurred or cloudy vision) in a subject with PCO, reduce light sensitivity or glare in a subject with PCO, reduce or prevent fibrosis (e.g., fibrosis near an implanted lens, such as fibrosis on or near the posterior capsule), reduce or inhibit lens epithelial cell proliferation, reduce or prevent Preventing lens fiber differentiation or reducing or preventing eye inflammation in a subject with PCO, treating cardiac hypertrophy, treating cardiac fibrosis, slowing or preventing the development of cardiac hypertrophy, slowing or preventing the development of cardiac fibrosis, reversing cardiac fibrosis, reducing or inhibiting cardiac scarring, increasing or inducing cardiac regeneration, or improving one or more symptoms of cardiac hypertrophy or cardiac fibrosis (e.g., increasing exercise capacity, increasing ejection volume, reducing left ventricular end-diastolic pressure, reducing pulmonary capillary wedge pressure, increasing cardiac output, increasing cardiac index, reducing pulmonary artery pressure, reducing left ventricular end-systolic and end-diastolic dimensions, reducing left and right ventricular wall stress, reducing wall tension and / or wall thickness, increasing myocardial contractility, reducing extracellular matrix deposition in the myocardium, improving quality of life,and / or reduce disease-related morbidity and mortality). Bone mineral density can be assessed using well-established clinical techniques known to those skilled in the art (e.g., by dual-energy x-ray absorptiometry). Red blood cell levels can be assessed using standard blood tests that measure red blood cell counts and hemoglobin levels. Symptoms of FOP (e.g., heterotopic ossification) and MO (e.g., osteochondroma) can be assessed using standard imaging methods, such as radiographs (e.g., X-rays), CT (computed tomography), and / or MRI (magnetic resonance imaging). DIPG tumor size, growth, volume, or metastasis can be assessed using imaging methods (such as MRI). Symptoms of cardiac hypertrophy and / or cardiac fibrosis can be assessed using clinical methods that assess cardiac function and morphology (e.g., stress testing, echocardiography, CT, MRI, cardiac magnetic resonance imaging, single photon emission computed tomography, positron emission tomography, balloon catheter-based methods, or histological analysis of biopsies). Sjögren's syndrome and PCO symptoms can be evaluated by assessing visual function and imaging the eye to evaluate inflammation and / or fibrosis (e.g., using slit lamp imaging to assess fibrosis formed on the posterior capsule). The methods described herein may also include the step of evaluating bone mineral density, red blood cell levels, or syndromes of FOP, DIPG, MO, PCO, Sjögren's syndrome, or cardiac hypertrophy and / or cardiac fibrosis in the subject before treatment with a composition described herein or administration of a composition described herein, or after administration of a composition described herein or treatment with a composition described herein. The subject can be evaluated 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, or longer after administration of the ALK2 antibody or antigen-binding fragment thereof (e.g., ALK2 binding fragment) or pharmaceutical composition, depending on the dose and route of administration used for treatment. Depending on the results of the evaluation, the subject may receive additional treatment. ,
[0506] Nucleic acids encoding ALK2 antibodies or antigen-binding fragments thereof (eg, ALK2 binding fragments) described herein or expression vectors containing the nucleic acids can also be administered according to any of the methods described herein. In any of the methods described herein, the polypeptide, nucleic acid or vector can be administered as part of a pharmaceutical composition.
[0507] Reagent test kit The compositions described herein may be provided in a kit for treating bone disease, anemia, FOP, Sjögren's syndrome (e.g., dry eyes associated with Sjögren's syndrome), MO, DIPG, PCO, or cardiac hypertrophy and / or cardiac fibrosis. The composition may include an ALK2 antibody or an antigen-binding fragment thereof (e.g., ALK2 binding fragment) described herein, and may be provided in a unit dosage form, optionally in a pharmaceutically acceptable excipient (e.g., saline), in an amount sufficient to treat bone disease, anemia, FOP, Sjögren's syndrome (e.g., dry eyes associated with Sjögren's syndrome), MO, DIPG, PCO, or cardiac hypertrophy and / or cardiac fibrosis. The kit may further include a package insert that instructs a user of the kit, such as a physician, to perform the methods described herein. The kit may optionally include a syringe or other device for administering the composition. Example
[0508] The following examples are provided to further illustrate some embodiments of the present invention but are not intended to limit the scope of the invention; it will be understood by their exemplary nature that other procedures, methods or techniques known to those skilled in the art may alternatively be used.
[0509] Example 1 - Generation of ALK2 Antibodies The antibodies were generated by panning a human combinatorial phage library against antibodies recognizing ALK2, followed by 2 rounds of enrichment and counterselection against closely related antigens to deplete nonspecific antibodies. After the second round of enrichment, rapid pool maturation was performed. (Prassler et al., Immunotherapy, 1(4), 571-583, 2009) is a registered trademark of MorphoSysAG). A highly diverse collection of CDR variability was cloned into the selected antibody pool, thereby further expanding the diversity of the pre-selected antibody pool. The amplified antibody library obtained by panning against ALK2 was enriched using high stringency washing conditions and two additional rounds of reducing the amount of antigen in the panning rounds, and counter-selection was performed against closely related antigens to deplete non-specific antibodies. After panning, the enriched antibody gene pool was subcloned from the phage display vector into a bacterial expression vector to determine the final Fab antibody format, as shown in Table 2 below. Table 2: Antibody CDR sequences
[0510] Example 2 - Evaluation of ALK2 Antibody Binding Affinity by Surface Plasmon Resonance (SPR) The GE Biacore 3000 was used to measure the kinetics of the interaction between the anti-ALK2 antibody (ligand) and ALK2-His / ALK2-mFC (analyte). Using an amine coupling kit, flow chambers 1-4 were immobilized with anti-human capture antibodies from GE. The anti-ALK2 protein was then captured in flow chambers 2-4 on the chip, with flow chamber 1 left empty as a reference chamber to measure and subtract any nonspecific binding. When running kinetic analysis on Biacore, it is best to allow a maximum analyte binding response (RMax) of 100 resonance units (RU). This is achieved by the formula RMax100 = (kDa analyte / kDa ligand) x fixed ligand RU. If the ligand density in the flow chamber is too high, it will result in an artificially low concentration of unbound analyte close to the chip surface, and the resulting sensorgram will not represent the true binding between the ligand and the analyte. This is called the mass transfer effect, and this is prevented by calculating the appropriate level of ligand binding to the chip surface and using a high flow rate of 40 μL / min. HBS-EP+ was used as running buffer and to dilute the protein. Each ligand was run in duplicate concentration series. At the end of each cycle, the chip was regenerated with 3 M MgCl2 to remove all bound anti-ALK2 and analyte. The kinetics of the interaction between the monovalent fAB antibody in the fAB-FH format and ALK2-FC was also measured using ForteBio Octet RED384.
[0511] The K values of the fABs of Antibody 1, Antibody 2, and Antibody 3 against ALK2-FC as measured by ForteBio Octet are shown in Table 3 below. D Values, and K values of intact antibodies against ALK2-His measured by GE Biacore D Table 4 shows the K values of Antibody 2 against ALK2-mFC measured by GE Biacore. D Table 5 shows the ka, kd and K values of the interaction between the monovalent fAB antibodies in fAB-FH format and ALK2-FC measured using ForteBio Octet RED384. D value. Table 3: K D value Table 4: K against ALK2-mFC D value <![CDATA[K D (nM)]]> Antibody GE Biacore 2 0.145 Table 5: Kinetics of monovalent fAB antibodies in fAB-FH format measured by ForteBio Octet
[0512] Example 3 - Detection and evaluation of ALK2 antibodies using a gene luciferase reporter assay C2C12-BRE-luciferase (SMAD1 reporter gene) cells were seeded in DMEM supplemented with 2% FBS on a 96-well plate and placed in an incubator for no less than 3 hours to adapt to the plate surface. For each fAb variant, a dilution series was prepared in 2% DMEM and administered to the cells. The remaining wells were used to repeat the positive control and background. The cells were then placed in an incubator at 37°C for 45 minutes. The wells were treated with vehicle (to determine the background value), BMP6 (to determine the ALK2 stimulation value), or with fAB and subsequent 40ng / mL BMP6 (to determine the IC50 of fAb). As an alternative to SMAD1 phosphorylation, the extent of BRE-stimulated luciferase was measured. The plate was incubated overnight and then read using Promega Steady Glo and Molecular Devices Spectramax M5e. Inhibition was calculated as the percentage of signal loss compared to the positive control well. Figure 1A-1B Shown are dose response curves of BMP6 inhibition of anti-ALK2 fABs in C2C12 cells using a SMAD1 luciferase reporter. The 50% inhibition values (IC50) of three- and four-parameter curve fits in Graphpad Prism are shown next to the curves. Figure 1A Results from the first four fABs generated are shown, and Figure 1B Shown are the results of five second round fABs generated using rapid pool maturation.
[0513] Example 4 - Effect of ALK2 Antibody in IRIDA Mouse Model Eight-week-old male C57BL / 6 mice were treated with vehicle or ALK2 antibody (5 mg / kg Antibody 2, twice a week, intraperitoneally). Six days after the start of dosing, vehicle-treated mice were intravenously administered lipid-encapsulated siRNA targeting luciferase (control) or TMPRSS6 (0.3 mg / kg). TMPRSS6 encodes a transmembrane type II serine protease that inhibits the secretion of hepcidin by cleaving hemojuvelin, and mutations in TMPRSS6 have been observed in human subjects with IRIDA. TMPRSS6 siRNA (0.3 mg / kg) was administered to ALK2 antibody-treated mice. Mice were euthanized 48 hours after siRNA administration. Whole blood was collected and hematological parameters were determined. As Figure 2 As shown in Figure 3, treatment with ALK2 antibody prevented the hemoglobin reduction associated with TMPRSS6 deficiency (* = p < 0.05; ** = p < 0.01).
[0514] In a second experiment, 8-week-old female albino C57BL / 6 mice were administered lipid-encapsulated siRNA (0.75 mg / kg) targeting either luciferase (control) or TMPRSS6 intravenously every three days. The mice received siRNA treatment until the point where the group receiving TMPRSS6 siRNA had increased hepcidin and decreased serum hemoglobin and serum iron. At this point, the mice were further randomized to receive vehicle or anti-ALK2 antibody (Antibody 2, 5 mg / kg, administered intraperitoneally). The mice were euthanized 12 days after their first siRNA administration. Whole blood was collected and hematological parameters were determined. In addition, serum was collected and hepcidin concentration was determined by ELISA, and total iron content was determined by colorimetric assay. Figure 3A As shown in Figure 3, treatment with ALK2 antibody reversed the hemoglobin reduction associated with TMPRSS6 deficiency (* = p < 0.05; ** = p < ALK2 antibody treatment also reversed the increase in serum hepcidin associated with TMPRSS6 deficiency (**=p < 0.01, Figure 3B ) and decreased serum iron associated with TMPRSS6 deficiency (* = p < 0.05; ** = p < 0.01, Figure 3C ).
[0515] Example 5 - Effects of ALK2 Antibodies in a Mouse Model of Osteoporosis C57BL / 6 mice received orchiectomy (ORX) or sham surgery at 9 weeks of age. After a six-week recovery period, during which time the ORX mice developed an osteoporotic phenotype, the ORX mice received twice-weekly intraperitoneal injections of vehicle or ALK2 antibody (5 mg / kg Antibody 2). Whole-body dual-energy X-ray absorptiometry (LunarPIXImus, GE Lunar Corp.) was performed 16 weeks after the start of dosing. High-resolution digital images were captured and referenced to hydroxyapatite phantoms to determine BMD (software version 2.10). Figure 4 As shown in , ORX mice treated with ALK2 antibody had greater BMD than vehicle-treated mice, suggesting that treatment with ALK2 antibody increases BMD or reduces bone loss.
[0516] Example 6 - Effect of ALK2 Antibody in MO Mouse Model The effect of ALK2 antibody on osteochondroma formation was determined using the MO mouse model. The mouse has an inducible, chondrocyte-specific, homozygous disruption of the Ext1 gene, and osteochondroma formation was observed in 100% of mutants after a single dose of doxycycline was administered to lactating female mice at P8. The mice were divided into two groups, which received intraperitoneal injections of ALK2 antibody (5 mg / kg) or vehicle twice a week starting from P8. Micro-CT imaging was performed weekly to monitor osteochondromas in the knee joint and thorax. Mice were killed at the end of the four-week treatment. In a subset of each group, bones were prepared by whole-body sealing and stained with Alizarin Red and Alcian Blue for imaging purposes. In the remaining mice, samples of the cartilage-bone junction of the hind limbs and thorax were harvested. The tissue was fixed in 4% paraformaldehyde, decalcified in EDTA, embedded in paraffin, and sliced at 5 μm thickness. Safarin O / Fast Green staining was then used to determine changes in cartilage morphology and the development of osteochondromas.
[0517] Example 7 - Effect of ALK2 Antibody on Posterior Capsular Opacification The effect of ALK2 antibody on the formation of posterior capsule opacity (PCO) after cataract surgery was determined using a mouse model of injury-induced PCO. Briefly, mice aged 10 to 16 weeks were divided into two groups, which received ALK2 antibody (5 mg / kg) or vehicle for two weeks before surgery, twice a week. Cataract surgery was performed under anesthesia, and one of the pupils was dilated with 2.5% phenylephrine hydrochloride and 1% tropicamide. Using an ophthalmic scalpel, an incision extending into the lens capsule was made in the central cornea. Aqueous separation with a balanced salt solution was used to separate the lens fiber block from the lens capsule, remove the lens fiber block, close the incision, and refill the anterior chamber with a balanced salt solution. In each group, a subset of mice were euthanized immediately after surgery and 1, 5, and 14 days after surgery. Mice continued to receive ALK2 antibody or vehicle twice a week until they were euthanized. Immediately before dissection, the animals were anesthetized and the presence or absence of corneal opacity, neovascularization, and the degree of pupil dilation were evaluated. At dissection, both surgical and non-surgical eyes (controls) were harvested and embedded, snap-frozen and stored at -80°C. Immunohistochemistry was then used to assess the presence of inflammatory cells, fibrotic markers (αSMA, fibronectin) and lens fiber differentiation markers (Prox1, cMaf).
[0518] Example 8 Effect of ALK2 Antibodies in a Murine Orthotopic Xenograft Model of DIPG The effect of ALK2 antibodies on inhibiting glioma growth in diffuse intrinsic pontine glioma (DIPG) was evaluated using a murine orthotopic xenograft model of DIPG. The model involves transplanting a patient-derived cell line (HSJD-DIPG-007) containing mutations in the HK27M and ACRV1 genes into the 4th ventricle of immunodeficient NOD-SCID mice. The primary outcome of the study was the duration of survival of the pups that received the transplant. Briefly, 3-week-old female NOD-SCID mice were transplanted with HSJD-DIPG-007 cells via stereotaxic surgery. 14 to 21 days after inoculation, mice were randomized into two groups and administered vehicle or ALK2 antibodies (5 mg / kg) twice a week. Mice are expected to become symptomatic within 21 days of inoculation, and without intervention, they are expected to have an average lifespan of ~60 days. The weight, health, and condition of the mice were closely monitored for the duration of the study period. Mice were euthanized and removed from the study if they lost more than 20% of their body weight or showed signs of poor health and distress.After termination, the brains of mice were carefully dissected and fixed in formalin for future histological evaluation and to determine the in vivo growth of HSJD-DIPG-007 cells.
[0519] Example 9 - Effect of ALK2 Antibody in Mouse Model of Sjögren's Syndrome The effect of ALK2 antibody on improving the symptoms of Sjögren's syndrome was determined in a non-obese diabetic (NOD) autoimmune mouse model. In addition to insulitis, NOD mice develop immune infiltration in the exocrine lacrimal and salivary glands, leading to final secretory dysfunction. The main phenotypic outcome measured in these mice is tear volume production. This is tested weekly to provide a longitudinal analysis of the progression of the disease and the efficacy of drug intervention. The antibody is administered twice a week via intraperitoneal injection at 5 mg / kg. In short, tear production of NOD mice (12 weeks old) was evaluated at baseline and then randomly divided into two groups to receive vehicle or ALK2 antibody for 8 weeks. During this duration, tear production of mice was tested weekly. At the end of the study, the tear glands were harvested to evaluate the mRNA expression of fibrosis (MMP9, MMP2, COL1A1, TIMP) and inflammatory (MCP1, IL6, TNF-α) markers. The contralateral lacrimal glands were dissected and fixed in formalin for histological analysis of inflammation and fibrosis.
[0520] Example 10 - Effect of ALK2 Antibody in Mouse Model of Cardiac Hypertrophy The effect of ALK2 antibody on the development of cardiac hypertrophy and fibrosis was determined using an angiotensin II (A2)-induced cardiac hypertrophy mouse model. Mice were divided into groups that received ALK2 antibody (5 mg / kg) or vehicle twice a week for two weeks before surgery, or groups that began dosing immediately after surgery. In brief, anesthetized mice were implanted with an osmotic minipump filled with A2 that released a constant dose of A2 for 2 or 4 weeks to induce cardiac hypertrophy. At the end of 2 or 4 weeks, mice underwent echocardiographic analysis under sedation. The whole heart and left ventricle (LV) were weighed, and the LV was divided into two halves and stored in liquid nitrogen or formalin. Tibia length (TL) was also measured. Changes in heart weight, the ratio of heart weight to TL ratio, LV weight, and LV to TL ratio were evaluated. In addition, the thickness of the intraventricular septum and posterior wall as well as the area of myocardial cells and fibrosis were determined.
[0521] Example 11 - Treatment of anemia by administration of ALK2 antibodies According to the methods disclosed herein, a physician in the art can treat a subject, such as a human patient, with anemia (e.g., IRIDA or anemia of inflammation) to increase hemoglobin levels, increase red blood cell counts, or reduce iron deficiency. Treatment methods may include diagnosing or identifying a subject as a candidate for treatment based on a blood test that measures hematological parameters. In order to treat a subject, a physician in the art can administer a composition containing an ALK2 antibody or an antigen-binding fragment thereof (e.g., ALK2 binding fragment) to the subject. A composition containing an ALK2 antibody or an antigen-binding fragment thereof (e.g., ALK2 binding fragment) can be administered to a subject, for example, by parenteral injection (e.g., intravenous injection) to treat anemia. The ALK2 antibody or its antigen-binding fragment (e.g., ALK2 binding fragment) is administered in a therapeutically effective amount, such as 0.01 to 500 mg / kg (e.g., 0.01, 0.1, 0.2, 0.3, 0.4, 0.5, 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg / kg). In some embodiments, the ALK2 antibody or its antigen-binding fragment (e.g., ALK2 binding fragment) is administered once every two months, once a month, once every two weeks, or at least once or more times a week (e.g., 1, 2, 3, 4, 5, 6, or 7 times a week or more). The ALK2 antibody or its antigen-binding fragment (e.g., ALK2 binding fragment) is administered in an amount sufficient to increase hemoglobin levels, increase red blood cell counts, or reduce iron deficiency.
[0522] After the composition is applied to the patient, those skilled in the art can monitor the improvement of the patient in response to the therapy by various methods. For example, the doctor can monitor the hemoglobin level, red blood cell count or iron deficiency of the patient by performing a blood test. Compared with the test results before applying the composition, the patient shows improved hemoglobin level, red blood cell count or iron deficiency after applying the composition, indicating that the patient responds well to treatment. Subsequent doses can be determined and applied as needed.
[0523] Example 12 - Treatment of bone disease by administration of ALK2 antibodies According to the methods disclosed herein, a physician skilled in the art can treat a subject, such as a human patient, with a bone disease (e.g., osteoporosis or osteopenia) in order to increase bone mineral density, increase bone formation, reduce bone resorption (e.g., bone loss), or reduce the risk of fractures. Treatment methods may include diagnosing or identifying the subject as a candidate for treatment based on standard clinical tests for bone mineral density (e.g., dual-energy X-ray absorptiometry). In order to treat the subject, a physician skilled in the art may administer to the subject a composition containing an ALK2 antibody or an antigen-binding fragment thereof (e.g., an ALK2 binding fragment). A composition containing an ALK2 antibody or an antigen-binding fragment thereof (e.g., an ALK2 binding fragment) can be administered to a subject, for example, by parenteral injection (e.g., intravenous injection) to treat a bone disease. The ALK2 antibody or its antigen-binding fragment (e.g., ALK2 binding fragment) is administered in a therapeutically effective amount, such as 0.01 to 500 mg / kg (e.g., 0.01, 0.1, 0.2, 0.3, 0.4, 0.5, 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg / kg). In some embodiments, the ALK2 antibody or its antigen-binding fragment (e.g., ALK2 binding fragment) is administered once every two months, once a month, once every two weeks, or at least once a week or more times (e.g., 1, 2, 3, 4, 5, 6, or 7 times a week or more). The ALK2 antibody or antigen-binding fragment thereof (eg, ALK2 binding fragment) is administered in an amount sufficient to increase bone mineral density, increase bone formation, reduce bone resorption (eg, bone loss), or reduce the risk of bone fracture.
[0524] After the composition is applied to the patient, those skilled in the art can monitor the improvement of the patient in response to therapy by various methods. For example, the physician can monitor the bone mineral density of the patient by performing dual-energy X-ray absorptiometry. Compared with the test results before applying the composition, the patient shows an increased bone mineral density, increased bone formation, reduced bone resorption (such as bone loss) or reduced fracture risk after applying the composition, indicating that the patient responds well to treatment. Subsequent doses can be determined and applied as needed.
[0525] Example 13 - Treatment of FOP by Administration of ALK2 Antibodies According to the methods disclosed herein, a physician skilled in the art can treat a subject with FOP, such as a human patient (e.g., a patient with a gain-of-function mutation in ALK2) to prevent or reduce heterotopic ossification, slow the progression of FOP, or delay the onset of FOP. Treatment methods may include diagnosing or identifying the subject as a candidate for treatment based on genetic testing for mutations in ALK2 or performing radiographic imaging, CT, or MRI. In order to treat the subject, a physician skilled in the art can administer a composition containing an ALK2 antibody or an antigen-binding fragment thereof (e.g., an ALK2 binding fragment) to the subject. A composition containing an ALK2 antibody or an antigen-binding fragment thereof (e.g., an ALK2 binding fragment) can be administered to a subject, for example, by parenteral injection (e.g., intravenous injection) to treat FOP. The ALK2 antibody or its antigen-binding fragment (e.g., ALK2 binding fragment) is administered in a therapeutically effective amount, such as 0.01 to 500 mg / kg (e.g., 0.01, 0.1, 0.2, 0.3, 0.4, 0.5, 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg / kg). In some embodiments, the ALK2 antibody or its antigen-binding fragment (e.g., ALK2 binding fragment) is administered once every two months, once a month, once every two weeks, or at least once a week or more times (e.g., 1, 2, 3, 4, 5, 6, or 7 times a week or more). The ALK2 antibody or antigen-binding fragment thereof (eg, ALK2-binding fragment) is administered in an amount sufficient to reduce heterotopic ossification, slow the progression of FOP, or delay the onset of FOP.
[0526] After the composition is applied to the patient, those skilled in the art can monitor the improvement of the patient in response to therapy by various methods. For example, the physician can use radiographs, CT and / or MRI to monitor the heterotopic ossification or disease progression of the patient. Compared with the test results before the application of the composition or compared with untreated subjects, after the application of the composition, the patient shows a decrease in heterotopic ossification (e.g., a decrease in the amount of heterotopic ossification or the formation of additional heterotopic bone), a delayed onset of failure to develop heterotopic ossification or FOP or a slow progress finding indicates that the patient responds well to treatment. Subsequent dosages can be determined and applied as needed.
[0527] Example 14 - Treatment of Sjögren's syndrome by administration of ALK2 antibodies According to the methods disclosed herein, a physician in the art can treat a subject, such as a human patient, with Sjögren's syndrome to improve or alleviate one or more symptoms of Sjögren's syndrome (e.g., dry eyes, dry mouth, eye irritation, blurred vision, tear gland fibrosis, tear gland inflammation, joint pain, or fatigue). In order to treat the subject, a physician in the art can administer a composition containing an ALK2 antibody or an antigen-binding fragment thereof (e.g., an ALK2 binding fragment) to the subject. A composition containing an ALK2 antibody or an antigen-binding fragment thereof (e.g., an ALK2 binding fragment) can be administered to a subject, for example, by parenteral injection (e.g., intravenous injection) to treat Sjögren's syndrome. The ALK2 antibody or its antigen-binding fragment (e.g., ALK2 binding fragment) is administered in a therapeutically effective amount, such as 0.01 to 500 mg / kg (e.g., 0.01, 0.1, 0.2, 0.3, 0.4, 0.5, 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg / kg). In some embodiments, the ALK2 antibody or its antigen-binding fragment (e.g., ALK2 binding fragment) is administered once every two months, once a month, once every two weeks, or at least once a week or more times (e.g., 1, 2, 3, 4, 5, 6, or 7 times a week or more). The ALK2 antibody or antigen-binding fragment thereof (e.g., ALK2 binding fragment) is administered in an amount sufficient to improve or reduce one or more symptoms of Sjögren's syndrome (e.g., dry eyes, dry mouth, eye irritation, blurred vision, tear gland fibrosis, tear gland inflammation, joint pain, or fatigue, such as by increasing tear or saliva production).
[0528] After the composition is applied to the patient, those skilled in the art can monitor the patient's improvement in response to therapy by various methods. For example, a physician can monitor the patient's symptoms of Sjögren's syndrome by assessing tear production (e.g., tear volume production), saliva production, vision, eye irritation, inflammation or fibrosis of the lacrimal gland, or a patient's report of joint pain or fatigue. The finding that the patient exhibits one or more symptoms of Sjögren's syndrome (e.g., dry eyes, dry mouth, eye irritation, blurred vision, lacrimal gland fibrosis, lacrimal gland inflammation, joint pain or fatigue) reduced after the composition is applied compared to the symptoms before the composition is applied or compared to an untreated subject indicates that the patient responds well to treatment. Subsequent doses can be determined and applied as needed.
[0529] Example 15 - Treatment of MO by administration of ALK2 antibodies According to the methods disclosed herein, a physician skilled in the art can treat a subject, such as a human patient, with MO to prevent or reduce the formation of osteochondromas, reduce the size of osteochondromas, reduce the number of osteochondromas, or slow the growth of osteochondromas. Treatment methods may include diagnosing or identifying a subject as a candidate for treatment based on genetic testing for mutations in EXT1 or EXT2 or performing radiographic imaging, CT, or MRI. In order to treat a subject, a physician skilled in the art may administer a composition containing an ALK2 antibody or an antigen-binding fragment thereof (e.g., an ALK2 binding fragment) to the subject. A composition containing an ALK2 antibody or an antigen-binding fragment thereof (e.g., an ALK2 binding fragment) can be administered to a subject, for example, by parenteral injection (e.g., intravenous injection) to treat MO. The ALK2 antibody or its antigen-binding fragment (e.g., ALK2 binding fragment) is administered in a therapeutically effective amount, such as 0.01 to 500 mg / kg (e.g., 0.01, 0.1, 0.2, 0.3, 0.4, 0.5, 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg / kg). In some embodiments, the ALK2 antibody or its antigen-binding fragment (e.g., ALK2 binding fragment) is administered once every two months, once a month, once every two weeks, or at least once a week or more times (e.g., 1, 2, 3, 4, 5, 6, or 7 times a week or more). The ALK2 antibody or antigen-binding fragment thereof (eg, ALK2 binding fragment) is administered in an amount sufficient to reduce the formation of an osteochondroma, reduce the size of an osteochondroma, reduce the number of osteochondromas, or slow the growth of an osteochondroma.
[0530] After the composition is applied to the patient, those skilled in the art can monitor the improvement of the patient in response to therapy by a variety of methods.For example, the doctor can use radiographs, CT and / or MRI to monitor the growth, quantity or size of osteochondroma in the patient.Compared with the test result before applying the composition or compared with untreated subjects, after applying the composition, the patient shows that osteochondroma formation reduces (for example, compared with untreated subjects or osteochondroma formation before treatment, no new osteochondroma is formed or less osteochondroma is formed), osteochondroma size is reduced, osteochondroma quantity is reduced or osteochondroma growth slows down, indicating that the patient responds well to treatment.Subsequent doses can be determined and applied as needed.
[0531] Example 16 - Treatment of DIPG by administration of ALK2 antibodies According to the methods disclosed herein, a physician in the art can treat a subject, such as a human patient, with DIPG to improve survival time, reduce tumor growth, reduce tumor size or volume, or prevent or reduce tumor metastasis. The treatment method may include diagnosing or identifying the subject as a candidate for treatment based on a genetic test for an activating mutation in ALK2. In order to treat the subject, a physician in the art can administer a composition containing an ALK2 antibody or an antigen-binding fragment thereof (e.g., an ALK2 binding fragment) to the subject. A composition containing an ALK2 antibody or an antigen-binding fragment thereof (e.g., an ALK2 binding fragment) can be administered to a subject, for example, by parenteral injection (e.g., intravenous injection) or by local administration to the central nervous system (e.g., intraventricular injection, intrathecal injection, or intracisternal injection). The ALK2 antibody or its antigen-binding fragment (e.g., ALK2 binding fragment) is administered in a therapeutically effective amount, such as 0.01 to 500 mg / kg (e.g., 0.01, 0.1, 0.2, 0.3, 0.4, 0.5, 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg / kg). In some embodiments, the ALK2 antibody or its antigen-binding fragment (e.g., ALK2 binding fragment) is administered once every two months, once a month, once every two weeks, or at least once a week or more times (e.g., 1, 2, 3, 4, 5, 6, or 7 times a week or more). The ALK2 antibody or antigen-binding fragment thereof (eg, ALK2-binding fragment) is administered in an amount sufficient to improve survival time, reduce tumor growth, reduce tumor size or volume, or prevent or reduce tumor metastasis.
[0532] After the composition is applied to the patient, those skilled in the art can monitor the improvement of the patient in response to therapy by various methods. For example, the physician can use imaging (e.g., MRI) to monitor the survival time or tumor size, growth or metastasis of the patient. Compared with untreated subjects or compared with the tumor growth, size or metastasis in the subject before application, the patient shows that the finding that tumor growth is reduced, tumor size or volume is reduced, tumor metastasis is reduced or the survival time is increased indicates that the patient responds well to treatment. Subsequent doses can be determined and applied as needed.
[0533] Example 17 - Treatment or prevention of PCO by administration of ALK2 antibodies According to the methods disclosed herein, a physician skilled in the art can treat a subject having PCO or at risk of developing PCO, such as a human patient (e.g., a patient having PCO or a patient who has undergone cataract surgery or is about to undergo cataract surgery, e.g., a patient who will undergo cataract surgery within 6 months, 5 months, 4 months, 3 months, 2 months, 1 month, 2 weeks, 1 week or less) to prevent the development of PCO, reduce PCO, improve visual acuity (e.g., reduce blurred or cloudy vision), reduce light sensitivity or glare, reduce or prevent fibrosis (e.g., fibrosis on or near the posterior capsule, e.g., fibrosis near an implanted lens), reduce or prevent lens fiber differentiation, reduce or inhibit lens epithelial cell proliferation, or reduce or prevent inflammation of the eye. To treat a subject, a physician skilled in the art can administer to the subject a composition containing an ALK2 antibody or an antigen-binding fragment thereof (e.g., an ALK2 binding fragment). Compositions containing an ALK2 antibody or antigen-binding fragment thereof (e.g., an ALK2 binding fragment) can be administered to a subject, for example, by parenteral injection (e.g., intravenous injection) or by administration to the eye (e.g., intraocular injection or topical administration) to treat PCO. The ALK2 antibody or antigen-binding fragment thereof (e.g., an ALK2 binding fragment) is administered in a therapeutically effective amount, such as 0.01 to 500 mg / kg (e.g., 0.01, 0.1, 0.2, 0.3, 0.4, 0.5, 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg / kg). In some embodiments, the ALK2 antibody or antigen-binding fragment thereof (e.g., ALK2 binding fragment) is administered once every two months, once a month, once every two weeks, or at least once a week or more (e.g., 1, 2, 3, 4, 5, 6, or 7 times a week or more). The ALK2 antibody or antigen-binding fragment thereof (e.g., ALK2 binding fragment) is administered in an amount sufficient to prevent the development of PCO, reduce PCO, improve visual acuity (e.g., reduce blurred or cloudy vision), reduce light sensitivity or glare, reduce or prevent fibrosis (e.g., fibrosis on or near the posterior capsule, e.g., fibrosis near an implanted lens), reduce or prevent lens fiber differentiation, reduce or inhibit lens epithelial cell proliferation, or reduce or prevent inflammation of the eye.
[0534] After applying the composition to the patient, those skilled in the art can monitor the patient's improvement in response to therapy by various methods. For example, the physician can monitor the patient's visual acuity, sensitivity to light or glare, opacity of the posterior capsule, or eye inflammation. The finding that the patient does not develop PCO or show improved visual acuity, reduced sensitivity to light or glare, reduced fibrosis, or reduced inflammation in the eye after applying the composition compared to untreated subjects or compared to the measured values from the patient before treatment indicates that the patient responds well to treatment. Subsequent doses can be determined and applied as needed.
[0535] Example 18 - Treatment of cardiac hypertrophy and / or cardiac fibrosis by administering ALK2 antibodies According to the methods disclosed herein, a physician skilled in the art can treat a subject, such as a human patient, with cardiac hypertrophy and / or cardiac fibrosis to slow or prevent the development of cardiac hypertrophy or cardiac fibrosis, reverse cardiac fibrosis, reduce or inhibit cardiac scarring, increase or induce cardiac regeneration, or improve one or more symptoms of cardiac hypertrophy or cardiac fibrosis (e.g., increase exercise capacity, increase ejection volume, reduce left ventricular end-diastolic pressure, reduce pulmonary capillary wedge pressure, increase cardiac output, increase cardiac index, reduce pulmonary artery pressure, reduce left ventricular end-systolic and end-diastolic dimensions, reduce left and right ventricular wall stress, reduce wall tension and / or wall thickness, increase myocardial contractility, reduce extracellular matrix deposition in the myocardium, or reduce fibrosis). To treat a subject, a physician skilled in the art can administer a composition containing an ALK2 antibody or an antigen-binding fragment thereof (e.g., an ALK2 binding fragment) to the subject. Compositions containing ALK2 antibodies or antigen-binding fragments thereof (e.g., ALK2 binding fragments) can be administered to a subject, for example, by parenteral injection (e.g., intravenous injection), to treat cardiac hypertrophy and / or cardiac fibrosis. The ALK2 antibody or antigen-binding fragment thereof (e.g., ALK2 binding fragment) is administered in a therapeutically effective amount, such as 0.01 to 500 mg / kg (e.g., 0.01, 0.1, 0.2, 0.3, 0.4, 0.5, 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg / kg). In some embodiments, the ALK2 antibody or antigen-binding fragment thereof (e.g., ALK2 binding fragment) is administered once every two months, once a month, once every two weeks, or at least once or more times a week (e.g., 1, 2, 3, 4, 5, 6, or 7 times or more per week). The ALK2 antibody or antigen-binding fragment thereof (e.g., ALK2 binding fragment) is administered in an amount sufficient to slow or prevent the development of cardiac hypertrophy or cardiac fibrosis, reverse cardiac fibrosis, reduce or inhibit cardiac scarring, increase or induce cardiac regeneration, or improve one or more symptoms of cardiac hypertrophy or cardiac fibrosis (e.g., increase exercise capacity, increase ejection volume, reduce left ventricular end-diastolic pressure, reduce pulmonary capillary wedge pressure, increase cardiac output, increase cardiac index, reduce pulmonary artery pressure, reduce left ventricular end-systolic and end-diastolic dimensions, reduce left and right ventricular wall stress, reduce wall tension and / or wall thickness, increase myocardial contractility, reduce extracellular matrix deposition in the myocardium, or reduce fibrosis).
[0536] After administering the composition to a patient, a person skilled in the art can monitor the patient's improvement in response to therapy by various methods. For example, a physician can use stress testing, echocardiography, MRI or other methods to monitor the patient's symptoms of cardiac hypertrophy or cardiac fibrosis (e.g., exercise capacity, ejection volume, left ventricular end-diastolic pressure, pulmonary capillary wedge pressure, cardiac output, cardiac index, pulmonary artery pressure, left ventricular end-systolic and end-diastolic dimensions, left and right ventricular wall stress, wall tension and / or wall thickness or myocardial contractility). The finding that the patient exhibits reduced cardiac fibrosis, increased cardiac regeneration, or one or more improvements in cardiac hypertrophy or symptoms of cardiac fibrosis (e.g., increased exercise capacity, increased blood ejection volume, reduced left ventricular end-diastolic pressure, reduced pulmonary capillary wedge pressure, increased cardiac output, increased cardiac index, reduced pulmonary artery pressure, reduced left ventricular end-systolic and end-diastolic dimensions, reduced left and right ventricular wall stress, reduced wall tension and / or wall thickness, increased myocardial contractility, reduced extracellular matrix deposition in the myocardium, or reduced fibrosis) after administration of the composition, compared to test results before administration of the composition or compared to untreated subjects, indicates that the patient responds well to treatment. Subsequent doses can be determined and administered as needed.
[0537] Other Implementations Although the invention has been described in conjunction with specific embodiments thereof, it will be understood that it is capable of further modifications, and this application is intended to cover any variations, uses, or adaptations of the invention which follow from the principles of the invention in general and include such departures from the present disclosure as come within known or customary practice in the art to which the invention pertains, and which may be applied to the basic features herein above described.
[0538] All publications, patents, and patent applications are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference in its entirety.
[0539] Other implementations are within the following claims.
Claims
1. An isolated antibody or ALK2 binding fragment thereof, comprising: (1) a light chain variable domain, comprising: a light chain complementary determining region (CDR) 1, comprising an amino acid sequence selected from the group consisting of: SGSSSNIGSNYVS (SEQ ID NO: 1) and SGDX1X2X3X4X5X6X7X8 (SEQ ID NO: 2, wherein X1 is S or N, X2 is I or L, X3 is P, G or R, X4 is S, T or K, X5 is F, K or Y, X6 is F, Y or S, X7 is A or V, and X8 is S, Y or H); a light chain CDR2, comprising the amino acid sequence X1X2IYX3X4X5X6RPS (SEQ ID NO: 3, wherein X1 is V or L, X2 is V or L, X3 is K, R, G or Y, X4 is N or D, X5 is N or S, and X6 is H, N, D or K); and a light chain CDR3 comprising an amino acid sequence selected from the group consisting of ASWDHSDRFYV (SEQ ID NO: 4), YVTAPWKSIW (SEQ ID NO: 5), YSADAQQMKA (SEQ ID NO: 6), QVYASVHRM (SEQ ID NO: 7), and QTYDWSHFGW (SEQ ID NO: 8); and (2) a heavy chain variable domain comprising: a heavy chain CDR1 comprising the amino acid sequence GX1TFX2SX3X4X5X6 (SEQ ID NO: 9, wherein X1 is G or F, X2 is S or N, X3 is Y, H, S or A, X4 is G or A, X5 is V, M or I, and X6 is S or H); a heavy chain CDR2 comprising an amino acid sequence selected from the group consisting of WMGX1IIPX2FGX3ANYAQKFQG (SEQ ID NO: 10 NO:10, wherein X1 is G or R, X2 is H or D, and X3 is I or T), WVGRIKSKX1DX2X3TTDYAAPVKG (SEQ ID NO:11, wherein X1 is A or R, X2 is S or G, and X3 is G or Y) and WVSVISSDGGSTYYADSVKG (SEQ ID NO:12); and a heavy chain CDR3 comprising an amino acid sequence selected from the group consisting of EIGSLDI (SEQ ID NO:13), DYGVAFAY (SEQ ID NO:14), DYGGLKFDY (SEQ ID NO:15), GPTQAIHYFAY (SEQ ID NO:16), and AGFILGSLGVAWMDV (SEQ ID NO:17).
2. The isolated antibody or ALK2-binding fragment thereof of claim 1, wherein the light chain CDR1 comprises the sequence SGSSSNIGSNYVS (SEQ ID NO: 1).
3. The isolated antibody or ALK2 binding fragment thereof of claim 1, wherein the light chain CDR1 comprises the sequence SGDSIPSFFAS (SEQ ID NO: 18).
4. The isolated antibody or ALK2 binding fragment thereof of claim 1, wherein the light chain CDR1 comprises the sequence SGDNIGTKYAY (SEQ ID NO: 19).
5. The isolated antibody or ALK2 binding fragment thereof of claim 1, wherein the light chain CDR1 comprises the sequence SGDNLRKYSAH (SEQ ID NO: 20).
6. The isolated antibody or ALK2 binding fragment thereof of claim 1, wherein the light chain CDR1 comprises the sequence SGDSLGSKSVH (SEQ ID NO: 21).
7. The isolated antibody or ALK2 binding fragment thereof of any one of claims 1 to 6, wherein the light chain CDR2 comprises the sequence VLIYKNNHRPS (SEQ ID NO: 24).
8. The isolated antibody or ALK2 binding fragment thereof of any one of claims 1 to 6, wherein the light chain CDR2 comprises the sequence LVIYRDSNRPS (SEQ ID NO: 25).
9. The isolated antibody or ALK2 binding fragment thereof of any one of claims 1 to 6, wherein the light chain CDR2 comprises the sequence LVIYGDSDRPS (SEQ ID NO: 26).
10. The isolated antibody or ALK2-binding fragment thereof of any one of claims 1 to 6, wherein the light chain CDR2 comprises the sequence LVIYYDNKRPS (SEQ ID NO: 27).
Citation Information
Patent Citations
Recombinant immunoglobin preparations
US4816567A
Parenterally administrable liposome formulation comprising synthetic lipids
US5466468A
